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Background: Obesity is a risk factor for metabolic abnormalities, including insulin resistance, which 
precedes type II diabetes and cardiovascular diseases. White adipose tissue (WAT) is an endocrine 
organ responsible for maintaining systemic energy homeostasis. Obesity results in dramatic changes 
in WAT behaviour, including ectopic visceral accumulation and dysregulated adipocyte metabolism 
and secretions, which may adversely affect peripheral organs. Ataxia-telangiectasia mutated kinase 
(ATM) regulates glucose and redox homeostasis, thereby contributing to normal cellular metabolism. 
However, ATM protein levels are down-regulated in muscle and cardiac tissues of obese and insulin 
resistant animals, and therefore represents a potential link between obesity and peripheral metabolic 
dysfunction. The underlying mechanism of cardiac ATM suppression in obesity, however, remains 
unknown.  
ATM protein levels are suppressed by specific microRNAs (miRNAs) in cancer cells. MiRNAs are 
short molecules that govern protein translation in health and disease. Therefore, this study investigates 
whether adipocyte secretions potentially regulate cardiomyoblast ATM protein levels through a 
miRNA-mediated mechanism in obesity. 
Methods: 1) H9c2 cardiomyoblasts were treated with combinations of high free fatty acids (FFAs; 
palmitic- and oleic acid), glucose and/or insulin (n=3) to establish whether cardiomyoblasts are 
metabolically sensitive to obese-simulating conditions. ATM levels and activation (phosphorylation), 
together with other relevant metabolic proteins, were determined through Western blotting. The 
expression of two miRNAs that target ATM in cancer (miRNA-421 and miRNA-18a) were 
determined with qRT-PCR.   
2) H9c2 cardiomyoblasts were treated with primary adipocyte-derived conditioned media to establish 
whether cardiomyoblasts are metabolically sensitive to adipocyte secretions. The adipocytes were 
differentiated from adipose stem cells (ASCs) originating from the subcutaneous and visceral fat 
depots of lean (control; n=4) and high-fat diet (HFD; n=4) male Wistar rats. The basal metabolic 
protein profiles of adipocytes were determined through Western blotting and the FFA composition of 
the conditioned media were determined through GC-FID. Cardiomyoblast ATM levels and 
activation, together with other relevant metabolic proteins, were determined through Western 
blotting. The expression of miRNA-421 and miRNA-18a, and four additional metabolic miRNAs that 
target ATM in silico (miRNA-194, miRNA-210, miRNA-322, miRNA-181b), were determined with 
qRT-PCR. 
Results: In H9c2 cells, ATM activity (phospho/total-ratio), but not protein levels, were i) decreased 





increased (p<0.05) in response to control- and HFD-derived adipocyte secretions compared to 
untreated cells. The basal metabolic protein profiles and FFA secretory profiles of adipocytes were 
not influenced by fat depot or diet, but by the adipocytic differentiation process. Lastly, visceral and 
subcutaneous adipose secretions down-regulated (p<0.01) miRNA-181b levels in H9c2 cells under 
HFD conditions. 
Discussion and conclusion: This study shows, for the first time, that cardiomyoblast i) ATM activity 
is influenced by high insulin, FFAs and adipose secretions, and ii) miRNA-181b expression is down-
regulated in response to HFD-derived adipose secretions. Reduced miRNA-181b levels were 
previously observed in the myocardium of obese mice and associates with inflammation, insulin 
resistance and cardiomyopathy. We speculate that cardiomyoblast miRNA-181b down-regulation in 









Agtergrond: Vetsug is ‘n risikofaktor vir metaboliese abnormaliteite, insluitend 
insulienweerstandigheid, wat lei tot tipe II diabetes en kardiovaskulêre siektes. Wit vetweefsel (WV) 
is ‘n endokriene orgaan verantwoordelik vir die instandhouding van sistemiese energie homeostase. 
Vetsug lei tot groot veranderinge in WV funksie, insluitend die ektopiese versameling van vet rondom 
organe en wangereguleerde adiposietmetabolisme en -sekresie, wat perifere organe nadelig kan 
beïnvloed. Ataxia-telangiectasia gemuteerde proteïenkinase (ATM) reguleer glukose- en redoks 
homeostase en dra sodoende by tot normale sellulêre metabolisme. ATM proteïenvlakke word egter 
onderdruk in spier- en hartweefsel van vetsugtige en insulienweerstandige diere en verteenwoordig 
dus a moontlike skakel tussen vetsug en perifere metaboliese disfunksie. Die onderliggende 
meganisme wat lei tot die onderdrukking van ATM in die hart tydens vetsug is egter onbekend.   
ATM proteïenvlakke word onderdruk deur spesifieke mikroRNAs (miRNAs) in kankerselle. 
MiRNAs is kort molekules wat proteïentranslasie onder normale en siektestoestande beheer. Die 
huidige studie ondersoek dus of adiposietsekresies moontlik ATM proteïenvlakke deur middel van 
miRNAs in kardiomioblaste tydens vetsug beheer. 
Metodes: 1) H9c2 kardiomioblaste is behandel met kombinasies van höe vrye vetsure (VV; palmitaat 
en oleaat), glukose en/of insulien (n=3) om vas te stel of kardiomioblaste metabolies sensitief is vir 
kondisies wat vetsug naboots. ATM vlakke en aktivering (fosforilering), asook ander metabolies-
verwante proteïene, is bepaal deur middel van Westerse-klad tegniek. Twee miRNAs wat ATM teiken 
in kanker (miRNA-421 en miRNA-18a) se uitdrukkingsvlakke is met qRT-PCR bepaal.  
2) H9c2 kardiomioblaste is behandel met gekondisioneerde media afkomstig van primêre adiposiete 
om metaboliese sensitiwiteit vir adiposietsekresies te bepaal. Die adiposiete is gedifferensieer vanaf 
adiposiet stamselle afkomstig van die subkutane en visserale vetkompartemente van kontrole (n=4) 
en hoë-vet dieet (HVD; n=4) manlike Wistar rotte. Die basale metaboliese proteïenprofiele van die 
adiposiete is deur middel van Westerse-klad tegniek bepaal en die VV samestelling van die 
gekondisioneerde media is met GC-FID bepaal. ATM vlakke en aktivering, asook ander relevante 
metaboliese proteïene, is ook deur middel van Westerse-klad tegniek bepaal. Die uitdrukkingsvlakke 
van miRNA-421 en miRNA-18a, asook vier addisionele metaboliese miRNAs wat ATM in silico 
teiken (miRNA-194, miRNA-210, miRNA-322, miRNA-181b), is met qRT-PCR bepaal. 
Resultate: In H9c2 selle is ATM aktiwiteit (fosfo/totaal-verhouding), maar nie proteïenvlakke nie, i) 
afgereguleer deur ‘n kombinasie van VV en insulien in vergelyking met VV alleen en insulien alleen 
en ii) opgereguleer (p<0.05) deur gekondisioneerde media van adiposiete afkomstig van kontrole en 





sekresieprofiele van adiposiete is nie beïnvloed deur die vetkompartement of dieet nie, maar deur die 
adiposiet-spesifieke differensiasieproses. Die miRNA-181b vlakke is afgereguleer (p<0.01) in H9c2 
selle deur visserale en subkutane adiposietsekresies onder HVD kondisies. 
Bespreking en gevolgtrekking: Hierdie studie toon vir die eerste keer dat kardiomioblast i) ATM 
aktiwiteit deur hoë insulien, VV en adiposietsekresies beïnvloed word en ii) miRNA-181b 
uitdrukkingsvlakke in ‘n HVD omgewing onderdruk word. Onderdrukte miRNA-181b vlakke is 
voorheen in die miokardium van vetsugtige muise waargeneem en assosieer met inflammasie, 
insulienweerstandigheid en kardiomiopatie. Ek spekuleer dat HVD-afkomstige adiposietsekresies 
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Chapter 1  
Study introduction 
Adipose tissue constitutes an essential organ with a dual function: the rapid storage of energy 
following feeding and the secretion of various hormones and inflammatory cytokines for vital 
communication with distant organs (Kershaw and Flier, 2004). Adipose tissue expansion is driven by 
a positive energy balance, which occurs as a result of chronic overfeeding and a sedentary lifestyle – 
two characteristics of modern-day living.  
Obesity is notoriously associated with metabolic abnormalities, such as insulin resistance, which 
predispose individuals to the development of type II diabetes and cardiovascular diseases. On an 
anatomical level, obesity is associated with ectopic adipose tissue accumulation around central organs 
(Virtue and Vidal-Puig, 2010). On a physiological level, obesity associates with dysregulated 
adipocyte metabolism and secretions, which may adversely affect other peripheral organs to 
culminate in systemic disease (Longo et al., 2019). As such, obesity is recognised as a major health 
threat to the global population (Jaacks et al., 2019).  
Ataxia telangiectasia mutated (ATM) is an apical protein kinase responsible for maintaining DNA 
integrity in response to double-stranded breaks (Lavin and Kozlov, 2007). Furthermore, ATM plays 
an important metabolic role in the cytoplasm, independent from its participation in the DNA damage 
repair response. Two major metabolic pathways that rely on ATM activity include insulin signalling 
(Yang and Kastan, 2000) and redox signalling (Guo et al., 2010). Therefore, individuals with ataxia-
telangiectasia (A-T), a rare genetic disorder caused by mutations in the Atm gene, are predisposed to 
the development of cancer, insulin resistance, type II diabetes and ischaemic heart disease (Rothblum-
Oviatt et al., 2016). Interestingly, animal studies have shown an association between obesity and 
decreased peripheral ATM protein levels (Halaby et al., 2008; Huisamen et al., 2016). However, the 
exact underlying mechanism of this obesity-related ATM reduction is unknown.   
MicroRNAs (miRNAs) regulate gene expression through posttranscriptional silencing of messenger 
RNA (mRNA) transcripts (Bartel, 2004), thereby meticulously controlling the proteins that will be 
translated under a specific condition. Despite playing important physiological roles, miRNAs have 
been implicated in various disease states such as cancer (Peng and Croce, 2016), obesity, and type II 
diabetes (Landrier, Derghal and Mounien, 2019). Therefore, these small regulatory RNAs represent 
an attractive mechanism to consider for the regulation of ATM protein levels during obesity. In fact, 
miRNAs have been shown to suppress ATM protein levels in the context of cancer (Hu et al., 2010; 





posttranscriptional regulation. Studies investigating their potential involvement in the regulation of 
ATM in a metabolic context, however, remain lacking.   
Due to the involvement of ATM in various metabolic signalling networks, its reduction in obesity 
might explain some of the metabolic abnormalities that manifest in obese individuals. If the 
mechanism by which ATM protein levels are dysregulated in obesity is better understood, ATM may 







Chapter 2  
Literature review 
2.1. White adipose tissue (WAT) 
2.1.1. Introduction to structure and function 
Generally known as “fat”, adipose tissue represents a loose connective tissue that is organised into 
large lobular structures within the body. Two types of adipose tissue exist: brown adipose tissue 
(BAT), which mainly dissipates energy for thermoregulation in infants, and white adipose tissue 
(WAT), which enables the storage of energy as triglycerides (Cinti, 2012). WAT is a heterogeneous 
tissue that consists of mature adipocytes and preadipocytes (adipocyte precursors) situated in a 
surrounding matrix comprised of collagen fibres, fibroblasts, blood vessels and macrophages 
(Trayhurn and Beattie, 2001). A characteristic feature that discern mature adipocytes from 
preadipocytes is the presence of a large, single lipid droplet that occupies the majority of the 
cytoplasm, thereby displacing the nucleus to the extremity of the cell as more triglycerides are stored 
within the adipocyte (Cinti, 2012).    
WAT is a dominant role player in energy homeostasis as it is the major site for lipid storage and 
release. This balance of lipid flux is finely regulated by integrative signals of nutrient, neural and 
hormonal origin (reviewed by Spiegelman and Flier, 1996). In the event where more calories are 
consumed than is needed for immediate metabolic requirements, various signals mediate the storage 
of excess free fatty acids (FFAs) as triglycerides within WAT during lipid accumulation. Conversely, 
in the fasted state, the mobilisation of FFAs from storage is stimulated by opposing signals and results 
in the release of FFAs from WAT.  
In addition to functioning as a biological reservoir for excess energy, WAT is a dynamic organ with 
important endocrine and metabolic roles. This is due to its ability to secrete a plethora of bioactive 
compounds into circulation that exert physiological effects at both local (autocrine and paracrine) and 
systemic (endocrine) levels (Coelho, Oliveira and Fernandes, 2013). The initial indication of this 
added endocrine potential surfaced in 1987 with the discovery of sex steroid production (Siiteri, 1987) 
and adipsin secretion (Flier et al., 1987) by adipocytes. Thereafter, the discovery of leptin in 1994 
(Zhang et al., 1994) led to the firm recognition of WAT as an endocrine organ in its own right. WAT 
therefore contains the metabolic machinery to synthesize and secrete circulating factors that enable 





2.1.2. Adipocyte metabolism: roles of AMPK, PKB and mTORC1 
Central to adipocyte function is the maintenance of energy homeostasis through its ability to store 
lipids in times of nutrient excess and to mobilise it again in times of nutrient deficiency. Various 
protein signalling pathways play important collective or opposing roles in adipocyte metabolism that 
are dependent on this nutrient availability (Figure 2.1). One such protein is adenosine monophosphate 
(AMP)-activated protein kinase (AMPK), whose activation stimulates energy-producing catabolic 
processes (fatty acid metabolism; β-oxidation) while inhibiting energy-consuming anabolic processes 
(lipid synthesis; lipogenesis) in times of nutrient deficiency. AMPK is activated under conditions of 
elevated AMP (thus decreased adenosine triphosphate; ATP) levels to promote signalling pathways 
that will restore the ATP balance within the cell.  A down-stream target of AMPK is acetyl-coenzyme 
A carboxylase (ACC), a lipogenic enzyme responsible for the conversion of acetyl-coA to malonyl-
coA. In turn, malonyl-coA serves as a substrate for lipogenesis and inhibits FFA uptake into the 
mitochondria for energy production. Activated AMPK phosphorylates, and thereby inhibits, ACC in 
order to limit lipogenesis while favouring mitochondrial β-oxidation (Daval, Foufelle and Ferré, 
2006).  
On the contrary, proteins such as protein kinase B (PKB, also known as Akt) and mammalian target 
of rapamycin (mTOR) are activated in times of nutrient surplus to promote anabolic processes such 
as lipogenesis and preadipocyte differentiation into mature adipocytes (adipogenesis). WAT, similar 
to cardiac and skeletal muscle tissue, is sensitive to insulin, a hormone that is secreted in response to 
food intake. Once circulating insulin binds to its receptor located in the adipocyte cell membrane, a 
cascade of protein phosphorylation leads to PKB activation. Activated PKB subsequently targets 
down-stream proteins to facilitate the storage of excess FFAs and glycerol as triacylglycerol within 
the lipid droplet. One such down-stream target is mTOR complex 1 (mTORC1), which in turn 
activates S6-kinase (S6K), to promote lipogenesis and adipogenesis (Caron, Richard and Laplante, 
2015). Prolonged activation of the mTORC1/S6K pathway results in the serine phosphorylation, and 
therefore inhibition, of insulin receptor substrate 1 (IRS-1), an upstream kinase of PKB. Therefore, 
S6K-facilitated inhibition of IRS-1 leads to the attenuation of PKB activity in a negative feedback 
loop (Manning, 2004). Additionally, PKB and mTORC1 block various distinctive catabolic 
processes. For example, PKB negatively regulates β-oxidation by phosphorylating (inhibiting) 
AMPK on a specific serine residue (Berggreen et al., 2009), whereas mTORC1 negatively regulates 
lipolysis through the inhibition of adipose triglyceride lipase (ATGL), a lipolytic enzyme (Caron, 






Figure 2.1: Adipocyte metabolism. 
In response to nutrient deficiency (purple arrows), pathways in adipocytes are activated to promote catabolic processes. 
Energy-depletion activates AMPK, which in turn phosphorylates and inhibits ACC to promote mitochondrial β-oxidation. 
In response to nutrient surplus (green arrows), pathways in adipocytes are activated to promote anabolic processes. 
Insulin-stimulated PKB phosphorylation leads to the down-stream phosphorylation of the mTORC1/S6K pathway to 
promote lipogenesis and adipogenesis. S6K, in turn, inhibits IRS-1 in a negative feedback fashion. mTORC1 inhibits 
ATGL and, subsequently, lipolysis. PKB inhibits AMPK to block mitochondrial β-oxidation. Figure designed in Microsoft 
PowerPoint Office 365 by the author of the thesis. 
As mentioned previously, mTORC1 plays a central role in adipogenesis. Similarly, both AMPK and 
PKB have been implicated as important role players in this process. Several studies have 
demonstrated that activated AMPK prevents preadipocyte differentiation by limiting lipid 
accumulation and inhibiting key adipogenic genes in different cell models (Dagon, Avraham and 
Berry, 2006; Lee, Jeong and Park, 2018). Conversely, PKB and mTORC1 activation is critical for 
adipocyte differentiation to commence, as have been shown by PKB (Peng et al., 2003) and mTORC1 
(Polak et al., 2008) knock-down studies.  
2.1.3. Adipogenesis: from adipose stem cell to adipocyte 
In vivo 
Increased caloric intake relative to energy output drives WAT expansion in the form of adipocyte 
hyperplasia, a proliferative occurrence that results in increased adipocyte number. Mature adipocytes 





precursors to mature adipocytes. Firstly, pluripotent adipose stem cells (ASCs) residing in the WAT 
vascular stroma are recruited and promoted to commit to the adipocyte phenotype by a surplus energy 
balance. Once this occurs, ASCs are converted to preadipocytes, which in turn differentiate into 
mature lipid-carrying adipocytes (reviewed by Tang and Lane, 2012). The chain of events leading to 
terminally differentiated adipocytes is controlled by transcription factor-mediated gene expression. 
Particularly, proliferator-activated receptor gamma (PPARɣ) and CCAAT/enhancer binding protein 
alpha (C/EBPα) are considered to be the fundamental transcription factors induced during 
adipogenesis and are collectively responsible for initiating the adipogenic gene programme 
(Siersbæk, Nielsen and Mandrup, 2010).   
In vitro 
The use of both primary ASCs and clonal preadipocyte cell lines as experimental models have greatly 
contributed to the general understanding of adipocyte biology. The 3T3-L1 and 3T3-F442A 
immortalised preadipocyte cell lines (Green and Kehinde, 1974, 1975, 1976) are the most frequently 
used laboratory models and have guided the characterisation of the adipocyte differentiation program.  
Despite the ease of use of a clonal cell line, it is arguable whether cell lines can be manipulated to 
accurately reflect an in vivo environment, and whether they are therefore physiologically relevant. A 
recent review article highlights the advantages of using primary ASCs as a superior alternative to 
immortalised cell lines to study adipocyte differentiation and function ex vivo (Sadie-Van Gijsen, 
2019). Amongst others, the greatest advantage of using a primary ASC model is that these stem cells 
can be isolated from subjects that have been exposed to experimental interventions in vivo, such as a 
high-fat diet, and the biology of the cells can be studied ex vivo. This application allows researchers 
to gain a more accurate understanding of the physiological impact of the intervention. 
The in vitro differentiation of primary ASCs and clonal preadipocytes are generally achieved by 
subjecting post-confluent cells to a hormone-based adipogenic cocktail containing mainly insulin, 
isobutylmethylxanthine (IBMX) and dexamethasone (Rubin et al., 1978). The degree of adipocyte 
differentiation can be verified through standard Oil Red O (ORO) staining (Ramírez-Zacarías, Castro-
Muñozledo and Kuri-Harcuch, 1992) of the intracellular lipid droplets. 
2.1.4. Adipogenic memory 
Epigenetic changes refer to modifications to the DNA sequence without altering the sequence itself, 
resulting in the expression or silencing of specific genes under certain conditions. Andersen and 
colleagues demonstrated that ASCs are susceptible to epigenetic reprogramming by factors present 





by other studies (Nilsson et al., 2014; Rønningen et al., 2015). For example, long term exposure to 
obesity and type II diabetes can alter the differentiation potential and metabolic activities of these 
adipocyte precursors. Andersen et al. (2019) have demonstrated this when primary ASCs harvested 
from type II diabetic obese individuals displayed altered differentiation capacity and insulin 
signalling in vitro. This finding suggests that ASCs are not only susceptible to epigenetic modification 
in response to their environment, but also retain an adipogenic memory of their in vivo milieu. This 
memory of an obese and type II diabetic environment therefore persists when isolated ASCs are 
differentiated into mature adipocytes in culture. 
2.1.5. Obesity and the metabolic syndrome 
Even though WAT is necessary to maintain systemic energy and hormonal homeostasis, it has been 
implicated as a major risk factor for metabolic disease. The commencement of the industrial 
revolution has facilitated a shift from nutrient deprivation to nutrient excess, which, in combination 
with other lifestyle factors, has given rise to what is now known as the modern-day obesity epidemic 
(Caballero, 2007). This epidemic no longer pertains to wealthy Western counties exclusively, but has 
also started to infiltrate poorer developing countries (Prentice, 2006; Caballero, 2007). By definition, 
obesity refers to the pathological excess of WAT to a health-threatening extent (James, 2004) and is 
the central causal risk factor of the metabolic syndrome. The metabolic syndrome is a compound 
condition that is also characterised by insulin resistance, dyslipidaemia and hypertension, which 
predisposes individuals to the development of type II diabetes and cardiovascular diseases (Eckel, 
Grundy and Zimmet, 2005) (Figure 2.2). However, not all obese individuals are metabolically 
challenged, and even lean individuals can exhibit obesity-associated metabolic complications. This 
obesity paradox (Elagizi et al., 2018) suggests that the WAT mass itself is unlikely to contribute to 
the health risks associated with obesity.  
2.1.6. Subcutaneous and visceral adiposity  
The risk of developing obesity-associated diseases relates to the distribution of adiposity rather than 
total adiposity (Ibrahim, 2009), but the exact mechanism remains a point of discussion. As a result, 
various hypotheses exist on how excessive adiposity leads to systemic metabolic complications. The 
most renowned hypothesis is that of limited WAT expandability. WAT can accumulate in two distinct 
anatomical regions, namely the subcutaneous (superficial to the skin) and visceral (in and around 
abdominal organs) compartments. The subcutaneous fat depot serves as the normal physiological 
storehouse for excess energy that accompanies a high-caloric diet. Adipocytes residing in this depot 
act as metabolic sinks that store surplus FFAs and glycerol as triglycerides (Ibrahim, 2009). In times 





adipocytes respond by increasing in amount (hyperplasia) and size (hypertrophy) to compensate for 
the additional lipids present in circulation. Once these adipocytes have reached their maximum 
expansion capacity, a phenomenon known as lipid “spill over” (dyslipidaemia) occurs and excess 
circulating FFAs are shunted to the liver, kidneys, skeletal muscle, heart and pancreas and stored 
ectopically as visceral fat. This ectopic deposition of lipids in and around other peripheral tissues that 
are not equipped for fat storage consequently leads to metabolic defects, such as insulin resistance 
(Virtue and Vidal-Puig, 2010). Visceral obesity, in particular, is therefore implicated as the central 
component in the pathogenesis of the metabolic syndrome (Figure 2.2).  
 
Figure 2.2: Visceral obesity and its relationship to the metabolic syndrome.  
Visceral obesity is the main driver of insulin resistance, dyslipidaemia and hypertension. The clustering of these 
complications is termed the metabolic syndrome, which is a risk factor for the development of type II diabetes and 
cardiovascular diseases. Figure designed in Microsoft PowerPoint Office 365 by the author of the thesis based on content 
by Virtue and Vidal-Puig (2010). 
2.1.7. Adipose tissue secretions in obesity 
Owing to its endocrine function, WAT is not only responsible for the release of FFAs into circulation, 
but also the secretion of various hormones (referred to as adipokines) and inflammatory cytokines. 
Obesity, especially in the visceral compartment, and its related metabolic abnormalities are strongly 
associated with a state of chronic systemic inflammation due to the aberrant release of FFAs, 
adipokines and pro-inflammatory cytokines from WAT (Kershaw and Flier, 2004). Therefore, in 
addition to anatomical differences, visceral WAT differs from subcutaneous WAT on an 





Free fatty acids (FFAs) 
Subcutaneous and visceral WAT display differential lipolytic activities. Insulin opposes lipolysis 
while promoting lipogenesis within adipocytes. Subcutaneous adipocytes are normally highly 
sensitive, whereas visceral adipocytes are more resistant, to the anti-lipolytic action of insulin. 
Therefore, the rate of FFA secretion from visceral adipocytes is suggested to be higher compared to 
that of subcutaneous adipocytes (Arner, 1995).  
In obesity, the circulating FFA concentration is increased and contributes to the development of 
insulin resistance in peripheral organs (Boden, 2008). In short, circulating FFAs that enter non-
adipose cells are either oxidised to produce energy or re-esterified as triglycerides. Chronically 
elevated levels of circulating FFAs overwhelms the cell’s ability to use or store the FFAs, resulting 
in the accumulation of intracellular triglycerides and metabolites of the re-esterification process. 
These intermediates contribute to the production of reactive oxygen species (ROS) and consequent 
oxidative stress, which attenuates insulin signalling and renders the cell insulin resistant.  
Studies (Wajchenberg, 2000; Bjørndal et al., 2011) have highlighted a positive correlation between 
visceral WAT and circulating FFAs in obesity, thereby assuming that visceral adipocytes contribute 
to systemic FFA levels to a greater degree compared to subcutaneous adipocytes. This may not be 
the case as the majority of circulating FFAs seem to originate from the abdominal subcutaneous WAT 
as opposed to visceral WAT in obese individuals (Jensen, 2006), despite a higher lipolytic rate in the 
visceral depot. This finding focuses attention on the deranged behaviour of subcutaneous adipocytes 
in the obese condition, which is often overlooked. 
Lastly, the plasma composition of dietary FFAs also influences widespread insulin sensitivity. More 
specifically, saturated FFAs have been found to induce peripheral insulin resistance in rats, whereas 
the addition of unsaturated FFAs restored insulin sensitivity (Storlien et al., 1991). Studies in humans 
(Vessby, Tengblad and Lithell, 1994; Hekmatdoost et al., 2011) have corroborated this pattern where 
increased insulin resistance was strongly associated with increased serum concentrations of saturated 
FFAs, especially palmitic acid. Lovejoy and colleagues investigated the effects of saturated, 
unsaturated, and trans FFA-enriched diets on healthy lean and obese individuals (Lovejoy et al., 
2002). The authors observed no association between dietary FFA composition and insulin sensitivity 
in lean subjects, but overweight subjects had a higher propensity for developing insulin resistance 
while consuming a diet high in saturated FFAs. This suggests that the effect of dietary circulating 






WAT also displays differential secretion of adipokines in obesity and related metabolic conditions. 
Elevated circulating levels of monocyte chemoattractant protein-1 [MCP-1; a macrophage-recruiting 
hormone] (Takahashi et al., 2003), plasminogen activator inhibitor-1 [PAI-1; an anti-fibrinolytic 
glycoprotein] (Landin et al., 1990), acylation-stimulating protein [ASP; a lipid storage protein] 
(Cianflone, Xia and Chen, 2003), resistin [a molecule induced during adipogenesis] (Steppan et al., 
2001) and leptin [an insulin-responsive hormone with levels proportional to the amount of WAT] 
(Considine et al., 1996) correlate with obesity and the development of insulin resistance and type II 
diabetes. Conversely, reduced circulating levels of adiponectin [a hormone involved in the regulation 
of nutrient metabolism] is associated with the development of systemic insulin resistance (Weyer et 
al., 2001).   
Pro-inflammatory cytokines 
The expression of tumour necrosis factor-α (TNF-α), a pro-inflammatory cytokine secreted by WAT, 
is markedly elevated in the WAT of obese animals (Hotamisligil, Shargill and Spiegelman, 1993) and 
humans (Hotamisligil et al., 1995) compared to their lean counterparts, which strongly correlates with 
peripheral insulin resistance. When comparing TNF-α expression between the two fat depots, studies 
have shown that TNF-α expression was higher in subcutaneous WAT compared to visceral WAT, 
but disagreed whether this was in a body mass index (BMI)-dependent (Fain et al., 2004) or -
independent (Winkler et al., 2003) manner. Although expressed in subcutaneous WAT, no TNF-α 
was found to be secreted from this depot in obese individuals (Mohamed-Ali et al., 1997), suggesting 
that expression does not necessarily correlate with secretion. Lastly, Tsigo and colleagues reported 
that circulating TNF-α levels were significantly increased in obese individuals with visceral adiposity 
compared to obese individuals with subcutaneous adiposity (Tsigos et al., 1999), suggesting that 
WAT distribution affects TNF-α secretion.  
Interleukin-6 (IL-6), another pro-inflammatory cytokine secreted by WAT, is also elevated in obesity 
and has been shown to be secreted at a higher concentration by visceral WAT compared to 
subcutaneous WAT (Fried, Bunkin and Greenberg, 1998; Fain et al., 2004). The same pattern 
(visceral > subcutaneous) was observed when adipocytes were isolated from both WAT depots, 
however these secretions only accounted for approximately 10% of the total IL-6 released from WAT 
(Fried, Bunkin and Greenberg, 1998).  
It is important to note that adipocytes themselves are responsible for only a small percentage of the 
circulating pro-inflammatory cytokines released from WAT. As WAT expands during obesity, 





These immune cells, in turn, are responsible for the release of the majority of pro-inflammatory 
cytokines that give rise to the systemic inflammatory profile associated with obesity (Weisberg et al., 
2003).        
2.1.8. Role of macrophages in obesity 
In the obese state, WAT itself becomes insulin resistant and inflamed, which is associated with 
increased pro-inflammatory macrophage infiltration and activation (Weisberg et al., 2003). Briefly, 
due to the potent anti-lipolytic action of insulin, insulin resistant hypertrophic adipocytes secrete 
increased levels of FFAs and MCP-1 into circulation. The latter recruits macrophages to the WAT, 
where they are directly activated by the elevated FFA levels. Active macrophages express and secrete 
pro-inflammatory cytokines, which in turn suppress adipogenesis. Since the affected adipocytes are 
unable to increase in number the cells further increase in size, promoting the continuation of a vicious 
cycle (for full review, see Virtue and Vidal-Puig, 2010) (Figure 2.3). 
 
Figure 2.3: Adipocyte hypertrophy and macrophage infiltration during obesity. 
During obesity, a high-caloric diet leads to chronically elevated levels of circulating FFAs, which leads to adipose 
expansion by means of adipocyte hypertrophy. In the insulin resistant individual, the hypertrophic adipocytes are 
insensitive to the anti-lipolytic action of insulin, resulting in an increase in FFA and MCP-1 secretion. Macrophages are 
recruited by the circulating MCP-1 to the WAT, where they are activated by the secreted FFAs. Active macrophages 
secrete pro-inflammatory cytokines that inhibit adipogenesis and drives adipocyte hypertrophy even further. Figure 






It has been suggested that hypertrophic adipocytes, rather than hyperplasic adipocytes, are typically 
more pathological because of their association with increased macrophage infiltration and insulin 
resistance (Skurk et al., 2007). As in vivo adipocytes reside in a collagenous matrix, it is necessary 
for the matrix to remodel to allow for hypertrophy to occur. Therefore, enlarged adipocytes are likely 
to experience pressure exerted by the rigid matrix causing them to rupture, leading to an increase in 
lipid release and subsequent macrophage activation (reviewed by Virtue and Vidal-Puig, 2010). 
Taken together, visceral and subcutaneous WAT have unique diet-dependent metabolisms, which are 
responsible for generating differential secretory profiles that might distinctively affect peripheral 
organ metabolism. In addition, the role of macrophages and adipocyte hypertrophy play important 
roles in mediating local WAT and wide-spread systemic inflammation. 
2.2. The heart 
2.2.1. Cardiomyocyte energy metabolism 
The contracting heart is the most energy-intensive organ in the body due to its constant mechanical 
activity. To meet its high energy requirements, cardiomyocytes are metabolically geared to utilise a 
variety of fuel substrates, such as carbohydrates and lipids, in order to sustain its continuous need for 
energy production. Therefore, the myocardial metabolism of these two macronutrients is of particular 
importance for proper cardiac function.   
Glucose 
Circulating glucose molecules can only enter cardiomyocytes through facilitative transmembrane 
glucose transporters (GLUTs). GLUT1 is the constitutively expressed isoform responsible for basal 
glucose uptake, and GLUT4 is the predominant isoform responsible for the majority of glucose uptake 
into the adult cardiomyocyte. In the unstimulated cardiomyocyte, the GLUT4 transporters reside 
within cytoplasmic vesicles. The two major stimuli that induce the translocation of these vesicles to 
the sarcolemma, are insulin and cellular contraction. The role of insulin and the protein signalling 
pathway resulting in GLUT4-mediated glucose uptake have been extensively described in literature 
(Bryant, Govers and James, 2002; Thong, Dugani and Klip, 2005; Chanda, Luiken and Glatz, 2016). 
In the fed state, increased circulating glucose levels stimulate the secretion of insulin from the 
pancreas. Insulin binds to the insulin receptor situated in the sarcolemma of cardiomyocytes, resulting 
in the autophosphorylation of the receptor’s tyrosine residues. IRS-1 and phosphatidylinositol 3-
kinase (PI3K) are subsequently recruited and phosphorylated, respectively. The latter catalyses the 
conversion of phosphatidylinositol (4,5)P2 to phosphatidylinositol (3,4,5)P3 [PIP2 → PIP3], which 





phosphoinositide-dependent kinase-1 (PDK1) and mTORC2. Akt substrate of 160 kDa (AS160) is a 
down-stream target of activated PKB and is responsible for initiating the translocation of GLUT4 
vesicles to the sarcolemma. Once inserted, GLUT4 facilitates the uptake of extracellular glucose 
molecules into the cardiomyocyte. AS160 is also activated through contraction, however this 
activation is suggested to be at least partially mediated by AMPK (Schwenk et al., 2008).   
The breakdown of intracellular glucose for ATP production consists of two major processes 
(reviewed by Chanda, Luiken and Glatz, 2016). The first, glycolysis, occurs in the cytoplasm where 
glucose molecules are converted to pyruvate through a series of reactions catalysed by various 
enzymes. Glycolysis can commence under anaerobic conditions, however, it is responsible for merely 
10% of the net ATP generated within a healthy heart. The second, glucose oxidation, occurs in the 
mitochondria where the product of the first process, pyruvate, is further metabolised. Unlike 
glycolysis, glucose oxidation requires oxygen and contributes to the majority of glucose-derived ATP 
production (Figure 2.4). 
 
Figure 2.4: Cardiomyocyte glucose metabolism. 
In the fed state, insulin binds to its transmembrane receptor and triggers an intracellular phosphorylation cascade. IRS-
1 phosphorylation leads to PI3K phosphorylation, which converts PIP2 to PIP3. PIP3, together with PDK1 and mTORC2, 
stimulate PKB phosphorylation and the subsequent AS160-mediated translocation of GLUT4 vesicles to the sarcolemma 
for glucose uptake. Intracellular glucose molecules are metabolised through glycolysis (cytoplasm) and oxidation 
(mitochondria) for energy. Alternatively, AS160 is activated by contraction, possibly by means of AMPK. Figure designed 






The utilisation of glucose for ATP generation, however, is not favoured under normal aerobic 
conditions. Rather, the myocardium switches to and preferentially metabolises FFAs to meet its 
energy needs (Hue and Taegtmeyer, 2009). In fact, approximately 60-70% of the total ATP required 
for sufficient myocardial contraction under steady state conditions is obtained through mitochondrial 
FFA β-oxidation (Van Der Vusse, Van Bilsen and Glatz, 2000). 
Initially, circulating FFAs bound to either plasma albumin or lipoproteins are liberated in order to 
transverse the cardiomyocyte sarcolemma. This crossing is facilitated by plasmalemmal fatty acid-
binding proteins (FABPₚₘ) and cluster of differentiation 36 (CD36, also known as fatty acid 
translocase; FAT) (Van Der Vusse, Van Bilsen and Glatz, 2000). Similar to GLUT4, CD36 reside 
within intracellular vesicles that are shuttled between the cytoplasm and the sarcolemma. This 
recruitment of CD36 is also stimulated by both the insulin-dependent PKB pathway and the 
contraction-induced AMPK pathway that converge onto AS160 (Steinbusch et al., 2011).  
Once inside the cytoplasm, the FFAs are bound to cardiac-specific fatty acid-binding proteins 
(FABPs) and converted to long-chain acyl-CoA moieties by the acyl-CoA synthase enzyme. These 
moieties are shuttled to the mitochondrial matrix by an enzymatic complex consisting of carnitine 
palmitoyltransferase 1 (CPT1), carnitine:acyl carnitine translocase, and carnitine palmitoyltransferase 
2 (CPT2). Here, the long-chain acyl-CoA enters the β-oxidation system where a series of enzymes 
shorten the moiety during each successive cycle to produce ATP (reviewed by Lopaschuk et al., 






Figure 2.5: Cardiomyocyte fatty acid metabolism. 
In the fed state, insulin binds to its transmembrane receptor and triggers an intracellular phosphorylation cascade. IRS-
1 phosphorylation leads to PI3K phosphorylation, which converts PIP2 to PIP3. PIP3, together with PDK1 and mTORC2, 
stimulate PKB phosphorylation and the subsequent AS160-mediated translocation of CD36 vesicles to the sarcolemma 
for albumin/lipoprotein-linked FFA uptake. Intracellular FFAs are enzymatically converted to long-chain acyl-CoA, 
which are shuttled into the mitochondria by the CPT complex. The long-chain acyl-CoA moieties are metabolised through 
β-oxidation for energy. Alternatively, AS160 is activated by contraction, possibly by means of AMPK. Figure designed in 
Microsoft PowerPoint Office 365 by the author of the thesis. 
Taken together, a wide variety of ATP-producing mechanisms are available to the heart under normal 
conditions, highlighting its metabolic flexibility in order to meet its continuous energetic need. 
2.2.2. Metabolic consequences of obesity 
Chronically dysregulated nutrient metabolism in the heart and the progression to myocardial 
dysfunction are closely associated with obesity. Although similar pathways are responsible for 
GLUT4-facilitated glucose uptake and CD36-facilitated FFA uptake into cardiomyocytes, differences 
in their subcellular trafficking machinery allows for an imbalance in substrate utilisation in metabolic 
diseases (Steinbusch et al., 2011). An early metabolic maladaptation observed in the hearts of the 
obese and insulin resistant is the permanent recruitment of CD36 to the cardiomyocyte sarcolemma, 
together with the internalisation of GLUT4. This inverse presence of the nutrient transporters means 
that FFA uptake into cardiomyocytes far outweighs that of glucose. The sarcolemmal amount of 





inversely correlating with insulin-mediated GLUT4 translocation and subsequent glucose uptake. The 
preferential uptake of FFAs at the expense of glucose, together with the limited oxidative capacity of 
the mitochondria, result in an intracellular accumulation of lipid metabolites such as ceramide and 
diacylglycerol (DAG), which contribute to the development of myocardial lipotoxicity and insulin 
resistance (Schwenk et al., 2008; Steinbusch et al., 2011).      
Another metabolic consequence of obesity is oxidative stress due to excessive mitochondrial ROS 
production. ROS are highly destructive, short-lived molecules that readily reacts with surrounding 
molecules. The production of basal levels of ROS is an unavoidable consequence of mitochondrial 
ATP generation. Fortunately, low levels of ROS are metabolically necessary for the regulation of cell 
signalling, differentiation and proliferation (Hamanaka and Chandel, 2011). Due to the limited 
capacity of cardiomyocytes to store intracellular FFAs as triglycerides (Unger, Zhou and Orci, 1999), 
exposure to excess circulating lipids, as is the case in obesity, drives mitochondrial ROS production. 
When increased ROS production exceeds the level needed for normal physiological processes to the 
extent where it overwhelms the intracellular antioxidant systems, cardiomyocytes experience 
oxidative stress due to ROS-induced damage to cellular components. In severe cases, uncontrollable 
ROS production can ultimately lead to cell death by apoptosis (Ott et al., 2007). Therefore, chronic 
oxidative stress is an underlying feature of obesity and its related metabolic complications (Roberts 
and Sindhu, 2009; Marseglia et al., 2015).  
2.3. Ataxia-telangiectasia mutated (ATM) 
2.3.1. Introduction to ATM 
Ataxia-telangiectasia (A-T) is a rare genetic disorder that presents with two hallmark clinical features: 
uncoordinated movements (ataxia) and dilated oculocutaneous blood vessels (telangiectasia). This 
debilitating disease is further characterised by several other abnormalities, including cerebellar 
degeneration, accelerated aging, immune defects, ischaemic heart disease, insulin resistance, type II 
diabetes and cancer development (Rothblum-Oviatt et al., 2016). The discovery of the origin of the 
A-T disorder, which results due to mutations occurring throughout the Ataxia-telangiectasia mutated 
(Atm) gene (Savitsky et al., 1995), led to the identification of the encoded protein known as Ataxia-
telangiectasia mutated (ATM). ATM is a relatively large (350 kDa) serine/threonine protein kinase 
that forms part of the phosphatidylinositol 3-kinase-related protein kinase (PIKK) family. Some 
genetic mutations can lead to a reduction in expressed functional protein, whereas others can result 





Once autophosphorylated at serine 1981 (ser1981), nuclear ATM dimers convert to active monomers 
that orchestrate the signalling network responsible for the repair of double-stranded deoxyribonucleic 
acid (DNA) breaks, highlighting its crucial role in the prevention of cancer development. Its 
functional contribution to this defensive mechanism has been well documented (Banin et al., 1998; 
Canman et al., 1998; Cortez et al., 1999; Pandita et al., 2000; Bakkenist and Kastan, 2003). More 
recently, the identification of metabolic disturbances among A-T patients, such as type II diabetes 
and cardiovascular disease (reviewed by Espach et al., 2015), suggests additional functions and has 
directed research into the metabolic role of ATM in the cytoplasm.   
2.3.2. ATM and glucose homeostasis 
Insulin-dependent signalling 
ATM is an insulin-responsive protein kinase that contributes to glucose metabolism (Yang and 
Kastan, 2000), however its exact position within the insulin signalling pathway remains controversial 
(Figure 2.6). Depending on the cell type and metabolism, ATM may function either in a PKB-
dependent manner, or otherwise independently of PKB at the level of AS160. Viniegra and colleagues 
showed that ATM is required for the full activation of PKB in Cos and HEK 293T cells, both of 
which are kidney-derived cell lines (Viniegra et al., 2005). In mouse L6 myotubes, Halaby and 
colleagues confirmed that ATM is essential for full PKB activation upon insulin stimulation through 
inhibition of ATM with the ATM-specific inhibitor, KU55933 (Halaby et al., 2008). Similarly, a 
reduction in insulin-stimulated PKB phosphorylation was noted following treatment of C2C12 
(mouse myoblast cell line) cells with KU55933 (Jeong et al., 2010) and in extensor digitorum longus 
(EDL) muscle tissue from ATM knock-down mice (Ching et al., 2013). Based on these studies, ATM 
acts as an upstream regulator of PKB in the insulin signalling pathway.  
On the other hand, ATM has also been shown to act down-stream of PKB at the level of AS160. 
Contradicting the findings in the mouse EDL tissue, the soleus tissue of ATM knock-down mice 
revealed no interruption in PKB phosphorylation upon insulin stimulation, however the 
phosphorylation of AS160 failed to occur (Ching et al., 2013). This contradiction might be due to 
differences in muscle metabolism as EDL cells mainly utilise glycolysis and soleus cells mainly 
utilise oxidative phosphorylation. Conclusions by Jeong et al. (2010) verifies this finding when only 
a reduction in AS160 phosphorylation, and not PKB phosphorylation, was observed in mouse soleus 
tissue exposed to the KU55933 ATM-inhibitor. The authors further investigated the effect of 
KU55933 on mouse L6 myotubes and found only AS160 phosphorylation to be reduced, 





Regardless of the position of ATM relative to PKB and AS160, the insulin signalling pathway 
ultimately promotes GLUT4-mediated glucose uptake into the cell, protein synthesis, and cellular 
growth, while inhibiting protein degradation through autophagy. 
Lastly, a recent study showed that ATM activity contributes to glucose homeostasis at the level of 
GLUT4 by promoting its insulin-mediated translocation to the plasma membrane, while preventing 
its lysosomal degradation (Cheng et al., 2020). In the cerebral cortex of Atm knock-down mice, no 
differences were observed in general GLUT4 mRNA or protein levels, however GLUT4 levels within 
isolated lysosomes were significantly increased. Furthermore, wild-type cortical neurons exposed to 
the ATM-specific inhibitor, KU60019, displayed markedly increased levels of lysosome-associated 
GLUT4, as well as reduced insulin-mediated GLUT4 translocation to the plasma membrane. These 
results confirm that ATM-deficiency impedes GLUT4 translocation to the cell membrane by 
diverting it to the lysosomes for degradation, which ultimately limits cellular glucose uptake ability. 
Insulin-independent signalling 
ATM has also been shown to play a role in insulin-independent glucose homeostasis (Figure 2.6). 
GLUT1 contains an ATM-specific phosphorylation site (ser490) within its carboxy terminal 
(Matsuoka et al., 2007), which regulates the cellular localisation and activity of the insulin-
independent glucose transporter (Wiemand et al., 2009). This suggests that ATM may play a 
regulatory role in basal glucose uptake. Interestingly, ATM inhibition reduced GLUT1 localisation 
to the cell membrane and decreased GLUT1-mediated glucose uptake by nearly 50% in L6 myotubes 
due to decreased phosphorylation of its ser490 residue. Conversely, ATM activation increased the 
cell membrane localisation of GLUT1 and the subsequent GLUT1-mediated glucose uptake 
(Andrisse et al., 2013), confirming the role of ATM in basal glucose homeostasis.  
ATM also activates the PKB-mTORC1-S6K pathway in response to insulin-like growth factor 1 
(IGF-1) in skeletal muscle, independent of IRS-1 (Ching et al., 2013). C2C12 cells expressing ATM-
targeting short hairpin RNA (shRNA), or treated with KU55933 for acute ATM inhibition, and soleus 
muscle from Atm+/- mice exposed to IGF-1 showed reduced phosphorylation of PKB, mTORC1 and 
S6K, but not IRS-1. This data indicates that ATM plays a role in insulin-independent glucose 
homeostasis by participating in IGF-1 signalling, although the exact mechanisms of ATM 
autophosphorylation in response to IGF-1 binding, and the down-stream phosphorylation of PKB, 






Figure 2.6: ATM participates in insulin-dependent and -independent glucose homeostasis. 
ATM participates in insulin-dependent glucose homeostasis: insulin binds to its transmembrane receptor and triggers an 
intracellular phosphorylation cascade that promotes AS160/GLUT4-mediated glucose uptake and mTORC1/S6K-
mediated protein synthesis and cell growth, while inhibiting autophagy. However, it remains unclear whether ATM 
functions up-stream of PKB, or down-stream of PKB at the level of AS160. In addition, ATM participates in insulin-
independent glucose homeostasis: ATM activates the PKB-mTORC1-S6K pathway, independent of IRS-1, in response to 
IGF-1. Furthermore, ATM phosphorylates GLUT1 at a specific site to promote its localisation to the plasma membrane, 
thereby regulating basal glucose uptake. Figure designed in Microsoft PowerPoint Office 365 by the author of the thesis. 
2.3.3. ATM and redox homeostasis 
Another important metabolic function of ATM is its ability to regulate intracellular redox homeostasis 
in response to oxidative stress, independently of DNA damage (Figure 2.7). ATM is directly 
activated by ROS in the cytoplasm through a mechanism that differs from that of nuclear ATM by 
double-stranded DNA damage. Instead of monomerization occurring, oxidation by ROS results in the 
formation of active ATM dimers bound together with intermolecular disulphide bonds between 
various cysteine (cys) residues, especially cys2991 (Guo et al., 2010). 
Once oxidised by ROS, ATM activates the liver kinase B1 (LKB1)/AMPK pathway, resulting in the 
activation of both tuberous sclerosis complex 2 (TSC2) and unc-51-like kinase 1 (ULK1). TSC2 
inhibits mTORC1 to allow the activation of ULK1 and the induction of autophagy (Alexander et al., 
2010; Zhang et al., 2015). ROS-activated ATM also directs the selective degradation of peroxisomes 





participate in the break-down of long-chain fatty acids through β-oxidation, generating ROS as a by-
product. Zhang and colleagues demonstrated that ATM is localised to the peroxisome by binding to 
PEX5, a peroxisome import receptor. ROS-activated ATM phosphorylates PEX5 at ser141, which 
promotes PEX5 ubiquitination and its subsequent recognition by the autophagy adaptor protein, p62. 
Finally, the autophagosome is directed to the peroxisome by p62 for pexophagy to occur (Zhang et 
al., 2015). 
In addition, ROS-activated ATM aids in antioxidant defence against oxidative stress by enhancing 
glucose-6-phosphate dehydrogenase (G6PD) activity within the pentose phosphate pathway (PPP) to 
produce nicotinamide adenine dinucleotide phosphate hydrogen (NADPH), an important antioxidant 
co-factor (Cosentino, Grieco and Costanzo, 2011; Zhang et al., 2018).  
 
Figure 2.7: ATM participates in redox homeostasis. 
ATM is directly activated by ROS. Once oxidised, inactive ATM monomers form active dimers that are bound together by 
disulphide bonds between various cys residues, especially cys2991. ATM promotes the LKB1/AMPK pathway, which 
inhibits mTORC1 and activates ULK1 to induce autophagy. ROS-activated ATM also localises to peroxisomes by binding 
to and phosphorylating PEX5, promoting PEX5 ubiquitination and its subsequent recognition by p62. The latter event 
directs the autophagosome to the peroxisome for pexophagy. Furthermore, ROS-activated ATM activates G6PD, an 
enzyme within the PPP, for the production of the antioxidant co-factor, NADPH. Figure designed in Microsoft 





2.3.4. ATM and the metabolic syndrome 
Due to the prominent involvement of ATM in both insulin and ROS signalling networks, it is possible 
that ATM-deficiency or -dysfunction is central to the development of the metabolic syndrome, a 
compound disease associated with systemic insulin resistance and oxidative stress. Indeed, various 
studies have highlighted associations between decreased ATM and key features of the metabolic 
syndrome. 
Reduced ATM protein levels have been linked with obesity and insulin resistance. Halaby et al. 
(2008) were able to show that ATM levels were significantly reduced in the skeletal muscle tissue of 
high-fat diet-induced insulin resistant rats compared to lean control rats. The authors therefore 
suggested that decreased ATM contributes to the development of insulin resistance in obesity. Similar 
results were observed in the cardiac tissue of high-fat fed rats (Huisamen et al., 2016). 
ATM-deficiency has further been linked with the development of various other components of the 
metabolic syndrome. An extensive study by Schneider and colleagues revealed that Atm-/-ApoE-/- mice 
on a high-fat diet developed abdominal adiposity, hypertension, glucose intolerance, insulin 
resistance and accelerated atherosclerosis compared to Atm+/+ApoE-/- mice (Schneider et al., 2006). 
The authors concluded that ATM-deficiency might be a possible contributing mechanism to the 
development of the metabolic syndrome in obesity. Interestingly, similar studies (Wu et al., 2005; 
Mercer et al., 2010) showed that even heterozygous Atm+/-ApoE-/- mice on a high-fat diet developed 
the metabolic features described by Schneider and colleagues (2006), suggesting that ATM 
haploinsufficiency is sufficient for the development of obesity-related metabolic complications.  
A recent comprehensive review article by Wingard and colleagues discussed the parallel nature of 
the cardiometabolic abnormalities associated with ATM-deficiency and that of diabetic 
cardiomyopathy (Wingard et al., 2020). While the authors touch on several interesting connection 
points, only two of these will be mentioned here. Firstly, cardiac ATM expression is increased in 
response to β-adrenergic receptor (β-AR) stimulation (Foster et al., 2011). Once stimulated by 
norepinephrine, a catecholamine associated with sympathetic activity, the β-AR modulates heart rate 
and myocardial contractility. This suggests a role for ATM in the sympathetic response of the heart. 
The β-AR has been implicated in cardiomyopathy and is down-regulated in heart failure (Wachter 
and Gilbert, 2012), thereby also implying that decreased ATM may play a role in heart failure 
development. In fact, ATM-deficiency has been associated with cardiac remodelling (Foster et al., 
2012), a key feature of heart failure. And secondly, type II diabetes associates with reduced cardiac 
angiogenesis (blood vessel formation), which could greatly contribute to the development of related 





heterozygous mutations in the Atm gene is associated with the development of ischaemic heart disease 
(Su and Swift, 2000), which could allude to a role for ATM in angiogenesis.          
Lastly, ATM-deficiency has been linked with abnormal adipose tissue deposition, altered adipocyte 
metabolism and impaired adipocyte differentiation (Takagi et al., 2015). Atm-/- mice displayed 
decreased subcutaneous fat accumulation, increased visceral fat accumulation, and reduced serum 
levels of adiponectin and leptin compared to their wild-type counterparts, suggesting defective 
adipocyte functioning in the absence of ATM. Furthermore, in vitro experiments with Atm-/- mouse 
embryonic fibroblasts (MEFs) confirmed that ATM is necessary for the initiation of the adipocyte 
differentiation program through the induction of C/EBPα and PPARγ. Based on this novel role for 
ATM in adipogenesis, ATM-deficiency may be partly responsible for the adipose-related 
abnormalities observed in obesity, and subsequently the metabolic syndrome.    
2.4. MicroRNAs (miRNAs) 
2.3.1. Overview of the central dogma 
In 1958, Francis Crick famously explained the relation between the three central macromolecules of 
genetic information, namely DNA, ribonucleic acid (RNA) and proteins, to construct what is known 
as the central dogma of molecular biology (Crick, 1958). In the simplest form, the dogma states that 
the genetic message encoded within DNA is transcribed to messenger RNA (mRNA), which is 
subsequently translated into a functional protein (Figure 2.8). Therefore, mRNA plays an important 
intermediary role within the process of protein synthesis. The simplicity of this process, however, can 
be misleading as it is, in actual fact, a more complex dynamic with many checkpoints governed by 
several regulatory mechanisms to ensure proper function. One such mechanism includes RNA 
interference through small RNAs (Morange, 2009), known as microRNAs (miRNAs).  
 
Figure 2.8: The central dogma of molecular biology. 
The central dogma of molecular biology states that DNA is transcribed to mRNA, which is translated into protein. Figure 





2.3.2. miRNA biology 
MicroRNAs are short segments (approximately 22 nucleotides in length) of non-coding RNA that 
play a fundamental role in regulating cellular gene expression, predominantly on a post-
transcriptional level, in response to environmental changes. These endogenous RNAs represent an 
abundant group of gene-governing molecules that have been conserved across evolution, emphasising 
their important biological role (O’Brien et al., 2018). 
miRNA biogenesis 
MicroRNA biogenesis is a complex, multi-step process involving an initial nuclear processing phase, 
followed by a cytoplasmic processing phase (Lee et al., 2002) (Figure 2.9). Briefly, depending on a 
cell’s need, specific miRNA genes are transcribed by the RNA polymerase II (pol II) enzyme to 
produce stem-loop transcripts known as primary miRNA (pri-miRNA). A protein complex consisting 
of Drosha and DiGeorge syndrome critical region in gene 8 (DGCR8) is responsible for cleaving the 
pri-miRNA to generate 60-70 nucleotide hairpin intermediates known as precursor miRNA (pre-
miRNA). The original pri-miRNA contains the mature miRNA sequence in the arm-portion of the 
stem-loop structure, which remains conserved in the arm of the pre-miRNA intermediate. To allow 
for further maturation, the pre-miRNA is recognized by the nuclear transport receptor exportin-5 
(EXP5) and subsequently transported to the cytoplasm through a protein pore inserted within the 
nuclear membrane (Lei and Silver, 2002). Once inside the cytoplasm, the pre-miRNA is further 
cleaved into a ~22 nucleotide double-stranded miRNA (ds-miRNA) molecule with a forward strand 
(5’→ 3’; miRNA-5p) and a reverse strand (3’ → 5’; miRNA-3p) by the highly specific Dicer enzyme 
(Park et al., 2011). One strand of the miRNA duplex is generally degraded, whereas the remaining 
strand (guide miRNA) is integrated into a gene silencing effector complex known as the RNA-






Figure 2.9: The biogenesis of miRNAs. 
Nuclear processing of miRNA biogenesis: a specific miRNA gene is transcribed by the RNA pol II enzyme into a pri-
miRNA transcript. The DGCR8-complex cleaves the pri-miRNA to produce a pre-miRNA intermediate, which contains 
the mature miRNA sequence in the arm-portion. Cytoplasmic processing of miRNA biogenesis: the pre-miRNA is exported 
by EXP5 to the cytoplasm, where it is cleaved into a ds-miRNA molecule by Dicer. One strand is typically discarded, 
while the remaining (guide) strand is incorporated into RISC for gene silencing. Figure designed in Microsoft PowerPoint 
Office 365 by the author of the thesis. 
miRNA function 
MicroRNAs were described for the first time in 1993 in the context of developmental timing in the 
nematode Caenorhabditis elegans with the discovery of lin-4 miRNA (Lee, Feinbaum and Ambros, 
1993; Wightman, Ha and Ruvkun, 1993). However, it was not until 2001 (Lagos-Quintana et al., 
2001; Lau et al., 2001; Lee and Ambros, 2001) that the profound role of miRNAs in various 
physiological processes were realised. Essentially, miRNAs influence protein-coding gene outputs 
by targeting specific expression messages for silencing. Once incorporated within RISC, the guide 
miRNA directs the complex to its corresponding target mRNA transcript, which is subsequently 
silenced through either cleavage or insufficient translation. The choice of repression mechanism 
depends on the degree of complementarity between the guide miRNA and the binding site sequence 
in the 3ꞌ-untranslated region (UTR) of its target mRNA (Bartel, 2004). Perfectly matched base pairing 
will result in endonucleolytic cleavage, which occurs at a discrete position near the centre of the 
overlapping area. In the case of partial complementarity, the translation of the target mRNA will be 





expression to ensure that the appropriate proteins are synthesised. As such, miRNAs play an integral 
role as biological regulators in various cellular processes such as proliferation, differentiation, 
developmental timing and programmed cell death (Ambros, 2004).   
Organisms constantly face fluctuations in their environment, such as changes in temperature and 
limited nutrient availability. Modern humans, on the other hand, face opposite challenges of nutrient 
excess and lack of physical exercise. When presented with such challenging external conditions, it is 
critical for cells to regain internal homeostasis in order to survive. In an effort to do so, the cell can 
implement various stress-associated mechanisms to modulate miRNA activity in response to certain 
environmental cues (Leung and Sharp, 2010). For example, hypoxia-inducible factor (HIF) has been 
shown to direct the transcription of miRNA-26a, -107 and -210 in response to limited oxygen 
(Kulshreshtha et al., 2006). Another example includes the activation of the transcription factor and 
tumour suppressor, p53. Various studies (Chang et al., 2007; He et al., 2007; Raver-Shapira et al., 
2007) have shown that p53-mediated expression of miRNA-34 can occur in response to DNA damage 
to ultimately prevent cancer development. Therefore, the miRNA transcriptome can be adapted by 
stress-induced factors to determine the proteins that will be available in the cell under a given stress 
condition. When the system is unable to counteract a certain stress state, homeostasis is compromised, 
resulting in disease development such as cancer, diabetes and cardiovascular disease (Leung and 
Sharp, 2010). 
2.3.3. miRNAs in disease 
By understanding the physiological role of miRNAs in tailoring the intracellular protein levels in 
response to a fluctuating environment, we can begin to understand the adversity associated with 
miRNA dysfunction. As previously mentioned, miRNAs mostly assist with the cell’s response to 
physiologic and pathophysiologic stresses (Leung and Sharp, 2010). This function has been verified 
through knock-down studies, which concluded that the inhibition of individual miRNAs resulted in 
aberrant responses to various stress conditions (reviewed by Mendell and Olson, 2012). This forecasts 
the involvement of abnormally behaving miRNAs in the development of disease. 
Cancer 
One of the earliest indications of miRNA involvement in a pathological setting derived from studies 
performed in cancer cells (reviewed by Mendell and Olson, 2012). The initial study that provided 
evidence for associating miRNAs with cancer development in humans found that miRNA-15 and 
miRNA-16 are down-regulated in most chronic lymphocytic leukaemia patients (Calin et al., 2002). 
Following this discovery, the aberrant expression of specific miRNAs has also been implicated in 





miRNA expression profile compared to non-cancerous tissue. This differential expression of miRNAs 
allows for the creation of distinct miRNA signatures that can be used as biomarkers for diagnostic 
and prognostic purposes in almost all human malignancies (Calin and Croce, 2006). 
Metabolic disease 
Likewise, unique miRNA profiles have been identified as potential biomarkers for various metabolic 
disorders. For example, various miRNAs, some that have been linked with maintaining nutrient 
homeostasis and some whose functions remain to be established, are differentially expressed in the 
liver, WAT and skeletal muscle of obese and diabetic animal models compared to their healthy 
control counterparts (extensively reviewed by Guay et al., 2011). Additionally, miRNAs that 
originate from non-vascular cells are detected in the blood stream. Profiling of these circulating 
miRNAs can provide insights into the pathophysiological state of an individual and is currently being 
considered as potential biomarkers for diagnosing and tracking the disease progression of type II 
diabetes (Sebastiani et al., 2017; Vaishya, Sarwade and Seshadri, 2018).      
2.3.4. miRNA-mediated regulation of ATM  
With ATM emerging as a central protein kinase in various cell signalling networks, it is curious that 
the regulation of its protein levels through miRNA-mediated inhibition has not yet been extensively 
investigated. Studies in various cancer types established that ATM protein levels are negatively 
regulated by miRNA-18a (Song et al., 2011; Shen and Houghton, 2013; Wu et al., 2013) and miRNA-
421 (Hu et al., 2010; Shen and Houghton, 2013) through posttranscriptional suppression. Shen and 
Houghton (2013) further demonstrated that these ATM-suppressing miRNAs are upregulated by the 
PKB-mTORC1-S6K pathway. Therefore, ATM is susceptible to posttranscriptional regulation 
through an insulin-responsive mechanism in a cancer context, however studies investigating its 
regulation in a metabolic context are lacking. Even though no direct association has yet been made, 
there are four miRNAs that have been implicated in metabolic diseases known to be linked with 
abnormal ATM function (Figure 2.10).  
Latouche and colleagues performed a series of in vivo and in vitro experiments to highlight an 
association between type II diabetes and miRNA-194 levels in skeletal muscle (Latouche et al., 2016). 
Firstly, miRNA-194 levels were significantly reduced in the skeletal muscle tissue of patients with 
pre- and established type II diabetes compared to healthy individuals. Secondly, the same 
phenomenon was observed in the insulin resistant offspring of high-fat fed rats. Lastly, the inhibition 
of miRNA-194 in L6 myotubes resulted in an increase in insulin-stimulated PKB phosphorylation, 
glucose uptake and subsequent glucose metabolism. Based on the in vivo human and rodent findings, 





resistance (pre-diabetes) to established type II diabetes. Based on the in vitro study, the authors 
suggested that the involvement of miRNA-194 in various stages of PKB-dependent glucose 
metabolism might be the reason for its down-regulation in pre-diabetic patients as an adaptive 
mechanism to the onslaught of insulin resistance. Interestingly, another study identified four 
significantly increased circulating miRNAs in the sera of patients with metabolic syndrome that 
progressed to the development of type II diabetes compared to healthy individuals, with miRNA-194 
being one of the four. Serum levels of miRNA-194 were also elevated in diabetic mice compared to 
control mice, highlighting miRNA-194 as a potential predictive biomarker for diabetic disease 
progression (Jaeger et al., 2018).  
Another miRNA that has been linked to the progression of type II diabetes, and suggested as a 
potential biomarker thereof, is miRNA-210. Ghai and colleagues observed significantly elevated 
miRNA-210 levels in the sera of pre-diabetic patients who developed type II diabetes compared to 
pre-diabetic patients who did not (Ghai et al., 2019). This increase was further found to be 
exacerbated by obesity. In a quest to investigate the role of miRNA-210 in the cellular response to 
hypoxia, a different research group (Mutharasan et al., 2011) was able to show that PKB increased 
the induction of miRNA-210 in hypoxic cardiomyoblasts. Although this mechanism has been 
described in a hypoxic context, with obesity being a chronic hypoxic state, a link between PKB and 
the regulation of intracellular miRNA-210 levels has been established. The authors further found that 
overexpression of miRNA-210 in hypoxic cardiomyoblasts appeared to be cardioprotective in 
response to oxidative stress as it reduced mitochondrial ROS production and cell death.    
Min and colleagues highlighted an association between increased miRNA-322 (murine orthologue of 
human miRNA-424) and the development of obesity-associated insulin resistance in the liver (Min, 
Yang and Lee, 2018). HepG2 cells treated with a saturated FFA (palmitate) and liver tissue from 
high-fat diet-induced obese mice displayed elevated miRNA-424/322 levels and impaired insulin 
signalling. This occurred as a result of decreased expression of the insulin receptor, suggesting that 
saturated FFA-induced miRNA-424/322 represses the insulin receptor mRNA. A study by Marchand 
et al. confirms that miRNA-322 targets the insulin receptor mRNA (Marchand et al., 2016). In vitro 
experiments with rat vascular smooth muscle cells showed that overexpression of miRNA-322 
resulted not only in decreased insulin receptor levels, but also in a significant reduction of insulin-
stimulated PKB phosphorylation and subsequent glucose uptake. The authors also reported that 
miRNA-322 is highly expressed in the cardiac tissue of mice. Interestingly, these animal studies 
revealed that high-fat fed mice displayed cardiac dysfunction with no changes in miRNA-322 levels 
compared to control mice, however age-matched ob/ob mice exhibited no cardiac dysfunction with 





increased miRNA-322 expression could potentially protect the heart against cardiac damage 
associated with a high-fat diet.  
Lastly, reduced expression of miRNA-181b have been implicated in the development of insulin 
resistance in adipose-derived endothelial cells of high-fat diet-induced obese mice. Once miRNA-
181b levels were restored, an improvement in the insulin sensitivity and glucose metabolism were 
observed (Sun et al., 2016), suggesting that miRNA-181b might play an important role in the 
regulation of the insulin signalling pathway. Decreased miRNA-181b levels have also been observed 
in the arterial plaques of ApoE-/- rats fed a high-fat diet. Notch1, a transmembrane receptor involved 
in angiogenesis, was found to be a direct target of miRNA-181b and was therefore up-regulated in 
these plaques. The authors suggested that this inverse relationship between miRNA-181b and Notch1 
might constitute a protective mechanism against the development of obesity-induced atherosclerosis 
(Sun et al., 2019).  
 
Figure 2.10: Differential expression of four miRNAs have been implicated in obesity and progression to 
or established type II diabetes in various tissue and cell types. 
Four miRNAs (miR-194, -210, -424/322, and -181b) show differential expression in obesity and related type II diabetes 
in various tissue and cell types, which have in turn been linked with metabolic abnormalities or, at least, adaptive 
mechanisms against the development of metabolic abnormalities. Figure designed in Microsoft PowerPoint Office 365 





Taken together, the abnormal behaviour of four miRNAs have been implicated in obesity and related 
metabolic complications, which have in turn been associated with reduced or deficient ATM protein 
levels. Therefore, the potential pathological regulation of ATM protein levels by these four miRNAs 
during obesity needs to be explored.   
2.5. Concluding remarks, the main study aim, and study objectives 
Obesity constitutes a global health risk and is associated with metabolic derangements in various 
organs that ultimately lead to the development of diseases such as type II diabetes and cardiovascular 
dysfunction. As a result, the link between obesity and the establishment of peripheral metabolic 
malfunction has enjoyed extensive research. Obesity is a complex systemic disease due to the 
endocrine function of WAT, which becomes altered during obesity progression. Furthermore, it is 
suggested that the pathology associated with obesity correlates with the accumulation of visceral 
adiposity, indicating a metabolic distinction between the two fat depots.  
An interesting observation that has been observed in obesity and insulin resistance is the reduction in 
protein levels of ATM, a kinase central to the insulin and redox signalling networks, in peripheral 
tissue (Halaby et al., 2008; Huisamen et al., 2016). However, the respective effects of subcutaneous 
and visceral obesity on, as well as the underlying mechanism of, reduced peripheral ATM levels are 
unknown. Even though a miRNA-mediated mechanism for the suppression of ATM protein levels 
has been described in cancer cells, studies investigating its posttranscriptional regulation under 
chronic metabolic stress remain lacking. Therefore, the current study aimed to investigate whether 
adipocyte secretions influence cardiac ATM protein levels in obesity, as previously observed in vivo 
in our laboratory (Huisamen et al., 2016), potentially through a miRNA-mediated mechanism using 
an in vitro cardiomyoblast model. The objectives of the study are as follow:  
Objective 1 
To establish a suitable in vitro cardiomyoblast model that is metabolically sensitive to the effects of 
obesity. This objective entails the prolonged exposure of H9c2 cardiomyoblasts to high 
concentrations of nutrients (glucose and FFAs) and/or insulin to investigate the effects on i) cell 
viability by means of an MTT assay, ii) the total and phosphorylated levels of metabolic proteins 
(ATM, PKB, mTORC1, S6K and AMPK) through Western blot analysis, and iii) the expression 
levels of two miRNAs (miR-421 and miR-18a) that regulate ATM protein levels in cancer cells with 
quantitative real-time polymerase chain reaction (qRT-PCR). This objective is important to establish 
whether the obese-simulating treatments can influence metabolic protein expression and miRNA 






Objective 2  
To investigate the basal metabolic protein profiles of adipocytes differentiated from primary ASCs 
originating from the visceral and subcutaneous fat depots harvested from lean and high-fat diet (HFD) 
rats. More specifically, the total and phosphorylated levels of several metabolic proteins (ATM, 
mTORC1, S6K, PKB, AMPK, and ACC) will be analysed through Western blot analysis. This 
objective is important to shed some light on whether adipocytes originating from two different fat 
depots (subcutaneous and visceral) and dietary backgrounds (control and HFD) display differential 
basal metabolic profiles.  
Objective 3 
To determine the respective effects of subcutaneous and visceral adipocyte secretions, under normal 
and HFD conditions, on the total and phosphorylated levels of various metabolic proteins (ATM, 
AMPK, mTORC1 and PKB), as well as the expression levels of six miRNAs (miR-421, miR-18a, 
miR-194, miR-210, miR-322 and miR-181b) in H9c2 cardiomyoblasts through Western blot analysis 
and qRT-PCR, respectively. This objective involves the treatment of H9c2 cells with conditioned 
media (CM) derived from the ASCs and their adipocyte counterparts originating from the 
subcutaneous and visceral fat depots of control and HFD rats (refer to objective 2), followed by the 
protein and miRNA quantification analyses. Lastly, the FFA composition of the respective CM will 
be analysed through gas chromatography-flame ionisation detection (GC-FID) by Dr P. van Jaarsveld 
at the South African Medical Research Council (SAMRC) to investigate the secretory profiles of the 





Chapter 3  
Materials and Methods 
3.1. Cell culture 
This study used H9c2(2-1) cardiomyoblasts, an embryonic rat ventricular-derived cell line (Kimes 
and Brandt, 1976), as an in vitro model to investigate the effects of obesity on cardiac metabolism. 
The H9c2 cells were generously gifted by the Department of Physiology, Stellenbosch University 
(originally obtained from the ATCC® CRL-1446™). This cell line was selected for its ease of use 
and phenotypical homogeneity, which is important for the generation of consistent and reproducible 
results. 
Reagents 
H9c2 cells were grown in complete Dulbecco’s Modified Eagle Medium (DMEM) growth medium, 
which consisted of high glucose DMEM (4.5 g/l, Lonza™ BioWhittaker™, 12-604F) supplemented 
with 10% foetal bovine serum (Capricorn, Biocom Biotech, FBS-GI-12A or Hyclone, SV30160.03) 
and 1% Penicillin-Streptomycin (Sigma-Aldrich, P4333). A 10x dilution of 2.5% Trypsin from Gibco 
(15090-046) was used to detach cells from the cell culture plate during passaging. Chemicals used 
for phosphate-buffered saline (PBS) solution (137 mM NaCl, 2.7 mM KCl, 10 mM Na₂HPO₄, 1.8 
mM KH₂PO₄; pH 7.4) were purchased from Sigma-Aldrich and Merck. 
Method 
H9c2 cardiomyoblasts were cultured in accordance with the ATCC® guidelines in a sterile 
environment. Freezer cultures (previously prepared with 10% dimethyl sulfoxide and complete 
DMEM media that were stored in the vapour phase of liquid nitrogen) were thawed and plated in 100 
mm culture dishes containing complete growth medium. Live cells were adherent to the surface of 
the culture dish, therefore no attachment factor was necessary. Adherent cells were allowed to grow 
in a humidified incubator (Shel Lab CO₂ Incubator) containing 5% carbon dioxide at 37°C. Sub-
confluent (80-90%) cells were passaged every third day in a 1:3 ratio. For experimental seeding, cells 
were washed with pre-heated PBS solution, detached form the culture dish surface using 0.25% 
Trypsin-PBS, and centrifuged (Heraeus Megafuge 16R centrifuge, Thermo Fisher Scientific) at 92 
xg at 4°C for 4 minutes. The resulting cell pellets were resuspended in complete growth medium, 
counted using Trypan-blue for dead cell detection on the Countess™ II Automated Cell Counter 





cells/ml) into new culture dishes for respective experiments (Table 3.1), which will be discussed in 
more detail in the sections to follow.  
Table 3.1: Summary of H9c2 cell experimental seeding concentrations, treatment conditions and 
subsequent analyses. 
 Passage Seeding 
concentration 
















A 17 No cell count 
performed 
100 mm Insulin n=2-3 n=1 Western blot 
B Ranging 
from 17 to 
19 
5 to 7.5 x 105 100 mm FFAs, 
glucose, 
insulin 
n=3 n=3 Western blot 
C Ranging 
from 17 to 
19 







from 14 to 
18 




from 14 to 
18 
1 x 105 35 mm CM n=3 
(pooled) 
n=4 per diet 
group 
qRT-PCR 





n=3 n=1 MTT viability 
assay 
 
Following seeding, H9c2 cells were allowed to adhere to the culture dish surface for at least 24 hours, 
where after the complete DMEM media were replaced with the respective treatment media. 
3.2. Treatment preparation and administration 
The effect of obesity on cardiac metabolism was investigated by exposing H9c2 cells to different 
treatment conditions in two distinct sets of experiments. Firstly, H9c2 cells were treated with different 
combinations of high FFAs (palmitic acid and oleic acid), glucose and insulin. Secondly, H9c2 cells 
were treated with adipose-derived CM.  
3.2.1. Free fatty acids (FFAs), glucose and insulin 
In order to establish whether H9c2 cells represent an appropriate in vitro model to study the metabolic 
effects of obesity on the heart, we investigated whether the cell line is metabolically sensitive to high 






The palmitic acid (P0500, lot SLBJ3703V) and oleic acid (O1008, lot 0000032783) were purchased 
from Sigma-Aldrich. The anhydrous D(+)-glucose (108337, lot K49652937813) and ethanol absolute 
(107017) were purchased from Merck. The Humulin®R insulin (regular biosynthetic human insulin, 
Eli Lilly (S.A.) (Pty) Ltd, HI0210) was purchased commercially on prescription.  
Method 
In an initial optimisation experiment (Table 3.1 A), H9c2 cells were treated with complete DMEM 
media supplemented with 100 nM insulin for 15 minutes (acute exposure) and 24 hours (chronic 
exposure), respectively. 
Alternatively, H9c2 cells were treated with various combinations of nutrients and/or insulin for 24 
hours (Table 3.1 B and C). Treatment media consisted of complete DMEM media supplemented with 
either i) 0.2% ethanol (vehicle control), ii) 0.1 mM palmitic acid and 0.1 mM oleic acid, iii) 0.1 mM 
palmitic acid, 0.1 mM oleic acid and 5.5 mM glucose (DMEM contains 25 mM glucose; final 
concentration of 30.5 mM glucose), iv) 100 nM insulin, or v) 100 nM insulin, 0.1 mM palmitic acid 
and 0.1 mM oleic acid. The treatment duration and concentrations for palmitic acid and oleic acid 
(Wang et al., 2009; Nobuhara et al., 2013), glucose (Cai et al., 2002; Wang et al., 2009; Hu et al., 
2016) and insulin (Ha and Pak, 2005) were based on previous studies and have been optimised in our 
laboratory. The palmitic acid and oleic acid were dissolved in ethanol in a stock solution of 100 mM, 
respectively. FFAs oxidise readily, therefore the palmitic acid stock solution was prepared on the day 
of treatment, whereas aliquots of the oleic acid stock solution were exposed to nitrogen gas to displace 
the oxygen and stored at -20°C for use on experimental days. FFAs are light-sensitive, therefore care 
was taken to conceal the stock solutions with aluminium foil. Prior to treatment, the palmitic acid 
stock was heated to 37°C to ensure proper dissolution, whereas the oleic acid stock aliquot was 
allowed to thaw to room temperature. The combination of palmitic acid and oleic acid will herewith 
be referred to as the FFA treatment. Prior to treatment, glucose and insulin were directly dissolved in 
complete growth medium.  
Following the treatment duration, cells were prepared for either Western blotting (protein 
quantification) or qRT-PCR (miRNA quantification) purposes (detail provided in sections 3.4 
Western blot analysis and 3.5 Total RNA isolation and cDNA synthesis). To avoid performing 
these subsequent analyses simultaneously, the qRT-PCR cells were treated 24 hours after seeding, 
whereas the Western blot cells were treated 48 hours after seeding. An experimental timeline is 






Figure 3.1: Experimental timeline for H9c2 cardiomyoblasts treated with nutrients and/or insulin. 
H9c2 cells were treated with complete DMEM media supplemented with either i) 0.1 mM palmitic acid & 0.1 mM oleic 
acid, ii) 0.1 mM palmitic acid & 0.1 mM oleic acid & 5.5 mM glucose (final concentration of 30.5 mM), iii) 100 nM 
insulin, or iv) 100 nM insulin & 0.1 mM palmitic acid & 0.1 mM oleic acid for 24 hours and compared to a vehicle control 
(0.2% ethanol). Following treatment, cells were prepared for Western blotting (protein expression) and qRT-PCR 
(miRNA expression) analyses, respectively. To avoid conducting these down-stream analyses simultaneously, a staggered 
approach was followed where the cells intended for qRT-PCR analysis were treated 24 hours after seeding, while cells 
intended for Western blotting were treated 48 hours after seeding.  
3.2.2. Adipose-derived conditioned media (CM) 
To further investigate whether H9c2 cells are metabolically sensitive to subcutaneous and visceral 
adipocyte secretions, respectively, H9c2 cells were exposed to CM derived from adipose cells 
originating from both fat depots under control and HFD conditions.  
The CM used to treat the H9c2 cells (Table 3.1 D and E) were derived from ASCs, as well as their 
differentiated adipocyte counterparts, that were originally harvested from the subcutaneous (SC) and 
peri-renal (PR; representative of the visceral fat depot) fat depots from control (normal standard 
chow; n=4) and HFD (n=4) male Wistar rats. For diet compositions, see Appendix A Table A1. 
Ethical approval was obtained from the Stellenbosch University Research Ethics Committee: Animal 
Care and Use (ethical clearance number ACU-2018-6786). The feeding and maintenance of the rats, 
isolation of the ASCs, culturing of the ASCs, and in vitro differentiation of the ASCs to adipocytes 






After a subset of the isolated ASCs had been differentiated to mature adipocytes by Dr H. Sadie-van 
Gijsen (refer to Appendix A), the complete growth media were aspirated from the ASCs (technical 
n=4) and their differentiated adipocyte counterparts (technical n=4). The cells were washed with pre-
heated PBS and fresh complete growth media were placed onto the cells for 24 hours. During this 
period, the cells were maintained in a humidified incubator containing 5% carbon dioxide at 37°C. 
Thereafter, the complete growth media, now referred to as CM, were collected. The CM collected 
from the four technical repeats of ASCs and adipocytes were pooled, respectively, and stored at -
80°C for future use i) as treatment for H9c2 cells and ii) for gas chromatography-flame ionisation 
detection (GC-FID) analysis of the FFA composition. The collection of the CM is summarised in 
Figure 3.2.  
 
Figure 3.2: Schematic of adipose-derived CM harvested from a particular fat depot (SC and PR) from a 
particular rat (control and HFD). 
50 ml Falcon tubes containing 40 ml each of conditioned medium (CM) harvested from the subcutaneous adipose stem 
cells (SC ASCs), subcutaneous adipocytes (SC Adipo), peri-renal adipose stem cells (PR ASCs) and peri-renal adipocytes 
(PR Adipo) were obtained per rat per diet group (control and high-fat) and stored at -80°C. 
H9c2 cells were treated with the respective CM for 24 hours. Prior to treatment, the respective CM 
were thawed and allowed to reach 37°C. To account for the fact that the complete DMEM media 





prior to collection, we included an H9c2 control group that was treated with complete DMEM media 
24 hours before the CM were administered to the rest of the H9c2 groups. Similar to the previous set 
of experiments, the H9c2 cells for qRT-PCR purposes were treated 24 hours after seeding, whereas 
the H9c2 cells for Western blotting purposes were treated 48 hours after seeding, to avoid performing 
these subsequent analyses simultaneously. An experimental timeline is provided in Figure 3.3. 
 
Figure 3.3: Experimental timeline for H9c2 cardiomyoblasts treated with adipose-derived CM. 
H9c2 cells were treated with conditioned media (CM) harvested from i) subcutaneous adipose stem cells (SC ASCs), ii) 
subcutaneous adipocytes (SC Adipo), iii) peri-renal adipose stem cells (PR ASCs), and iv) peri-renal adipocytes (PR 
Adipo) for 24 hours and compared to a DMEM control. Following treatment, cells were prepared for Western blotting 
(protein expression) and qRT-PCR (miRNA expression) analyses, respectively. To avoid conducting these down-stream 
analyses simultaneously, a staggered approach was followed where the cells intended for qRT-PCR analysis were treated 
24 hours after seeding, while cells intended for Western blotting were treated 48 hours after seeding.  
3.3. MTT viability assay 
A 3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide (MTT) colorimetric assay was 
used to quantitatively determine cell viability of H9c2 cells treated with combinations of FFAs, 
glucose and insulin (refer to section 3.2.1 Fatty acids, glucose and insulin). Briefly, the assay relies 
on a mitochondrial enzyme, succinate dehydrogenase, to catalyse the conversion of soluble 
tetrazolium salt to insoluble formazan crystals within live cells (Mosmann, 1983). The absorbance of 
the formazan crystals is directly proportional to mitochondrial function and, therefore, cell viability.   
Reagents 
The thiazolyl blue tetrazolium bromide (MTT) powder (M5655) and dimethyl sulfoxide (DMSO; 





with Calcium and Magnesium was purchased from Lonza™ (BioWhittaker™, 17-513F). The 
chemicals used for the Sorenson’s glycine buffer (0.1 M glycine, 0.1 M NaCl; pH 10.5) were 
purchased from Merck. 
Method 
H9c2 cells were cultured as described previously (section 3.1 Cell culture) and seeded into a 24-well 
plate at a seeding concentration of 2 x 104 live cells per plate (Table 3.1 F). Cells were allowed to 
adhere to the surface for at least 24 hours, where after cells were treated with combinations of FFAs, 
glucose and insulin (refer to section 3.2.1 Free fatty acids (FFAs), glucose and insulin) in triplicate 
for 24 hours. A complete DMEM media condition (DMEM control) and complete DMEM 
supplemented with 0.2% ethanol (vehicle control) were included. After 24 hours, the treatment media 
were aspirated, cells were washed with 500 μl of pre-heated DPBS, and 500 μl of pre-heated MTT 
solution (2 mg/ml DPBS) was placed into each well. As the MTT is light-sensitive, the 24-well plate 
was covered with aluminium foil and allowed to incubate for 2 hours at 37°C. After incubation, the 
MTT solution was aspirated and 50 μl of room temperature Sorenson’s glycine buffer, followed by 
400 μl of DMSO, were added to each well. The 24-well plate was once again covered with foil and 
incubated for 30 minutes. The buffer terminated the enzymatic reaction, whereas the DMSO served 
as an organic solvent for the water-insoluble formazan crystals. Following the second incubation, the 
absorbance of the formazan crystals was measured at 570 nm using a FLUOstar® Omega BMG 
LABTECH microplate reader (refer to Appendix B Figure B1 for absorbance measurements).      
3.4. Western blot analysis 
The total and phosphorylated levels of the metabolic proteins of interest were quantified using 
Western blotting (Towbin, Staehelin and Gordon, 1979), an immunodetection technique based on the 
separation of individual proteins in a sample lysate according to size.  
3.4.1. Protein lysate preparation 
To analyse the total and phosphorylated levels of individual intracellular proteins, cells have to be 
lysed in order to release its protein content. This is achieved with a specific lysis buffer containing 
chemicals that solubilise cellular membranes, as well as enzymes (protease and phosphatase 
inhibitors) that protect cellular proteins from degradation by proteases and dephosphorylation by 
phosphatases. We were interested in the proteins contained within the cytoplasm, therefore a lysis 






The bovine serum albumin (BSA) used for the standard curve was purchased from Sigma-Aldrich. 
The Bradford solution (0.12 mM Coomassie Brilliant Blue, 4.75% ethanol, 8.5% phosphoric acid) 
was prepared in-house with chemicals purchased from Sigma-Aldrich or Merck. Reagents for the 
lysis buffer used for cytoplasmic protein extraction and the 3x Laemmli sample buffer are 
summarised in Table 3.2 and Table 3.3, respectively.  
Table 3.2: Lysis buffer components. 
Reagent Final 
concentration 
Function Supplier Product 
code 
Tris-HCl 










EDTA 0.01 mM Mg2+/Mn2+-
metalloprotease inhibitor 
Sigma-Aldrich EDS 
NaCl 22.5 mM Buffering salt Merck 106404 
Na3VO4 0.1 mM Tyrosine phosphatase 
inhibitor 
Sigma-Aldrich S6508 









(dissolved in DMSO) 
0.3 mM Serine/Cysteine 
protease inhibitor 
Sigma-Aldrich P7626 










*DMSO: dimethyl sulfoxide; EDTA: ethylenediaminetetraacetic acid; EGTA: egtazic acid; PMSF: 
phenylmethylsulfonyl fluoride 
Table 3.3: 3x Laemmli sample buffer components. 
Reagent Final 
concentration 
Function Supplier Product 
code 
SDS 4% Denatures proteins & gives 
each an overall negative 
charge 
Sigma-Aldrich 74255 
Glycerol 20% Weighs samples down in 
gel wells 
Sigma-Aldrich G5516 
Bromophenol blue 0.004% Colour agent to show front 
of sample separation 
Sigma-Aldrich B8026 
Tris-HCl (pH 6.8) 0.125 M Buffering salt Merck 108382 
2-mercaptoethanol 
(add before use) 
10% Denatures proteins & 
prevents oxidation of 
cysteine residues 
Sigma-Aldrich M6250 






Following the removal of the treatment media from H9c2 cells and the CM from adipose-derived 
ASCs and differentiated adipocytes, cells were washed with pre-heated PBS. Cells were subsequently 
scraped from the culture dish surface in 10 ml fresh PBS and centrifuged (Sigma 1-14) at 92 xg for 4 
minutes at 4°C. The PBS solution was aspirated from the cell pellets, which were resuspended in 400 
μl ice-cold lysis buffer. In the case where protein lysates were not directly prepared following this 
step, the pellets were stored in lysis buffer at -80°C until the protein lysate preparation could 
commence. Otherwise, the resuspended pellets were transferred to 1.5 ml Eppendorf tubes containing 
equal amounts of 0.5 mm Zirconium Oxide beads (Next Advance, Biocom Biotech). Cell pellets were 
homogenised using a BulletBlender™ at 4°C in three consecutive cycles of 1 minute runs (level 4), 
followed by 5 minute rests after each homogenisation step. The homogenised samples were allowed 
to rest on ice for 20 minutes, where after the samples were centrifuged at 12 074 xg for 20 minutes at 
4°C. Cellular membrane debris and nuclei trapped within the resulting pellet were discarded, while 
the supernatant containing the cytoplasmic proteins were retrieved and transferred to new Eppendorf 
tubes. The supernatant from this step will hereafter be referred to as the lysate stock samples, which 
were stored at -80°C until use.  
The protein concentrations within each lysate stock sample were determined using the Bradford 
method (Bradford, 1976) and compared to a standard BSA dilution series (in duplicate). Briefly, a 
10x dilution with distilled water was prepared from each lysate stock sample in a final volume of 100 
μl, followed by a duplicated second 10x dilution of the first dilution in a final volume of 100 μl. Next, 
900 μl of diluted (5x with distilled water) and twice-filtered Bradford solution was added to each of 
the duplicated BSA standard dilutions and second dilutions of the lysate stock samples. To allow for 
proper binding of the Coomassie Brilliant Blue dye within the Bradford solution to the proteins within 
each sample, the samples were left for 15 minutes at room temperature. The absorption measures of 
each duplicate standard and lysate stock sample were noted using the SPECTRONIC® 20 
GENESYS™ or Libra S4+ spectrophotometer at a wavelength of 595 nm, which is the absorption 
maximum of protein-bound dye. Therefore, the absorbance is directly proportional to the amount of 
protein within each sample. Duplicate absorbance values were averaged, and a linear equation for the 
known protein concentrations of the BSA standard was used to calculate the unknown protein 
concentrations within the lysate stock samples.  
Lastly, the protein lysates were prepared for gel loading using Laemmli sample buffer (Laemmli, 
1970). In a fresh Eppendorf tube, a calculated volume of each lysate stock sample equal to the same 
amount (μg) of protein were added to Laemmli sample buffer (volume equal to 1/3 of the final 





lysates were boiled for 4 minutes to ensure proper unfolding of sample proteins and stored at -80°C 
until gel separation could commence.  
3.4.2. Protein separation and transfer 
Reagents 
Chemicals for hand-casted polyacrylamide running gels (0.5% 2,2,2-trichloroethanol, 0.375 M Tris-
HCl [pH 8.8], 0.1% SDS, 7.5% acrylamide, 0.05% APS, 0.2% TEMED) and stack gels (0.127 M 
Tris-HCl [pH 6.8], 0.1% SDS, 4% acrylamide, 0.1% APS, 0.2% TEMED) were purchased from 
Sigma-Aldrich or Merck, and pre-casted 26-well Criterion™ TGX Stain-Free™ gels (4-20% 
gradient, Bio-Rad Laboratories, Inc) were purchased from Lasec. Chemicals used for 10x running 
buffer (250 mM Tris, 1920 mM glycine, 1% SDS) and a modified 1x transfer buffer (25 mM Tris, 
192 mM glycine, 10% [v/v] methanol) were purchased from Sigma-Aldrich or Merck. 
Method 
All protein lysates were thawed on ice and boiled once more for 4 minutes prior to gel loading to 
ensure proper unfolding of proteins. Protein lysates were loaded into either 10- or 15-well hand-casted 
polyacrylamide gels or pre-casted 26-well Criterion™ TGX Stain-Free™ gels. Either the HiMark™ 
Pre-stained Protein Standard ladder (31-460 kDa range), Precision Plus Protein™ Dual Xtra 
Standards ladder (2-250 kDa range) or PageRuler™ Pre-stained Protein Ladder (10-180 kDa range) 
was loaded in the first lane as a marker for molecular weight determination. Tanks were filled with 
1x running buffer and the loaded gels were subjected to sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE), which separated the proteins according to molecular weight. The hand-
casted gels were subjected to an initial 100 V and 200 mA for 10 minutes, followed by 200 V and 
200 mA for 60 minutes. The pre-casted Criterion™ TGX Stain-Free™ gels were subjected to 200 V 
and 200 mA for 60 minutes. Thereafter, gels were activated and visualised using the ChemiDoc™ 
MP Imaging System (Bio-Rad Laboratories, Inc.) to establish equal loading and separation of 
proteins. In short, a stain-free tri-halo compound (2,2,2-trichloroethanol, Sigma-Aldrich, T54801) 
was incorporated into the gels that catalyses a reaction with the tryptophan residues of the sample 
proteins in response to ultra-violet (UV) irradiation, which can be detected and imaged by the 
ChemiDoc™ system. Next, tanks were filled with ice-cold transfer buffer and the proteins were 
transferred from the gels to polyvinylidene fluoride (PVDF) membranes (Immobilon-P Transfer 
Membrane, 0.45 μm pore size, Merck) that have been briefly soaked in methanol and ice-cold transfer 
buffer. The hand-casted gels were subjected to 200 V and 200 mA for 90 minutes, whereas the pre-





Following protein transfer, membranes were visualised and imaged using the ChemiDoc™ system to 
ensure the successful transfer of proteins. The stain-free membrane images (available in Appendices 
B, C and D) were stored for later use during protein normalisation. Membranes were submerged in 
methanol for 30 seconds to fix the proteins to the membrane. 
3.4.3. Immunodetection of target proteins  
Reagents 
Chemicals for 10x Tris-buffered saline (TBS) solution (1.37 M NaCl, 200 mM Tris; pH 7.6) were 
purchased from Merck. Tween® 20 was purchased from Sigma-Aldrich (P1379). The SignalBoost™ 
solutions for primary antibodies (KP31812) and secondary antibodies (KP31855) were purchased 
from Merck. 
Method 
Membranes were blocked with a mixture containing 5% fat-free milk in 1x TBS-Tween (TBS-T; 10% 
TBS and 1% Tween) for 2 hours at room temperature to prevent non-specific background binding of 
antibodies. Membranes were subsequently washed with TBS-T for three 5 minute cycles and cut at 
locations above and below the protein of interest. Membrane pieces were individually incubated in 
primary rabbit antibodies (optimised concentrations listed in Table 3.4) on a shaker at 4°C overnight. 
This step allowed for the specific binding of the primary antibody to the protein of interest. Following 
primary incubation, membrane pieces were washed with TBS-T and incubated in an anti-rabbit 
immunoglobulin G, horseradish peroxidase (HRP)-conjugated secondary antibody (Cell Signaling 
Technology, 7074; optimised concentrations listed in Table 3.4) on a shaker at room temperature for 
1 hour. This step allowed for the binding of the secondary antibody to the primary antibody. 
Following secondary incubation, membrane pieces were washed with TBS-T and submerged in 
Clarity™ enhanced chemiluminescence (ECL) reagent (Bio-Rad Technologies, Inc.) for 5 minutes 
before a chemiluminescent signal was detected using the ChemiDoc™ system. In short, when the 
HRP-linked secondary antibody reacts with the ECL, energy is emitted in the form of light. The light 
is captured by the CCD camera of the ChemiDoc™ and translated into pixels on an image. The signal 
is proportional to the number of pixels, which in turn relates to the amount of protein, and can 















Supplier Product code 
(lot) 
Dilution 







13 hours CST 5883 (6) 1:4000 
secondary SB 





1:1000 TBS-T 16 hours CST 2971 (20) 1:4000 TBS-T 
t-ACC1,2 260,280 1:500 TBS-T 16 hours CST 3662 (4) 1:4000 TBS-T 
p-ACC1,2 
(ser79) 
1:500 TBS-T 16 hours CST 3661 (9) 1:4000 TBS-T 
t-AMPK 62 1:1000 TBS-T 16 hours CST 2532 (19) 1:4000 TBS-T 
p-AMPKα 
(thr172) 
1:1000 TBS-T 16 hours CST 2535 (21) 1:4000 TBS-T 
t-PKB 56 1:1000 TBS-T 16 hours CST 9272 (28) 1:4000 TBS-T 
p-PKB 
(ser473) 
1:500 TBS-T 16 hours CST 4060 (25) 1:4000 
secondary SB 
*CST: Cell Signaling Technology; p: phospho; t: total; SB: SignalBoost™ 
3.4.4. Protein normalisation  
Target protein signals were normalised to the total protein transferred to the membranes to determine 
biological differences in total and phosphorylated levels across the various treatment conditions. This 
reliable and rapid Stain-Free-based normalisation method considers all the proteins contained within 
a sample (Gürtler et al., 2013), which negates the use of a house-keeping protein. Automated total 
protein normalisation using the stain-free membrane blot was performed in Image Lab™ (version 
6.0.1, Bio-Rad Technology Inc.), which generated a normalised raw pixel intensity per 
chemiluminescent protein band. Raw pixel intensity data were inserted into a Microsoft Excel 
spreadsheet, where the pixel intensities corresponding to each treatment sample were calculated as a 
fold-change of the mean pixel intensity of the control samples or another designated group (in the 
case where no control group is present).     
3.5. Total RNA extraction and cDNA synthesis 
In order to quantify the levels of target miRNAs through qRT-PCR, the total RNA was extracted 
(mirVana™ miRNA Isolation Kit, with acid-phenol:chloroform, Invitrogen™, Thermo Fisher 
Scientific) from the treated H9c2 cells (described in section 3.2 Treatment preparation and 





miRNA cDNA Synthesis Kit, Applied Biosystems™, Thermo Fisher Scientific). The latter is an 
important step in stabilising the RNA, as single-stranded RNA sequences are highly susceptible to 
degradation, whereas double-stranded cDNA is more robust and can be stored for up to two months 
at -20°C. 
Reagents 
Nuclease-free water was purchased from Qiagen and pure ethanol was purchased from Sigma-Aldrich 
(E7023).  
Method  
Following each treatment duration, the treatment media (refer to section 3.2 Treatment preparation 
and administration) were aspirated and the H9c2 cells were washed with pre-heated PBS. Cells 
within each culture dish were lysed using 100 μl of ice-cold lysis buffer (Lysis/Binding Buffer, 
component of isolation kit) and scraped from the dish surface. The scraped cells from each respective 
treatment condition were pooled in 1.5 ml Eppendorf tubes. The total RNA from each pooled sample 
was extracted as per the manufacturer’s instructions. Briefly, the isolation kit is designed to extract 
high concentrations of ultra-pure RNA molecules, including RNAs as small as 10 nucleotides, by 
employing a combination of chemical (organic) and solid-phase extraction. The first step, the organic 
extraction, relies on the use of chaotropic salts, together with acid-phenol-chloroform, to prevent 
RNA degradation and to purify RNA molecules from any other biological molecules within the cell 
lysate (Chomczynski and Sacchi, 1987). This entails phase separation through centrifugation to 
ensure that the hydrophilic RNA remains in the upper aqueous phase, whereas other hydrophobic 
biomolecules are trapped within the bottom organic phase. The RNA-containing aqueous phase is 
retrieved and subjected to alcohol precipitation to desalt the RNA. The second step, the solid-phase 
extraction, relies on the ability of the alcohol to promote the affinity of RNA molecules for silica 
(Boom et al., 1990), or in this case the glass-fibre filters (component of the kit). A series of washing 
and filtration steps using the Eppendorf Centrifuge 5410 completed the isolation process, and the 
resultant RNA molecules were eluted in pre-heated (95°C) nuclease-free water. 
The RNA concentration and purity were subsequently determined with the microvolume 
NanoDrop™ 2000c spectrophotometer (Thermo Fisher Scientific), which employed absorbance 
measurements. In addition to determining RNA concentration within a sample, which is directly 
proportional to its absorbance (Schmid, 2001), the spectrophotometer generates absorbance ratios as 
indicators of RNA purity. Various biomolecules absorb UV light at different wavelengths. The 
absorbance maxima of nucleic acids and proteins are at 260 and 280 nm, respectively. Therefore, a 





approximately 2.0 considered pure for RNA samples (Desjardins and Conklin, 2010). Furthermore, 
other organic compounds that typically contaminate RNA samples have absorbance maxima at 230 
nm. Therefore, a 260/230 ratio was used as an indicator of organic contamination, with ratios ranging 
between 1.8 and 2.2 considered pure for RNA samples (Desjardins and Conklin, 2010). Refer to 
Appendix B (Table B1) and Appendix D (Table D1) for RNA concentrations and absorbance ratios 
of H9c2 cells treated with nutrients and/or insulin and CM, respectively.  
Even though RNA purity could be established with absorbance ratios generated by the NanoDrop™ 
spectrophotometer, RNA integrity had to be assessed to ensure the success of the downstream 
applications. This was performed with an Agilent 2100 Bioanalyzer, a service provided by the DNA 
Sequencer Unit of the Central Analytical Facility, Stellenbosch University. In short, a small volume 
of sample is separated on a gel through electrophoresis and subjected to a fluorescent dye that 
intercalates with the RNA sequences. The fluorescent signal is detected and translated into peaks on 
electropherograms, which is used to calculate an RNA Integrity Number (RIN) for each sample. The 
allocated RIN serves as a measure of RNA quality and ranges on a scale of 1 (low integrity) to 10 
(high integrity) (Schroeder et al., 2006). Twelve randomised RNA samples generated from H9c2 cells 
treated with adipose-derived CM in different experiments were selected and 2.5 μl of each sample 
was stored separately at -80°C for quality evaluation (see Appendix D Figure D5 for RIN 
allocations).   
RNA does not serve as a suitable template for qRT-PCR for two reasons: RNA is highly susceptible 
to RNase-facilitated degradation and qRT-PCR relies on the function of a DNA polymerase. 
Consequently, the RNA sequences were reverse transcribed to cDNA through a series of enzymatic 
processes during various heating-cooling cycles using the GeneAmp® PCR System 2700 thermal 
cycler (Applied Biosystems) as outlined in the manufacturer’s protocol. Briefly, the total RNA was 
diluted to an input concentration of 5 ng/μl in a final volume of 2 μl. The first process, 
polyadenylation, involved the addition of a 3’-adenosine tail to each RNA strand. The second process, 
adaptor ligation, occurred at the 5’-end of the RNA strands where an adaptor is attached. These 
extensions serve as the binding sites for the reverse- and forward-primers involved in the subsequent 
processes. The third process, reverse transcription (RT), involves a universal RT primer that binds to 
the 3’-polyadenosine tail, which was added during the first process, in order to reverse transcribe the 
RNA sequence to form a DNA/RNA-hybrid molecule. The fourth and final process, amplification, is 
necessary to complement the DNA-portion of the hybrid molecule to form cDNA, and to amplify all 
the cDNA molecules present within the sample through the action of universal forward- and reverse-
primers. A non-template control (NTC) was also prepared. The NTC contained nuclease-free water 





and reagents. The resultant cDNA and NTC samples were stored at -20°C until qRT-PCR could 
commence. A simplified scheme of the total RNA extraction and cDNA synthesis processes is 
provided in Figure 3.4.    
 
Figure 3.4: Schematic of total RNA extraction and cDNA synthesis of H9c2 cardiomyoblasts following 
treatment. 
3.6. qRT-PCR 
PCR is a useful technique that amplifies specific DNA strands of interest for ultimate quantification. 
In this study, the employment of qRT-PCR using TaqMan™ Advanced miRNA Assays (Applied 
Biosystems™, Thermo Fisher Scientific) was particularly beneficial as it allows the use of RNA as 
template, provided it is reverse transcribed to cDNA. Using fluorescence-labelled primers (FAM™-
labelled TaqMan™ miRNA assays) that are specific for our target miRNA strands, it was possible to 
collect amplification data as the PCR process continued (i.e., in real time). To accompany the 
TaqMan™ Advanced reagents, we used 96-well MicroAmp® Optical Fast Blue Reaction Plates (Life 
Technologies™, Applied Biosystems™). 
Method 
Firstly, the cDNA templates were thawed on ice and amplification plots and standard curves (refer to 
Appendices B and D) for each primer were constructed by combining a small amount of each cDNA 





water) in duplicate (refer to standard curve qRT-PCR plate layouts in Appendix B Figure B7 and 
Appendix D Figure D6). This was necessary to ensure that i) each miRNA primer could generate a 
fluorescent signal that exceeded the signal threshold, ii) each miRNA primer met the efficiency 
criteria (discussed below), iii) the cDNA samples were diluted according to the most ideal dilution 
factor for the qRT-PCR reaction, and iv) the kit reagents were free of contaminants. For each 
amplification plot, the ∆Rn was plotted on the y-axis against the cycle number on the x-axis to 
represent the accumulation of product over time. The ∆Rn-value, or the normalised reporter value, 
represents the fluorescent signal of each experimental reaction normalised to the background signal 
produced by the instrument. The signal threshold refers to the ∆Rn-value at which the reaction 
fluorescence is considered a true signal. The Ct (threshold cycle)-value represents the cycle number 
at which a fluorescent signal exceeds the signal threshold and is inversely related to the amount of 
starting RNA. The maximum Ct-value was set at 35 PCR cycles, as samples with a Ct-value greater 
than 35 required too many cycles to accumulate to threshold. For each standard curve, the logarithm 
(log) of each known concentration factor in the dilution series were plotted on the y-axis against the 
corresponding Ct-value on the x-axis to allow for the assessment of reaction performance using 
several linear line parameters. For example, the slope is a measure of primer efficiency, with an 
optimal range of -3.58 to -3.10 corresponding to 90% to 110% efficiency, and the correlation 
coefficient (R2) is an indication of how well the data points fit the linear standard curve, with an 
optimal value as close to 1 as possible. 
Next, the cDNA templates were diluted (10x) with nuclease-free water. A PCR reaction mix for each 
target miRNA primer, as well as the endogenous control primer, were prepared as per the 
manufacturer’s protocol (primer information listed in Table 3.5). It was essential to include an 
endogenous control miRNA as a reference to reliably compare the relative expression of the target 
miRNAs and to minimise bias caused by experimental variation. The current study used U6 snRNA 
as a reference miRNA as it is commonly used in literature (Su et al., 2017; Kakimoto et al., 2018; 
Chen et al., 2019) and is stably expressed in H9c2 cells across various treatment conditions (refer to 
Appendix B Figure B12 and Appendix D Figure D15). The PCR reaction plates, with each well 
containing a primer-specific reaction mix and either a cDNA template, NTC or nuclease-free water 
in duplicate, were prepared and sealed with an optically-clear adhesive cover slip. The nuclease-free 
water was included as a second negative control (Neg) to ensure the purity of the reaction mix. The 
qRT-PCR plate layouts are illustrated in Appendix B Figure B11 and Appendix D Figure D14. The 
plates were inserted into the QuantStudio™ 7 Flex Real-Time PCR Instrument, 96-well FAST (Life 
Technologies™, Applied Biosystems™) for the amplification process to commence. Briefly, qRT-





steps: denaturation, annealing and elongation. With each cycle, the number of copies of a target 
template is doubled. Each primer (refer to Table 3.5) is labelled with a fluorescent reporter dye 
(FAM™). Once the primer anneals to its specific cDNA target, a DNA polymerase cleaves the dye 
during elongation to produce a fluorescent signal that is captured in real time by the QuantStudio™ 
RT-PCR instrument. The fluorescence is proportional to the number of target copies and is used for 
relative quantification of miRNA expression. 
Table 3.5: TaqMan™ Advanced miRNA primer information. 
microRNAs Sequence Assay ID Target species 
miR-194-3p CCAGUGGGGCUGCUGUUAUCU rno480975_mir Rat 
miR-322-5p CAGCAGCAAUUCAUGUUUUGGA rno481051_mir Rat 
miR-210-5p AGCCACUGCCCACAGCACACUG rno480994_mir Rat 
miR-181b-5p AACAUUCAUUGCUGUCGGUGGGU rno478583_mir Rat 
miR-18a-5p UAAGGUGCAUCUAGUGCAGAUAG rno480968_mir Rat 











To analyse the FFA composition of the adipose-derived CM, samples were subjected to GC-FID. The 
GC-FID analysis was kindly performed by Dr P. van Jaarsveld at the SAMRC.  
Gas chromatography (CG) is commonly used for the separation of various compounds within a 
sample mixture and is particularly advantageous due to the simplicity, sensitivity and efficiency of 
the analytical technique. Briefly, samples are introduced into a stream of a chemically inert carrier 
gas, usually helium, argon or nitrogen. This is referred to as the mobile phase. Liquid samples are 
then vaporised within a heated vaporisation chamber, and the gas stream containing the evaporated 
sample mixture is passed through a column that contains the stationary non-volatile phase. The 
components of the sample mixture pass through the column at velocities that are determined by their 
affinity for the stationary phase. Compounds that have a higher affinity for the stationary phase are 
slowed to a greater degree and are consequently separated from compounds with lower affinities. As 
compounds elute from the column, from lowest to highest affinity, they interact with a flame 
ionisation detector (FID). FID is highly suitable for the detection of volatile organic compounds that 
contain hydrocarbons, such as FFAs, however the major disadvantage is that the sample is destroyed 





at the location where the flame is produced, and a negative collector electrode situated above the 
flame. The column effluent is mixed with hydrogen and air and ignited. The combustion reaction 
releases mainly carbon ions from organic compounds, which generate an electrical current between 
the two electrodes that is proportional to the amount of compound that passes through the flame. The 
electrical current is measured by an electrometer and transmitted into an integrator for interpretation 
(information obtained from the Gas Chromatography and Flame Ionisation Detector application 
sheets, Linde Gases Division, Germany). The data are displayed as peaks on a graph, with the time 
of compound migration through the column on the x-axis and the area of the peak (indicating the 
amount of a specific compound) on the y-axis. 
3.8. Statistical analyses 
Briefly, the data generated from the various laboratory techniques required different processing to 
generate appropriate input data for statistical testing: 
For MTT viability assay analysis, the absorbance values were used to calculate a fold-change as a 
percentage relative to the DMEM control condition using Microsoft Excel.   
For Western blot analysis, the proteins of interest were normalised to the total protein transferred onto 
the stain-free membrane using Image Lab™ (version 6.0.1, Bio-Rad Technology Inc.). The 
automatically generated pixel densities were used to calculate a fold-change relative to a reference 
condition using Microsoft Excel.  
For qRT-PCR analysis, the delta-delta Ct (2-ΔΔCt)-method (Livak and Schmittgen, 2001) was 
employed to calculate the relative expression of a target miRNA normalised to U6 snRNA using 
Microsoft Excel. 
For GC-FID analysis, Dr P. van Jaarsveld kindly provided us with the FFA composition of each CM 
sample, which were expressed as either μg FFA per ml CM, or as a percentage of the total FFAs per 
ml CM.     
Using GraphPad Prism 5 software, an ordinary one-way Analysis of Variance (ANOVA) was 
employed where one variable between multiple groups were compared to determine whether a 
statistical difference existed between the various independent treatment groups or cell types, followed 
by a Bonferroni multiple-comparison test to correct for multiple testing and to determine whether 
there were significant differences between specific groups. For analyses where two variables were 
compared between multiple groups, a two-way ANOVA was employed, followed by a Bonferroni 
multiple-comparison test. For analyses where one variable between two groups were compared, a 





small to determine normality, therefore a normal distribution was assumed. Any difference between 
various group means were considered statistically significant if the probability value (p-value) was 






Figure 3.5: Schematic summary of study methods. Results of H9c2 cells treated with combinations of nutrients and insulin are discussed in Chapter 4; protein quantification 





Chapter 4  
Establishing a suitable in vitro cardiomyoblast model 
that is sensitive to the effects of obesity 
In order to investigate the potential metabolic effects of obesity on the heart, we first had to establish 
a suitable in vitro cardiomyoblast model. The H9c2 cardiomyoblast cell line is a well-known in vitro 
cardiac-derived model that has been extensively used as such throughout literature. Although H9c2 
cells share some phenotypical properties with skeletal muscle cells once confluency is reached 
(Kimes and Brandt, 1976), they also share similarities with isolated primary adult cardiomyocytes 
(Hescheler et al., 1991; Sipido and Marban, 1991). Therefore, we exposed H9c2 cells to various 
treatments that simulate obesity in order to investigate whether they are metabolically responsive. 
H9c2 cells were treated with combinations of high FFAs (palmitic acid and oleic acid), glucose and 
insulin for 24 hours to achieve a chronic obese effect as opposed to an acute nutrient response. 
Following the treatment period, we analysed H9c2 cell viability by performing an MTT assay, the 
total and phosphorylated levels of ATM and other metabolic proteins (PKB, mTORC1, S6K and 
AMPK) through Western blotting, and the expression levels of the two miRNAs (miR-421 and miR-
18a) that are known to regulate ATM protein levels in cancer cells with qRT-PCR.  
4.1. Prolonged exposure to combinations of excess nutrients and 
insulin appears to be non-lethal to H9c2 cells 
An MTT viability assay was performed after 24 hours of treatment with complete DMEM media 
supplemented with EtOH (0.2%; vehicle control), 0.2 mM FFAs, 0.2 mM FFAs with 5.5 mM glucose, 
100 nM insulin, and 100 nM insulin with 0.2 mM FFAs, respectively (Figure 4.1). The MTT assay 
was performed in a single experiment (biological n=1), with each treatment condition performed in 
triplicate (technical n=3). No statistical analysis was applied to the single biological replicate, and 
data are expressed as the mean percentage of viable cells ± SD relative to the untreated (complete 
DMEM medium-only, from herewith referred to as DMEM control) cells. 
There seemed to be no effect on cell viability across the different treatment conditions compared to 






Figure 4.1: Cell viability of H9c2 cardiomyoblasts treated with combinations of nutrients and insulin for 
24 hours. 
Percentage viability of H9c2 cells treated with combinations of 0.2 mM free fatty acids (FFA; palmitic and oleic), 5.5 
mM glucose (glu) and 100 nM insulin (ins), as well as a vehicle control (0.2% EtOH cnt), for 24 hours compared to a 
DMEM control. No differences in cell viability seemed to be observed (biological n=1; technical n=3; mean ± SD). 
4.2. Prolonged insulin stimulation appears to attenuate PKB 
phosphorylation in H9c2 cells 
To determine whether insulin resistance can be induced within H9c2 cardiomyoblasts, cells were 
subjected to 100 nM insulin for 15 minutes and 24 hours, respectively, to establish the acute and 
chronic effect on PKB phosphorylation. Following the treatment periods, the total PKB protein and 
phosphorylated (ser473) levels were determined through Western blot analysis. This experiment 
consisted of one biological replicate (n=1), where the DMEM control was analysed in duplicate 
(technical n=2) and the insulin treatments were analysed in triplicate (technical n=3). No statistical 
analysis was applied to the single biological replicate, and data are presented as the mean fold-change 
± SD relative to the DMEM control. 
Exposure to 15 minutes of insulin resulted in PKB phosphorylation compared to the DMEM control 
(5.35 ± 1.12 vs. 1 ± 0.21), whereas 24 hours of insulin stimulation did not result in PKB 






Figure 4.2: H9c2 cardiomyoblast insulin sensitivity following acute and chronic insulin stimulation. 
PKB total protein (t) and phosphorylation (p) levels in H9c2 cells following 100 nM insulin (ins) treatment for 15 minutes 
and 24 hours, respectively, compared to a DMEM control. PKB phosphorylation was observed in cells after 15 minutes 
of insulin stimulation, but not after 24 hours of insulin stimulation, compared to DMEM controls (technical n=2-3; 
biological n=1; normalised to total protein; mean ± SD). 
The binding of insulin to the transmembrane insulin receptor initiates a cascade of phosphorylation 
events that ultimately results in glucose uptake. PKB is an insulin-sensitive protein that is 
phosphorylated on certain amino acid residues for subsequent activation. Apart from threonine 308 
(thr308) phosphorylation by PDK1 (Alessi et al., 1997), PKB is phosphorylated on ser473 by the 
upstream kinase mTORC2 (Sarbassov et al., 2005) in response to insulin stimulation. This 
phosphorylation site has been used in literature as an indicator of intracellular insulin sensitivity (Coll 
et al., 2008; Kwon and Querfurth, 2015), and we were therefore able to utilise PKB ser473 
phosphorylation in H9c2 cells. Furthermore, it has been established that treatment of cells with a high 
concentration of insulin for 24 hours is sufficient to render cells insulin resistant (Ha and Pak, 2005), 
and the results shown in Figure 4.2 correspond with this observation.  
4.3. Prolonged exposure to a combination of excess insulin and free 
fatty acids might reduce ATM activity in H9c2 cells 
Following treatment of H9c2 cells with the various nutrient and insulin combinations for 24 hours, 
the total and phosphorylated levels of ATM, PKB, mTORC1, S6K and AMPK were determined 
through Western blot analysis. Experiments were performed in triplicate (biological n=3), with the 
vehicle (EtOH) control condition analysed in duplicate (technical n=2) and each treatment condition 
analysed in triplicate (technical n=3). The stain-free membranes used for ATM, mTORC1, S6K and 
AMPK protein quantification originated from 15-well polyacrylamide gels, where the sample lysates 
of the three individual experiments were unable to fit onto a single gel. No common control was 
included, thus the results of the three experiments were not pooled and are presented per experiment 





protein quantification data of ATM, mTORC1 and AMPK. 26-well Criterion™ TGX Stain-Free™ 
gels were used for PKB protein quantification, and common controls were included. Thus, the results 
of the three experiments were pooled. An ordinary one-way ANOVA was performed, followed by a 
Bonferroni post-hoc test. Results obtained for S6K could not be replicated and were excluded from 
the study. All data are presented as mean fold-change ± SD relative to the vehicle (EtOH) control. 
The p/t-ratio represents the phosphorylated protein as a fraction of the total protein and serves as an 
indicator of protein activity for all proteins analysed in these experiments.  
ATM total protein levels (Figure 4.3) did not seem to be influenced by the various treatment 
conditions compared to the vehicle control, however ATM activity (p/t-ratio) showed a decreased 
trend in H9c2 cells treated with a combination of FFAs and insulin compared to cells treated with 
insulin alone (experiment B; 0.35 ± 0.31 vs. 1.36 ± 0.07) and FFAs alone (experiment C; 0.33 ± 0.04 
vs. 1.19 ± 0.15).  
 
Figure 4.3: Total and phosphorylated levels of ATM in H9c2 cardiomyoblasts treated with combinations 





ATM total (t) and phosphorylated (p) levels in H9c2 cells treated with combinations of 0.2 mM free fatty acids (FFA; 
palmitic and oleic), 5.5 mM glucose (glu) and 100 nM insulin (ins) for 24 hours compared to a vehicle control (0.2% 
EtOH). ATM p/t-ratio showed a decreased trend in two of the three biological replicates (B and C) in cells treated with 
a combination of ins and FFA compared to cells treated with ins alone and FFA alone. Data are presented as three 
individual experiments (A, B and C; technical n=2-3; normalised to total protein; mean ± SD). 
ATM is an insulin-responsive protein kinase (Yang and Kastan, 2000), and its total protein levels are 
influenced under obese and insulin resistant conditions in vivo (Halaby et al., 2008; Huisamen et al., 
2016). In the current in vitro study, we observed an effect on ATM p/t-ratio in response to a 
combination of FFAs and insulin compared to FFAs or insulin, individually. These results suggest 
that ATM activity, but not its protein levels, might be down-regulated in H9c2 cells by high 
concentrations of insulin and intracellular FFAs. To confirm the uptake of FFAs by the H9c2 cells, 
we will have to analyse the intracellular FFA concentration with a technique such as Raman 
spectroscopy (Uematsu et al., 2020), which relies on the detection of molecular vibrations through 
laser light scattering.  
We acknowledge that the ATM phosphorylation site under investigation (ser1981) corresponds with 
the nuclear activation of ATM in response to DNA damage (Bakkenist and Kastan, 2003), as well as 
its DNA damage-independent activation by ROS (Guo et al., 2010), but it might not be a true 
reflection of the metabolic activity of ATM in response to insulin. To the best of our knowledge, no 
amino acid residue that is specifically phosphorylated in response to insulin stimulation has yet been 
identified, and ser1981 phosphorylation is generally used as an insulin-mediated activation site 
throughout literature. 
No significant changes were observed in the total and phosphorylated levels of PKB (Figure 4.4).  
 
Figure 4.4: Total and phosphorylated levels of PKB in H9c2 cardiomyoblasts treated with combinations of 





PKB total (t) and phosphorylated (p) levels in H9c2 cells treated with combinations of 0.2 mM free fatty acids (FFA; 
palmitic and oleic), 5.5 mM glucose (glu) and 100 nM insulin (ins) for 24 hours compared to a vehicle control (0.2% 
EtOH). No significant changes were observed. Data of all three experiments are pooled (biological n=3; technical n=2-
3; normalised to total protein; one-way ANOVA with Bonferroni post-test; mean ± SD). 
Observing no significant changes in PKB activity were unexpected. Obesity is associated with various 
metabolic abnormalities, including peripheral insulin resistance, which can be facilitated by 
circulating FFAs secreted from WAT and/or introduced through diet. Oleic acid (mono-unsaturated 
FFA) and palmitic acid (saturated FFA) are the most abundant dietary and plasma FFAs, which 
respectively account for approximately 32% and 28% of total circulating FFAs (Staiger et al., 2004). 
As such, the individual and combined effects of palmitic acid and oleic acid on cellular insulin 
sensitivity are well-established (Coll et al., 2008; Kwon and Querfurth, 2015; Perdomo et al., 2015). 
Palmitic acid treatment induces insulin resistance in C2C12 cells and cardiomyocytes by increasing 
intracellular DAG levels, which phosphorylates and inhibits IRS-1 and, subsequently, reduces PKB 
phosphorylation in response to insulin. Oleic acid treatment does not elicit this effect, and co-
treatment of palmitic acid and oleic acid protects against palmitic acid-induced insulin resistance. 
Therefore, oleic acid preserves insulin sensitivity in the presence of palmitic acid.    
In the current study, we considered the combined effect of equal concentrations of palmitic acid and 
oleic acid on PKB levels and phosphorylation, as the combination of these two FFAs more accurately 
reflects the circulating FFA profile in high-fat fed animals (Liu et al., 2015). Assessing the individual 
effects of these FFAs, however, provides unique insights into the protective effect of oleic acid against 
the development of insulin resistance when co-treated with palmitic acid, an effect that is likely 
masked in our results.  Therefore, we suggest that the absence of decreased PKB phosphorylation 
compared to the vehicle control is potentially due to the protective action of oleic acid against the 
palmitic acid-mediated attenuation of PKB phosphorylation.  
No consistent effects were observed on the total and phosphorylated levels of mTORC1 (Figure 4.5) 






Figure 4.5: Total and phosphorylated levels of mTORC1 in H9c2 cardiomyoblasts treated with 
combinations of nutrients and insulin for 24 hours. 
mTORC1 total (t) and phosphorylated (p) levels in H9c2 cells treated with combinations of 0.2 mM free fatty acids (FFA; 
palmitic and oleic), 5.5 mM glucose (glu) and 100 nM insulin (ins) for 24 hours compared to a vehicle control (0.2% 
EtOH). No consistent effects were observed. Data are presented as three individual experiments (A, B and C; technical 






Figure 4.6: Total and phosphorylated levels of AMPK in H9c2 cardiomyoblasts treated with combinations 
of nutrients and insulin for 24 hours. 
AMPK total (t) and phosphorylated (p) levels in H9c2 cells treated with combinations of 0.2 mM free fatty acids (FFA; 
palmitic and oleic), 5.5 mM glucose (glu) and 100 nM insulin (ins) for 24 hours compared to a vehicle control (0.2% 
EtOH). No consistent effects were observed. Data are presented as three individual experiments (A, B and C; technical 
n=2-3; normalised to total protein; mean ± SD). 
Although the various treatment conditions seemed to impact the total and phosphorylated levels of 
mTORC1 and AMPK, no consistent effects were observed across the three biological experiments. 
The mTORC1 and AMPK pathways play major opposing roles in intracellular energy homeostasis. 
Saturated and unsaturated FFAs have been shown to differentially affect mTORC1 signalling in an 
AMPK-dependent manner. C2C12 cells treated with palmitic acid displayed dysregulation of the 
mTORC1 pathway, as evidenced by increased activation of Raptor (a regulatory subunit of the 
mTORC1), decreased phosphorylation of eukaryotic translation initiation factor 4E-binding protein 
1 (4E-BP1; a down-stream target of mTORC1), increased  phosphorylation of S6K (a down-stream 





but no change in mTORC1 activation (ser2448 phosphorylation). Co-treatment of C2C12 cells with 
palmitic acid and oleic acid completely restored these palmitic acid-induced alterations to levels 
comparable with the control-treated cells, highlighting the protective role of oleic acid against 
metabolic dysregulation (Kwon and Querfurth, 2015).  
In the current study, we observed no consistent effects on mTORC1 or AMPK activities (p/t-ratios) 
in H9c2 cells treated with a combination of palmitic acid and oleic acid. Taken together, this might 
suggest that the protective action of oleic acid restores the palmitic acid-induced dysregulation of the 
mTORC1 and AMPK pathways. This will have to be confirmed by analysing the individual effects 
of the FFAs, as well as the effect on other proteins within the mTORC1 pathway.  
4.4. Prolonged exposure to combinations of excess nutrients and 
insulin does not affect miR-421 or miR-18a levels in H9c2 cells 
MiR-421 and miR-18a regulate ATM levels in cancer cells (Hu et al., 2010; Song et al., 2011; Shen 
and Houghton, 2013; Wu et al., 2013), however they have not been associated with ATM regulation 
in a metabolic context. Therefore, we investigated whether miR-421 and miR-18a levels can be 
influenced by combinations of excess nutrients and/or insulin to potentially regulate ATM protein 
levels in H9c2 cells. Following 24 hours of treatment, the total RNA was extracted and the expression 
levels of miR-421 and miR-18a were determined with qRT-PCR. Each individual experiment 
(biological n=3) consisted of the respective treatment conditions performed in triplicate (technical 
n=3), which were pooled. Each pooled sample was analysed in duplicate and the fold-changes were 
calculated using the 2-ΔΔCt method. U6 snRNA was used as endogenous control for normalisation. An 
ordinary one-way ANOVA was performed, followed by a Bonferroni post-hoc test, and data are 
presented as the mean fold-change ± SD relative to the vehicle (EtOH) control. 







Figure 4.7: Expression levels of target miRNAs in H9c2 cardiomyoblasts treated with combinations of 
nutrients and insulin for 24 hours. 
The relative expression levels of miR-421 (A) and miR-18a (B) in H9c2 cells treated with combinations of 0.2 mM free 
fatty acids (FFA: palmitic and oleic), 5.5 mM glucose (glu) and 100 nM insulin (ins) for 24 hours compared to a vehicle 
control (0.2% EtOH). No significant changes were observed (biological n=3; pooled technical n=3; normalised to U6 
snRNA; 2-ΔΔCt method; one-way ANOVA with Bonferroni post-test; mean ± SD). 
In addition to cancer, abnormal miR-421 and miR-18a expression have been implicated in metabolic 
disorders. MiR-18a is down-regulated in the renal tissue of diabetic mice compared to non-diabetic 
mice (Xu et al., 2017), whereas increased levels of miR-18a in human peripheral blood mononuclear 
cells is associated with an increased risk of developing type II diabetes (Wang et al., 2017). On the 
other hand, miR-421 has been implicated in myocardial dysfunction relating to mitochondrial 
fragmentation (Wang et al., 2015). The authors showed that the E2F1 transcription factor induced the 
expression of miR-421, which in turn suppressed the translation of the mitochondrial maintenance 
protein, Pink1. Reduced Pink1 levels resulted in mitochondrial fragmentation and subsequent 
cardiomyocyte apoptosis.  
In the current study, no significant differences in miR-421 and miR-18a levels were observed, 
suggesting that miR-421 and miR-18a expression levels are not influenced by combinations of excess 
nutrients and/or insulin in H9c2 cells. 
Chapter conclusion 
Taken together, H9c2 cells seem to be metabolically sensitive to extracellular factors (glucose, FFAs 
and insulin), and is therefore an appropriate in vitro model to use for experiments with adipose-





influenced by a combination of FFAs and insulin, whereas no significant effects on miR-421 and 






Chapter 5  
Investigating the basal metabolic protein profiles of 
subcutaneous and visceral adipocytes harvested from 
lean and high-fat diet animals 
Two WAT-associated pathologies that manifest during obesity are the ectopic fat deposition around 
abdominal organs, which is referred to as visceral adiposity, and the dysregulation of adipocyte 
metabolism and subsequent secretions. Although the central aim of this study is to investigate the 
effect of adipocyte secretions on cardiac metabolism in obesity, we first investigated whether 
differences in the basal metabolic protein profiles exist between adipocytes originating from the 
subcutaneous and visceral fat depots, and whether these profiles are influenced by diet (Figure 5.1). 
ASCs retain an adipogenic memory of their in vivo environment, which is regained once differentiated 
in culture (Andersen et al., 2019). Therefore, we investigated the total and phosphorylated levels of 
ATM, PKB, mTORC1, S6K, AMPK and ACC of adipocytes differentiated from visceral and 
subcutaneous ASCs harvested from lean and HFD rats through Western blot analysis. Each stain-free 
membrane included the ASCs and differentiated adipocytes (abbreviated as Adipo in figures) from 
the subcutaneous (abbreviated as SC in figures) and visceral (peri-renal; abbreviated as PR in figures) 
fat depots in triplicate (technical n=3) per rat (biological n=4 per diet). No common control was 
included, therefore the data are presented separately per rat and we were unable to compare results 
between the two diet groups. Rats A-D represent four control rats, whereas rats E-H represent four 
HFD rats within each figure. No statistical analyses were applied to the single biological replicates, 
and all data are presented as the mean fold-change ± SD relative to the SC ASCs. Results obtained 
for PKB and S6K could not be replicated and were excluded from the study. The p/t-ratio represents 
the phosphorylated protein as a fraction of the total protein and serves as an indicator of either protein 






Figure 5.1: Schematic of the comparison between the basal metabolic profiles of adipocytes differentiated 
from subcutaneous and visceral ASCs harvested from control and HFD rats. 
5.1. ATM 
ATM protein levels seemed to be lower in the visceral adipocytes compared to the subcutaneous 
adipocytes in rats A (1.12 ± 0.18 vs. 1.60 ± 0.08) and C (0.57 ± 0.21 vs. 0.99 ± 0.08) under control 
conditions (Figure 5.2), which was not observed under HFD conditions (Figure 5.3). ATM 
phosphorylation (activation) and p/t-ratio did not appear to differ between the subcutaneous and 
visceral adipocytes in either diet group. Although the effect of adipocyte differentiation on the basal 
metabolic profiles was not an objective of this study, we observed a trend towards lower ATM activity 
(p/t-ratio) in the subcutaneous adipocytes compared to their ASC counterparts in control rats A (0.32 
± 0.11 vs. 1.03 ± 0.34), B (0.51 ± 0.14 vs. 1.02 ± 0.17) and D (0.31 ± 0.04 vs. 1.03 ± 0.30) and HFD 
rats E (0.24 ± 0.08 vs. 1.03 ± 0.23) and F (0.32 ± 0.05 vs. 1.00 ± 0.24). This potential differentiation-













Figure 5.3: Total and phosphorylated levels of ATM in adipose-derived cells that originated from HFD rats. 
Total (t) and phosphorylated (p) levels of ATM in adipose stem cells (ACSs) and differentiated adipocytes (Adipo) originating form subcutaneous (SC) and visceral (PR) depots of 
control diet (A-D) and HFD (E-H) rats. Total ATM levels seemed to be lower in visceral compared to subcutaneous adipocytes under control conditions, but not HFD conditions 





The metabolic role of ATM has been widely investigated in various cell and tissue types, however 
studies investigating its role in adipocyte metabolism remain limited. Le Guezennec et al. showed 
that ApoE-/- mice deficient in Wip1, a protein phosphatase responsible for ATM dephosphorylation 
(inhibition), displayed a reduction in overall lipid accumulation and visceral fat depot size compared 
to ApoE-/- Wip1+/+ mice (Le Guezennec et al., 2012). While the focus of their study was on the role 
of ATM regulation in foam cell formation during the development of atherosclerosis, their data 
suggest that ATM protects against WAT accumulation, particularly in the visceral depot. In a 
pioneering study by Takagi and colleagues, a novel role for ATM in adipose tissue distribution and 
adipogenesis (adipocyte differentiation) was described (Takagi et al., 2015). The authors showed that 
Atm-/- mice displayed a shift towards increased visceral WAT accumulation at the expense of 
subcutaneous accumulation compared to wild-type mice, confirming that ATM protects against 
visceral obesity. In vitro experiments with mouse embryonic fibroblasts (MEFs) derived from Atm-/- 
mice further revealed that ATM plays a central role in initiating the adipocyte differentiation program 
through the induction of C/EBPα and PPARγ.  
In the current study, ATM levels appeared to be lower in visceral adipocytes compared to 
subcutaneous adipocytes originating from lean rats, however this did not necessarily result in lower 
ATM phosphorylation (activation). No apparent differences in ATM levels or phosphorylation were 
observed between the subcutaneous and visceral adipocytes originating from HFD rats. Based on 
previous studies, ATM activity is inversely related to lipid accumulation. Our data indicate similar 
levels of ATM activity between subcutaneous and visceral adipocytes, which is consistent with the 
observation that there was no significant difference in intracellular lipid quantity between 
subcutaneous and visceral adipocytes (refer to Appendix A Figure A2 for lipid quantification 
analysis). Taken together, our results suggest that there is no difference in lipid accumulation between 
subcutaneous and visceral adipocytes under control or HFD conditions in the rat model that this study 
is based on. 
To the best of our knowledge, no prior study has investigated the total or phosphorylated levels of 
ATM in adipocytes originating from the visceral and subcutaneous fat depots under control or HFD 
conditions. 
5.2. mTORC1 
No apparent differences in total or phosphorylated (activated) mTORC1 levels were observed 














Figure 5.5: Total and phosphorylated levels of mTORC1 in adipose-derived cells that originated from HFD rats. 
Total (t) and phosphorylated (p) levels of mTORC1 in adipose stem cells (ACSs) and differentiated adipocytes (Adipo) originating form subcutaneous (SC) and visceral (PR) depots 
of control diet (A-D) and HFD (E-H) rats. No apparent differences in total or phosphorylated mTORC1 levels were observed between subcutaneous and visceral adipocytes in either 





mTORC1 is a master regulator of various aspects of adipocyte metabolism. Specifically, mTORC1 
plays a central role in nutrient- and insulin-mediated adipogenesis (Bell, Grunder and Sorisky, 2000; 
Kim and Chen, 2004) and lipid accumulation (Polak et al., 2008; Chang et al., 2009) by positively 
regulating the expression of adipogenic and lipogenic genes. Obesity is characterised by increased 
WAT size, especially in the visceral depot, which arises from increased adipogenesis and fat 
accumulation. As such, mTORC1 activity is markedly up-regulated in various tissue types, including 
WAT, of obese animals (Um et al., 2004; Khamzina et al., 2005; Tremblay et al., 2007).  
In the current study, no apparent differences in mTORC1 levels or phosphorylation (activation) were 
observed between the subcutaneous and visceral adipocytes under control or HFD conditions. Similar 
to ATM, our data indicate no difference in mTORC1 activity between subcutaneous and visceral 
adipocytes, which is consistent with similar intracellular lipid quantities (refer to Appendix A Figure 
A2 for lipid quantification analysis). Taken together, our results suggest that there is no difference in 
lipid accumulation between subcutaneous and visceral adipocytes under control or HFD conditions 
in the rat model that this study is based on.  
5.3. AMPK 
AMPK protein levels seemed to be lower in the visceral adipocytes compared to the subcutaneous 
adipocytes in control rats B (0.69 ± 0.12 vs. 2.28 ± 0.16) and D (1.02 ± 0.02 vs. 2.19 ± 0.24) (Figure 
5.6) and HFD rats E (1.97 ± 0.41 vs. 4.50 ± 0.45) and H (1.97 ± 0.31 vs. 5.36 ± 0.40) (Figure 5.7). 
No apparent differences in AMPK phosphorylation (activation) or p/t-ratio were observed between 
subcutaneous and visceral adipocytes under control or HFD conditions.  
Although the effect of adipocyte differentiation on the basal metabolic profiles was not an objective 
of this study, we observed a trend towards higher AMPK total protein levels in the subcutaneous 
adipocytes compared to their ASC counterparts in control rats B (2.28 ± 0.16 vs. 1.00 ± 0.05), C (1.36 
± 0.09 vs. 1.00 ± 0.10) and D (2.19 ± 0.24 vs. 1.00 ± 0.07) and HFD rats E (4.50 ± 0.45 vs. 1.00 ± 
0.19), F (2.00 ± 0.32 vs. 1.00 ± 0.12) and H (5,36 ± 0.40 vs. 1.00 ± 0.13). We also observed this trend 
between visceral adipocytes and their ASC counterparts in all four control rats (A: 1.00 ± 0.12 vs. 
0.57 ± 0.07, B: 0.69 ± 0.12 vs. 0.13 ± 0.03, C: 1.74 ± 0.14 vs. 1.29 ± 0.10, D: 1.02 ± 0.02 vs. 0.30 ± 
0.12) and HFD rats E (1.97 ± 0.41 vs. 0.57 ± 0.18), F (3.29 ± 0.50 vs. 1.50 ± 0.12) and H (1.97 ± 0.31 
vs. 0.39 ± 0.06).  
Interestingly, AMPK activity (p/t-ratio) appeared to be lower in the subcutaneous adipocytes 
compared to their ASC counterparts in control rats A (0.38 ± 0.17 vs. 1.00 ± 0.15), B (0.19 ± 0.05 vs. 
1.00 ± 0.04) and D (0.20 ± 0.05 vs. 1.00 ± 0.12) and HFD rats E (0.08 ± 0.01 vs. 1.00 ± 0.20), F (0.30 





adipocytes compared to their ASC counterparts in control rats B (0.33 ± 0.01 vs. 1.32 ± 0.15), C (0.44 
± 0.31 vs. 1.29 ± 0.34) and D (1.71 ± 0.19 vs. 6.28 ± 1.83) and all four HFD rats (E: 0.20 ± 0.13 vs. 
1.66 ± 0.97, F: 0.09 ± 0.07 vs. 0.85 ± 0.15, G: 0.30 ± 0.26 vs. 1.45 ± 0.37, H: 0.13 ± 0.01 vs. 1.69 ± 













Figure 5.7: Total and phosphorylated levels of AMPK in adipose-derived cells that originated from HFD rats. 
Total (t) and phosphorylated (p) levels of AMPK in adipose stem cells (ACSs) and differentiated adipocytes (Adipo) originating form subcutaneous (SC) and visceral (PR) depots of 
control diet (A-D) and HFD (E-H) rats. Total AMPK levels seemed to be lower in visceral compared to subcutaneous adipocytes in both diet groups (biological n=4 per diet group; 





AMPK is another major regulator of adipocyte metabolism. Activated AMPK limits lipid 
accumulation (Villena et al., 2004) and FFA secretion (Anthony, Gaidhu and Ceddia, 2009), while 
promoting β-oxidation (Kim et al., 2016). Abnormal AMPK expression or function in WAT has 
therefore been implicated in obesity and associated metabolic conditions. AMPK activity is down-
regulated by overnutrition during obesity (Coughlan et al., 2013), which is associated with the 
development of insulin resistance (Xu et al., 2012). This is because decreased AMPK activity results 
in increased mTORC1/S6K signalling, which in turn suppresses the insulin-mediated pathway 
through negative feedback inhibition of IRS-1 (Saha et al., 2011). Interestingly, AMPK activity was 
found to be lower in the visceral compared to subcutaneous WAT of obese individuals (Gauthier et 
al., 2011), highlighting a distinction between the two fat depots in obesity. 
In the current study, AMPK levels seemed to be lower in visceral adipocytes compared to 
subcutaneous adipocytes originating from lean and HFD rats, however this was not necessarily 
accompanied by lower AMPK phosphorylation (activation). Similar to ATM and mTORC1, our data 
indicate no apparent difference in AMPK activity between subcutaneous and visceral adipocytes, 
which is consistent with similar intracellular lipid quantities (refer to Appendix A Figure A2 for lipid 
quantification analysis). Taken together, our results suggest that there is no difference in lipid 
accumulation between subcutaneous and visceral adipocytes under control or HFD conditions in the 
rat model that this study is based on.  
5.4. ACC 
Acetyl-coenzyme A carboxylase (ACC) was expressed in the adipocytes, but not the ASCs, 
originating from both fat depots under control (Figures 5.8 and 5.10) and HFD (Figures 5.9 and 
5.11) conditions. ACC is an important enzyme that regulates fatty acid metabolism by catalysing the 
conversion of acetyl-coA to malonyl-coA. In turn, malonyl-coA serves a dual function as either a 
substrate for lipogenesis or an inhibitor of CPT1-mediated transport of fatty acids into the 
mitochondria, thereby limiting β-oxidation. This dual function is dependent on the respective actions 
of the two main ACC isoforms: ACC1 and ACC2 (Munday, 2002).  
5.4.1. ACC1 
Total and phosphorylated (inhibited) levels of ACC1 seemed to be lower in the visceral adipocytes 
compared to subcutaneous adipocytes in control rats B (total: 0.05 ± 0.04 vs. 1.00 ± 0.06, phospho: 
0.004 ± 0.003 vs. 1.00 ± 0.13), C (total: 0.57 ± 0.10 vs. 1.00 ± 0.11, phospho: 0.36 ± 0.15 vs. 1.00 ± 
0.31) and D (total: 0.19 ± 0.04 vs. 1.00 ± 0.07, phospho: 0.07 ± 0.03 vs. 1.00 ± 0.11) (Figure 5.8) 





0.45 ± 0.05 vs. 1.00 ± 0.10, phospho: 0.50 ± 0.08 vs. 1.00 ± 0.12) and H (total: 0.29 ± 0.08 vs. 1.00 
± 0.18, phospho: 0.06 ± 0.05 vs. 1.00 ± 0.45) (Figure 5.9).  
ACC1 p/t-ratio, an indicator of ACC1 inactivity, appeared to be lower in visceral adipocytes 
compared to subcutaneous adipocytes in control rats B (0.16 ± 0.16 vs. 1.00 ± 0.08) and D (0.34 ± 












Figure 5.9: Total and phosphorylated levels of ACC1 in adipose-derived cells that originated from HFD rats. 
Total (t) and phosphorylated (p) levels of ACC1 expressed in differentiated adipocytes (Adipo) originating from the subcutaneous (SC) and visceral (PR) depots of control diet (A-D) 
and HFD (E-H) rats. Total and phosphorylated levels seemed to be lower in visceral compared to subcutaneous adipocytes in both diet groups (biological n=4 per diet group; technical 





Although ACC1 is widely expressed in the cytoplasm of various tissue types, its expression is 
enriched within WAT because the malonyl-coA product specifically feeds into the lipogenesis 
pathway. Once phosphorylated on ser79 by AMPK, ACC1 is inhibited and lipogenesis is 
subsequently blocked (Hardie and Pan, 2002). The role of ACC1 in the development of obesity-
associated pathology has been investigated, however results remain inconclusive. ACC1 expression 
(mRNA levels) was reported to be lower in the subcutaneous WAT of obese individuals compared to 
that of lean individuals, with no difference in expression in visceral WAT (Auguet et al., 2014; Guiu-
Jurado et al., 2015). These results suggest that lipogenesis in the subcutaneous depot is reduced during 
obesity, whereas lipogenesis in the visceral depot remains unchanged. In contrast, Ortega and 
colleagues reported a decrease in ACC1 expression in the visceral WAT of obese individuals 
compared to that of lean individuals (Ortega et al., 2010), suggesting that lipogenesis in the visceral 
depot is in fact affected by obesity. 
In the current study, ACC1 was exclusively expressed in the adipocytes, and not the ASCs. ACC1 
levels seemed to be lower in the visceral adipocytes compared to the subcutaneous adipocytes under 
control and HFD conditions. ACC1 phosphorylation (inhibition) also appeared lower in the visceral 
adipocytes compared to the subcutaneous adipocytes in both diet groups, which could be explained 
by the lower amount of ACC1 protein available for phosphorylation in the visceral adipocytes. 
Interestingly, the p/t-ratios seemed to be lower in the visceral adipocytes compared to the 
subcutaneous adipocytes in both diet groups, suggesting that a bigger proportion of ACC1 is in the 
non-phosphorylated activated state in the visceral adipocytes. However, since the absolute levels of 
active ACC1 within the subcutaneous and visceral adipocytes are unknown, the biological 
significance of the observation is unclear. Lastly, we are unable to correlate AMPK phosphorylation 
(activation) with ACC1 phosphorylation (inhibition), since ACC1 displays differential total protein 
levels between the subcutaneous and visceral adipocytes.  
5.4.2. ACC2 
Total and phosphorylated (inhibited) ACC2 levels seemed to be lower in the visceral adipocytes 
compared to subcutaneous adipocytes in control rats A (total: 0.36 ± 0.17 vs. 1.00 ± 0.06, phospho: 
0.34 ± 0.20 vs. 1.00 ± 0.25), B (total: 0.06 ± 0.05 vs. 1.00 ± 0.14, phospho: 0.004 ± 0.0008 vs. 1.00 
± 0.29) and D (total: 0.14 ± 0.03 vs. 1.00 ± 0.13, phospho: 0.06 ± 0.02 vs. 1.00 ± 0.26) (Figure 5.10) 
and HFD rats E (total: 0.34 ± 0.16 vs. 1.00 ± 0.07, phospho: 0.31 ± 0.10 vs. 1.00 ± 0.36) and H (total: 
0.39 ± 0.14 vs. 1.00 ± 0.19, phospho: 0.08 ± 0.03 vs. 1.00 ± 0.19) (Figure 5.11). ACC2 was not 
detected in visceral adipocytes from rat G. ACC2 p/t-ratio, an indicator of ACC2 inactivity, appeared 
to be lower in visceral adipocytes compared to subcutaneous adipocytes in control rat B (0.15 ± 0.17 












Figure 5.11: Total and phosphorylated levels of ACC2 in adipose-derived cells that originated from HFD rats. 
Total (t) and phosphorylated (p) levels of ACC2 expressed in differentiated adipocytes (Adipo) originating from the subcutaneous (SC) and visceral (PR) depots of control diet (A-D) 
and HFD (E-H) rats. Total and phosphorylated levels seemed to be lower in visceral compared to subcutaneous adipocytes in both diet groups. ACC2 was not detected in the visceral 





ACC2 is highly expressed in oxidative tissues of animals such as skeletal muscle and cardiac tissue, 
with lower expression in WAT (Oh et al., 2005). Whereas ACC1 is mainly localised in the cytoplasm, 
ACC2 co-localises with the CPT1 transporter in the mitochondrial membrane, where its malonyl-coA 
product inhibits CPT1-mediated β-oxidation (Wakil and Abu-Elheiga, 2009). ACC2 is also a down-
stream target of AMPK, which phosphorylates and inhibits ACC2 on an amino acid residue (ser219) 
that is the conserved equivalent of ser79 in ACC1 (Hardie and Pan, 2002). The role of ACC2 in 
obesity has been described in various other tissues. ACC2 expression was shown to be up-regulated 
in the liver, pancreas and skeletal muscle of obese and diabetic rats compared to lean control rats 
(Kreuz et al., 2009). Furthermore, ACC2-deficient mice on a HFD were protected against obesity and 
the development of type II diabetes, partly due to increased β-oxidation in the skeletal muscle and 
liver (Abu-Elheiga et al., 2003). Because ACC2 is not the predominant isoform in animal WAT (Oh 
et al., 2005), its role in WAT-related pathology during obesity requires further investigation.  
In the current study, ACC2 was exclusively expressed in the adipocytes, and not in ASCs. Similar to 
ACC1, ACC2 total and phosphorylated (inhibited) levels showed a trend towards lower levels in the 
visceral adipocytes compared to the subcutaneous adipocytes under control and HFD conditions. The 
p/t-ratios were not necessarily lower in the visceral adipocytes compared to the subcutaneous 
adipocytes in both diet groups, suggesting that a similar proportion of ACC2 is in the non-
phosphorylated activated state in visceral and subcutaneous adipocytes. Since the absolute levels of 
active ACC2 within the subcutaneous and visceral adipocytes are unknown, the biological 
significance of the observation is unclear. Similar to ACC1, we are unable to correlate AMPK 
phosphorylation (activation) with ACC2 phosphorylation (inhibition), since ACC2 also displays 
differential total protein levels between the subcutaneous and visceral adipocytes. 
Chapter conclusion 
Taken together, the fat depot had seemingly no effect on the metabolic activities of ATM, mTORC1 
or AMPK within adipocytes under control or HFD conditions. Although the diet groups were not 
compared, the biometric data of the four control and four HFD rats (collected by Dr H. Sadie-van 
Gijsen) from which the ASCs were harvested revealed that the HFD did not lead to a significant 
increase in body weight or visceral fat accumulation compared to the control diet (refer to Appendix 
A Figure A1). Furthermore, the HFD did not cause insulin resistance compared to the control diet, 
despite a non-significant trend towards increased insulin resistance in the HFD rats (refer to Appendix 
A Figure A1). ACC showed adipocyte-specific expression, with seemingly lower protein levels of 





groups. ACC1 phosphorylation (inhibition) might be further regulated in visceral adipocytes, 
however the biological significance thereof remains unclear. 
Interestingly, we observed potential changes in ATM activity levels in the subcutaneous fat depot, 
and AMPK total and activity levels in both fat depots, between the ASCs and their adipocyte 
counterparts originating from control and HFD rats. These results indicate a possible differentiation-
dependent effect on these two metabolic proteins. However, the impact of adipocyte differentiation 







Chapter 6  
Investigating a posttranscriptional mechanism of 
cardiomyoblast ATM protein regulation during obesity 
During obesity, adipocyte metabolism becomes dysregulated, which leads to abnormal endocrine 
function. Abnormal WAT secretions in circulation, in turn, might influence the metabolism of 
peripheral organs. ATM protein levels are down-regulated in the hearts of obese and insulin resistant 
animals (Huisamen et al., 2016), suggesting a potential link between obesity and dysregulated cardiac 
metabolism. However, the mechanism linking ectopic adiposity and reduced cardiac ATM levels 
remains unclear. To address this unknown, the current study aimed to investigate whether adipocyte 
secretions can affect cardiomyoblast ATM protein levels in obesity in vitro, and if it can be through 
a miRNA-mediated mechanism. To achieve this aim, H9c2 cells were exposed to CM derived from 
the visceral and subcutaneous ASCs and adipocytes (analysed in Chapter 5) for 24 hours. The CM 
represents a more physiological treatment compared with treatments consisting of individual FFAs 
(investigated in Chapter 4). The FFA composition of the CM was analysed by the SAMRC using GC-
FID to establish whether fat depot and diet influence the FFA secretory profiles of adipocytes. We 
investigated the respective effects of visceral and subcutaneous adipose secretions on cardiomyoblast 
ATM levels, as well as other metabolic proteins (PKB, mTORC1 and AMPK), through Western 
blotting. Furthermore, as a potential posttranscriptional mechanism of ATM protein regulation in 
obesity, we analysed the expression levels of two miRNAs that are known to regulate ATM in cancer 
cells (miR-421 and miR-18a), and four metabolic miRNAs that target ATM mRNA in silico and 
display aberrant expression in obesity and related co-morbidities (miR-194, miR-210, miR-322 and 
miR-181b), with qRT-PCR. These six miRNAs have not been associated with the posttranscriptional 
regulation of ATM protein levels in a metabolic context before. 
6.1. Diet and fat depot do not influence the adipocyte secretion of 
palmitic-, stearic- and oleic acid, the most abundant secreted free 
fatty acids  
The GC-FID analysis of the CM was kindly performed by Dr P. van Jaarsveld in collaboration with 
the SAMRC to establish the FFA profiles secreted by the adipose cells. The FFA composition of each 
CM sample (SC ASC, SC Adipo, PR ASC, PR Adipo) were analysed per rat (n=3 per diet group). A 
two-way ANOVA was performed, followed by a Bonferroni post-hoc test, and data are presented as 





The FFA composition of the CM derived from subcutaneous and visceral ASCs and adipocytes 










Figure 6.1: FFA secretory profiles of adipose-derived cells. 
The FFA composition per 1 ml CM: subcutaneous adipose stem cells originating from control rats (A); subcutaneous 
adipocytes originating from control rats (B); peri-renal adipose stem cells originating from control rats (C); peri-renal 
adipocytes originating from control rats (D); subcutaneous adipose stem cells originating from HFD rats (E); 
subcutaneous adipocytes originating from HFD rats (F); peri-renal adipose stem cells originating from HFD rats (G); 
peri-renal adipocytes originating from HFD rats (H) (n=3 per diet group; each FFA is presented as a percentage ± SD 
of the total FFA content). 
Based on the CM composition data, we were interested in determining whether the adipose cells 
originating from different depots and dietary backgrounds displayed differential secretion of the three 
most abundant FFAs, which were palmitic acid (16-carbon saturated FFA), stearic acid (18-carbon 
saturated FFA) and oleic acid (18-carbon mono-unsaturated FFA).  
 
Figure 6.2: Differential secretion of palmitic acid, stearic acid and oleic acid from adipose-derived cells. 
Palmitic acid (A), stearic acid (B) and oleic acid (C) secreted from subcutaneous (SC) and visceral (peri-renal; PR) 
adipose stem cells (ASCs) and adipocytes (Adipo) originating from control and HFD rats. Differential secretion was 
observed in palmitic acid and oleic acid between the adipocytes and their ASC counterparts in both depots and diet 
groups, with no differences between diet groups (n=3 per diet group; two-way ANOVA with Bonferroni post-test; mean 





We observed no significant differences in palmitic-, stearic-, or oleic acid secretion between the 
subcutaneous and visceral adipocytes, or between adipocytes originating from control and HFD rats 
(Figure 6.2). Interestingly, the subcutaneous and visceral adipocytes secreted higher levels of 
palmitic acid compared to their ASC counterparts in both diet groups (Figure 6.2 A), whereas the 
subcutaneous and visceral adipocytes secreted lower levels of oleic acid compared to their ASC 
counterparts in both diet groups (Figure 6.2 C).  
Circulating FFAs are increased in obesity and are suggested to be a major contributing factor to the 
development of systemic insulin resistance and inflammation, which precedes metabolic diseases 
such as type II diabetes and cardiovascular diseases (Boden, 2008). However, it is important to 
consider the type of circulating FFAs, because saturated and unsaturated FFAs have differential 
effects on systemic health. Whereas saturated FFAs (such as palmitic acid) promotes peripheral 
insulin resistance and inflammation, unsaturated FFAs (such as oleic acid) protect against these 
metabolic risk factors (Palomer et al., 2018). In a study by Liu and colleagues, the serum FFA 
composition of rats fed a HFD showed that saturated FFAs constituted 47% of total FFAs (compared 
to 45% in control rats), whereas poly-unsaturated FFAs constituted 31% of total FFAs (compared to 
23% in control rats), and mono-unsaturated FFAs the remaining 22% (compared to 32% in control 
rats) (Liu et al., 2015), demonstrating that diet affects the circulating FFA composition.   
Our results indicate that fat depot and diet did not influence the secretion of palmitic-, stearic- or oleic 
acid from adipocytes. However, adipocyte differentiation influenced palmitic- and oleic acid 
secretion, where adipocytes secreted more palmitic acid, but less oleic acid, compared to their ASC 
counterparts. Although not significant, the pattern of stearic acid secretion from the adipose cells 
mimics that of palmitic acid secretion, suggesting that the adipocytes secrete higher levels of the two 
most abundant saturated FFAs compared to their ASC counterparts. This differentiation-dependent 
effect on FFA secretion is consistent with the differentiation-dependent effect observed on basal 
metabolic protein profiles but lies beyond the scope of this study.     
6.2. Cardiomyoblast AMPK and mTORC1, but not ATM, protein levels 
are down-regulated by adipocyte secretions in response to high-
fat feeding  
The total and phosphorylated levels of ATM, as well as the metabolic proteins PKB, mTORC1 and 
AMPK, were determined in H9c2 cells treated with the respective CM or complete DMEM media 
only (control) for 24 hours. Each treatment condition was performed in triplicate (technical n=3) per 
experiment, and each experiment was repeated four times (biological n=4 per diet group). Due to 
insufficient amounts of protein (<10 μg protein per 15 μl cell lysate) from H9c2 cells treated with the 





Western blot analysis. In order to compare results between individual experiments, a common DMEM 
control was included (refer to Appendix D). The common DMEM control was used to calculate the 
fold-change of each treatment condition. The technical repeats per treatment conditions were 
averaged and a two-way ANOVA was performed, followed by a Bonferroni post-hoc test. Data are 
presented as mean fold-change ± SD relative to the common DMEM control. The p/t-ratio represents 
the phosphorylated protein as a fraction of the total protein and serves as an indicator of protein 
activity for all proteins analysed in these experiments.  
Neither visceral nor subcutaneous adipocyte secretions under HFD conditions had a significant effect 
on cardiomyoblast ATM protein levels (Figure 6.3), however the p/t-ratios (activity) were 
significantly increased by the CM compared to the common DMEM control (p<0.05) in both diet 
conditions.  
 
Figure 6.3: Total and phosphorylated levels of ATM in H9c2 cardiomyoblasts treated with adipose-derived 
CM. 
The total (t) and phosphorylated (p) levels of ATM in H9c2 cells treated with CM derived from subcutaneous adipose 
stem cells (SC ASC), subcutaneous adipocytes (SC Adipo), peri-renal adipose stem cells (PR ASC) and peri-renal 
adipocytes (PR Adipo) harvested from control and HFD rats for 24 hours compared to a common DMEM control. ATM 





was driven by a non-significant increase in phosphorylated levels (biological n=3 per diet group; technical n=3; 
normalised to total protein; two-way ANOVA with Bonferroni post-test; mean ± SD; *p<0.05).  
ATM is a metabolic protein that participates in the insulin-mediated PKB/mTORC1 pathway (Yang 
and Kastan, 2000), which negatively regulates AMPK activity. Furthermore, ATM acts as a redox 
sensor that is directly activated by ROS (Guo et al., 2010), a by-product of nutrient metabolism. ROS-
activated ATM induces autophagy by activating AMPK, which in turn inhibits mTORC1 (Alexander 
et al., 2010). These two signalling pathways highlight the different relationships between ATM, 
mTORC1 and AMPK.    
Our data indicate that the total levels of cardiomyoblast ATM were not affected by the HFD-derived 
CM, which does not mimic what has been observed in vivo in obese and insulin resistant rats 
(Huisamen et al., 2016). Rather, our results suggest that the CM up-regulated ATM activity in 
cardiomyoblasts, which could be due to a requirement for nutrient metabolism brought about by the 
adipose secretions, and/or as a result of ROS production during said nutrient metabolism. 
Interestingly, ATM activity was non-significantly lower in response to the adipocyte secretions, 
which contained higher levels of palmitic acid and lower levels of oleic acid, compared to ASC 
secretions. Lastly, we have previously observed (Chapter 4) that cardiomyoblast ATM activity is 
down-regulated in response to a combination of high FFAs (palmitic- and oleic acid) and insulin. The 
CM contained no additional insulin but may contain adipose-secreted cytokines and adipokines. 
These results suggest that ATM activity might be influenced by insulin and/or adipose-secreted 
factors.    
No significant differences in phosphorylated AMPK levels were observed (Figure 6.4), suggesting 
that either the ROS-mediated pathway or insulin-mediated PKB/mTORC1 pathway could potentially 
mediate increased ATM activation. However, AMPK protein levels were significantly down-
regulated under HFD conditions compared to control conditions (p<0.05). Since a smaller amount of 
AMPK protein is available for activation in response to an HFD, it could account for a loss of 
increased phosphorylated levels that we would expect to see in the ROS-activated pathway. The 
pattern of AMPK activation (p/t-ratio) in response to the respective CM, however, showed an inverse 
pattern compared to ATM activation under control and HFD conditions, suggesting that the insulin-
mediated PKB/mTORC1 pathway, rather than the ROS-mediated pathway, predominates. No 
significant differences were observed between the subcutaneous- and visceral-derived CM, 






Figure 6.4: Total and phosphorylated levels of AMPK in H9c2 cardiomyoblasts treated with adipose-
derived CM. 
The total (t) and phosphorylated (p) levels of AMPK in H9c2 cells treated with CM derived from subcutaneous adipose 
stem cells (SC ASC), subcutaneous adipocytes (SC Adipo), peri-renal adipose stem cells (PR ASC) and peri-renal 
adipocytes (PR Adipo) harvested from control and HFD rats for 24 hours compared to a common DMEM control. AMPK 
levels (t) were significantly down-regulated by the CM derived from HFD rats compared to control rats (biological n=3 
per diet group; technical n=3; normalised to total protein; two-way ANOVA with Bonferroni post-test; mean ± SD; 
*p<0.05).  
AMPK is a nutrient sensor that activates catabolic pathways for energy production, while inhibiting 
anabolic pathways that consume energy in times of nutrient deprivation. As mentioned previously, 
AMPK also regulates autophagy through the inhibition of mTORC1 in response to ROS (Alexander 
et al., 2010). The role of AMPK in the development of obesity-associated metabolic dysfunction have 
been widely investigated in skeletal muscle and the liver. Overall, decreased AMPK activation 
(phosphorylation) is thought to be an early event in the development of insulin resistance due to 
chronic nutrient overload (reviewed by Coughlan et al., 2015). However, the role of AMPK in 
obesity-related cardiac dysfunction remains inconclusive. Niemann and colleagues investigated the 





in LKB1-mediated AMPK activation (p/t-ratio) in obese compared to lean patients (Niemann et al., 
2013). However, they observed no changes in mTORC1 phosphorylation, or any other down-stream 
AMPK targets, between the obese and control groups and concluded that AMPK might remain 
inactive albeit phosphorylated during obesity. Conversely, Ko et al. reported a non-significant 
decrease in AMPK protein levels and a significant reduction in the AMPK p/t-ratio in the cardiac 
tissue of diet-induced obese mice compared to control mice (Ko et al., 2009). Finally, neither total 
nor phosphorylated AMPK levels showed significant differences in the cardiac tissue between diet-
induced obese rats and control rats (Nascimento et al., 2011). Interestingly, the HFD applied in the 
latter study failed to affect the serum FFA and triglyceride levels in the obese rats, and there were no 
evidence of altered triglyceride content or lipid peroxidation (a consequence of increased ROS) in the 
cardiomyocytes. As such, the lipid-associated aspect of obesity and its effect on cardiac metabolism 
is not accurately reflected in their study, but it highlights a link between the presence of lipotoxicity 
and altered AMPK signalling in the heart. 
Our results indicate that cardiac AMPK protein levels were down-regulated in response to adipose 
secretions in a HFD setting, with no significant changes in phosphorylated levels. Therefore, we 
speculate that this down-regulation might be an early adaptive response to metabolic overload driven 
by the HFD-derived adipose secretions in an attempt to keep its activation levels comparable with 
normal conditions. By doing so, the cells restrict excess fatty acid uptake and subsequent oxidation 
in order to limit lipotoxicity and excessive ROS production, an unavoidable by-product of cellular 
metabolism that activates AMPK in an ATM-dependent positive feedback loop.      
No significant differences were observed in phosphorylated mTORC1 levels (Figure 6.5), however 
the activation (p/t-ratio) levels in response to both the control- and HFD-derived CM display an 
opposite pattern to that of AMPK activation levels, confirming their inverse relationship. 
Interestingly, mTORC1 protein levels were also down-regulated in response to HFD conditions 
compared to control conditions (p<0.05). Since less mTORC1 protein was available for activation 
under HFD conditions, but no significant reduction in its phosphorylated levels were observed, it 
could suggest that the positive regulation of mTORC1 activity by ATM within the insulin-mediated 
PKB pathway predominates the negative regulation of mTORC1 activity by ATM in response to 
ROS. In fact, the pattern of mTORC1 activation (p/t-ratio) in response to the respective CM mimics 
the activation pattern of ATM under control and HFD conditions, which is consistent with the activity 
of the PKB/mTORC1 pathway rather than the ROS-mediated pathway. Lastly, no significant 
differences were observed between the subcutaneous- and visceral-derived CM, suggesting adipose 






Figure 6.5: Total and phosphorylated levels of mTORC1 in H9c2 cardiomyoblasts treated with adipose-
derived CM. 
The total (t) and phosphorylated (p) levels of mTORC1 in H9c2 cells treated with CM derived from subcutaneous adipose 
stem cells (SC ASC), subcutaneous adipocytes (SC Adipo), peri-renal adipose stem cells (PR ASC) and peri-renal 
adipocytes (PR Adipo) harvested from control and HFD rats for 24 hours compared to a common DMEM control. 
mTORC1 levels (t) were significantly down-regulated by the CM derived from HFD rats compared to control rats 
(biological n=3 per diet group; technical n=3; normalised to total protein; two-way ANOVA with Bonferroni post-test; 
mean ± SD; *p<0.05).  
mTORC1 is another important metabolic sensor that is activated in response to growth hormones, 
such as insulin and IGF-1, and nutrients, such as amino acids. The mTORC1 pathway promotes 
anabolic processes such as protein synthesis, while inhibiting catabolic processes such as autophagy. 
In addition, mTORC1 plays an important role in lipid metabolism by regulating the fatty acid 
transporter protein 1 (FATP1)-mediated uptake of long-chain fatty acids through S6K (Arif et al., 
2017), as well as promoting cardiac β-oxidation (Zhu et al., 2013). Studies indicate that mTORC1 
activity is up-regulated during obesity and related metabolic conditions in various tissues (Khamzina 
et al., 2005), including the heart (Li et al., 2012; Uchinaka et al., 2017). It is thought to be as a result 





(Sciarretta, Volpe and Sadoshima, 2014), and is consequently associated with suppressed autophagy 
(Che et al., 2018) and the development of insulin resistance through the negative feedback inhibition 
of S6K on IRS-1 (Khamzina et al., 2005). Interestingly, in pigs fed a high-fat/high-cholesterol diet, 
total cardiac mTORC1 levels were significantly up-regulated compared to control animals. However, 
mTORC1 levels  strongly correlated with serum cholesterol and high-density lipoprotein levels, with 
no correlation between mTORC1 levels and serum triglycerides (Glazer et al., 2009), highlighting 
differential effects between different types of circulating lipids on cardiac mTORC1 expression.   
Similar to AMPK, our results show that cardiac mTORC1 protein levels are down-regulated in 
response to adipose secretions in a HFD setting, with no significant changes in phosphorylated levels. 
We therefore speculate that this down-regulation is also an early adaptive response aimed at lowering 
mTORC1 activity to normal levels in order to counteract the elevated mTORC1 activation (and 
suppressed autophagy) associated with obesity.  
PKB protein levels were slightly increased under control and HFD conditions compared to the 
common DMEM control, although not significantly (Figure 6.6). Despite no significant differences 
in phosphorylated levels, the pattern of PKB activation (p/t-ratio) in response to the respective CM 
corresponds to that of ATM and mTORC1, but displays an inverse pattern to that of AMPK, under 
control conditions. This confirms the likelihood that the PKB/mTORC1 pathway predominates, as 
opposed to the ROS-mediated pathway. Interestingly, an inverse pattern in PKB activation is 
observed under HFD conditions, which is an unexpected observation as it rather correlates with 
AMPK activation. Again, no significant differences were observed between the subcutaneous- and 






Figure 6.6: Total and phosphorylated levels of PKB in H9c2 cardiomyoblasts treated with adipose-derived 
CM. 
The total (t) and phosphorylated (p) levels of PKB in H9c2 cells treated with CM derived from subcutaneous adipose 
stem cells (SC ASC), subcutaneous adipocytes (SC Adipo), peri-renal adipose stem cells (PR ASC) and peri-renal 
adipocytes (PR Adipo) harvested from control and HFD rats for 24 hours compared to a common DMEM control. PKB 
levels (t) were significantly up-regulated by the SC ASC CM derived from control rats compared to the DMEM control 
(biological n=3 per diet group; technical n=3; normalised to total protein; two-way ANOVA with Bonferroni post-test; 
mean ± SD; *p<0.05).  
PKB is an insulin-responsive positive regulator of nutrient metabolism essential for cell growth and 
survival. PKB promotes anabolic processes by activating AS160/GLUT4-mediated glucose uptake 
(for glycogenesis), AS160/CD36-mediated FFA uptake (for lipogenesis) and mTORC1/S6K-
mediated protein synthesis, while limiting catabolic processes through the inhibition of AMPK. 
Furthermore, ATM has been suggested to facilitate the full activation of PKB in response to insulin 
stimulation in some cell types (Viniegra et al., 2005; Halaby et al., 2008; Jeong et al., 2010; J. Ching 
et al., 2013).  
Different aspects of obesity, such as increased blood glucose, insulin, lipid and pro-inflammatory 





2013), which in turn associates with decreased glucose uptake and utilisation. In particular, fatty acid-
induced insulin resistance can arise due to a build-up of intracellular fatty acid metabolites, such as 
DAG and ceramide, which leads to the serine phosphorylation and inhibition of IRS-1, and a 
consequent reduction in PKB phosphorylation (Shulman, 2000). Although established insulin 
resistance is generally associated with various insulin signalling pathway alterations, including 
decreased PKB phosphorylation, early molecular signs of cellular insulin resistance is thought to be 
only observed at the level of GLUT4, and not PKB. In fact, insulin signalling to PKB remains 
unaltered, but a disruption in GLUT4 translocation is responsible for the initial reduction in cellular 
glucose uptake (Abel, O’Shea and Ramasamy, 2012).   
In the current study, no significant differences in PKB phosphorylation were observed. The only 
source of insulin was from the DMEM in the growth media, which formed the background of all the 
CM. The only other factors that might affect insulin signalling in H9c2 cells are adipose-secreted pro-
inflammatory cytokines, adipokines and FFAs, which had no differential effects on PKB activity 
between the subcutaneous and visceral fat depots, or between the control and HFD conditions. 
Although not significant, the adipocyte secretions under HFD conditions resulted in increased PKB 
activation compared to the control counterparts, which could suggest an early adaptation to greater 
metabolic pressure without the presence of established insulin resistance. A final interesting 
observation is that the pattern of PKB activity in the HFD setting deviates from that in the control 
setting, resembling the pattern of AMPK rather than those of ATM and mTORC1. This could further 
indicate an early change in cardiomyoblast PKB activity in response to adipose secretions during 
high-fat feeding.  
6.3. miR-18a, miR-194, miR-210, miR-181b and miR-322 are able to 
target rat ATM mRNA in silico 
Previous studies have shown that miR-421 and miR-18a function down-stream of the nutrient sensor 
mTORC1 (Shen and Houghton, 2013) to target ATM mRNA in human and mouse cancer cells (Hu 
et al., 2010; Song et al., 2011; Wu et al., 2013). Although miRNAs are generally well conserved 
among different animal species (Bartel, 2004), mRNA binding sites of target proteins are not 
necessarily conserved. In the current study, in silico analysis using the TargetScan and miRMap 
algorithm software confirmed that miR-18a targets ATM mRNA in rats (Figure 6.7 A), but not miR-
421. Furthermore, miR-194 (Figure 6.7 B), -210, (Figure 6.7 C) -181b (Figure 6.7 D) and -322 






Figure 6.7: In silico analysis showing the exact binding locations on the ATM 3' UTR for the target 
miRNAs. 
The exact binding positions (nucleotides) on the 3’ untranslated region (UTR) of ATM mRNA for miR-18a-5p (A), miR-
194-3p (B), miR-210-5p (C), miR-181b-5p (D), and miR-322-5p (E). Figure designed in Microsoft PowerPoint Office 
365 by the author of the thesis based on information accessible on TargetScan and miRMap algorithm software.  
6.4. Cardiomyoblast miR-181b is down-regulated by normal adipocyte 
secretions, and more so by adipocyte secretions in response to 
high-fat feeding 
The relative expression levels of miR-421, miR-18a, miR-194, miR-210, miR-181b and miR-322 
were determined in H9c2 cells treated with the respective CM or complete DMEM media only 
(control) for 24 hours. Each treatment condition was performed in triplicate (technical n=3) and 
pooled per experiment, each experiment was repeated four times (biological n=4 per diet group), and 
samples were analysed in duplicate. Upon review of the amplification plots and standard curves for 
each miRNA, miR-194 was excluded from the qRT-PCR analysis based on poor primer efficiency 
(Appendix D Figure D9). No accurate conclusions from the relative expression data of miR-421, 
miR-18a or miR-210 could be formulated as their respective primer efficiencies were too high 
(Appendix D Figures D7, D8 and D10). NanoDrop™ spectrophotometry revealed sufficient RNA 
concentration and purity per sample (Appendix D Table D1), and RIN allocations revealed high RNA 
integrity across individual experiments (Appendix D Figure D5). Therefore, we speculate that either 





responsible for poor primer performance. In order to compare results between individual experiments, 
the Ct-values of each DMEM control-treated group were averaged for each miRNA and used to 
calculate the fold-change for each treatment group (refer to Appendix D Figure D16). A two-way 
ANOVA was performed, followed by a Bonferroni post-hoc test, and data are presented as mean fold-
change ± SD relative to the DMEM control.  
 
Figure 6.8: Expression levels of target miRNAs in H9c2 cardiomyoblasts treated with adipose-derived 
CM. 
The relative expression levels of miR-322 (A) and miR-181b (B) in H9c2 cells treated with CM derived from subcutaneous 
adipose stem cells (SC ASC), subcutaneous adipocytes (SC Adipo), peri-renal adipose stem cells (PR ASC) and peri-renal 
adipocytes (PR Adipo) harvested from control and HFD rats for 24 hours compared to a DMEM control. The CM from 
PR Adipo derived from control diet rats, as well as all HFD-derived CM, significantly down-regulated miR-181b in H9c2 
cells (biological n=4 per diet group; pooled technical n=3; normalised to U6 snRNA; 2-ΔΔCt method; two-way ANOVA 
with Bonferroni post-test; mean ± SD; *p<0.05; **p<0.01).  
No significant differences in miR-322 expression were observed (Figure 6.8 A). Ectopic miR-322 
expression has been linked with the development of insulin resistance. By negatively regulating the 
insulin receptor mRNA, overexpressed miR-322 leads to decreased insulin receptor expression, 
decreased down-stream PKB phosphorylation and reduced glucose uptake in rat vascular smooth 
muscle cells (Marchand et al., 2016). The authors further investigated the role of miR-322 in the 
development of cardiac dysfunction in obesity. Interestingly, it was observed that HFD mice with 
cardiac dysfunction displayed no significant changes in cardiac miR-322 levels compared to control 
mice, whereas age-matched ob/ob mice with no cardiac dysfunction displayed increased cardiac miR-
322 levels. The authors concluded that elevated miR-322 levels might be cardioprotective in response 
to metabolic overload in a HFD setting.  
Based on the animal study by Marchand and colleagues (2016), it is tempting to speculate that no 
significant changes in miR-322 levels in response to the adipose secretions under HFD conditions 





terms of H9c2 cells and confirmed by additional analyses. No change in miR-322 expression could, 
however, suggest that insulin resistance is likely not induced within the CM-treated H9c2, which is 
supported by no significant decreases in phosphorylated PKB levels (Figure 6.6).     
The most interesting finding was that miR-181b was significantly down-regulated by subcutaneous 
and visceral adipocyte secretions compared to the DMEM control (p<0.05) under normal conditions, 
and even more so by secretions from subcutaneous ASCs (p<0.01), subcutaneous adipocytes 
(p<0.01), visceral ASCs (p<0.05) and visceral adipocytes (p<0.01) compared to the DMEM control 
under HFD conditions (Figure 6.8 B). It is noticeable that the ASC secretions only had a significant 
effect on miR-181b expression levels under HFD conditions but not under control conditions. 
Interestingly, despite also being linked with the suppression of ATM when ectopically expressed in 
breast cancer (Bisso et al., 2013), miR-181b down-regulation has been linked with various aspects of 
obesity. Firstly, miR-181b negatively regulates cellular inflammation by targeting importin-α3, a 
protein required for the translocation of nuclear factor kappa B (NF-кB) to the nucleus for the 
transcription of inflammatory mediators (Sun et al., 2012). The authors showed that endothelial miR-
181b was down-regulated in response to pro-inflammatory molecules, which resulted in increased 
NF-кB signalling and, subsequently, cellular inflammation. Therefore, reduced cellular miR-181b 
might be associated with a pro-inflammatory state. Secondly, miR-181b is thought to play an 
important role in the regulation of the insulin signalling pathway, as its down-regulation in adipose-
derived endothelial cells of obese mice was associated with the development of insulin resistance. 
Furthermore, miR-181b was also down-regulated in cultured endothelial cells exposed to either 
palmitate, glucose or TNF-α, indicating that miR-181b expression can be influenced by nutrients and 
pro-inflammatory cytokines (Sun et al., 2016). Lastly, cardiac miR-181b expression was shown to be 
down-regulated in HFD-induced obese mice and was associated with the development of 
cardiomyopathy. This reduction in miR-181b levels in the heart correlated with circulating levels, 
highlighting miR-181b as a promising potential biomarker of cardiac dysfunction during obesity 
(Copier et al., 2017). In addition, the authors observed a significant down-regulation in cardiac miR-
322 levels in obese mice compared to control mice, which also correlated with circulating levels.  
In the current study, we show for the first time that cardiomyoblast miR-181b expression is further 
down-regulated in response to subcutaneous and visceral ASC and adipocyte secretions in a HFD 
setting. This down-regulation was not consistent with increased ATM protein levels (Figure 6.3), 
however this does not discount the hypothesis that miR-181b might regulate ATM under metabolic 
stress. Furthermore, these results suggest that adipose secretions within a HFD setting, and even 
adipocyte secretions under normal conditions, might trigger a miR-181b-mediated inflammatory 





secretions in vitro, and therefore might be a potential early indicator of metabolic dysregulation in 
the heart, prior to the development of insulin resistance, in response to high-fat feeding.  
Chapter conclusion 
Taken together, ATM activity is regulated in H9c2 cells in response to adipose secretions, 
independent of fat depot or diet. Furthermore, alterations in AMPK and mTORC1 total protein levels 
in response to HFD conditions might be an early adaptive mechanism employed by cardiomyoblasts 
to keep the activation levels of these nutrient sensors comparable to control conditions. Lastly, we 
show, for the first time, that cardiomyoblast miR-181b levels are further down-regulated in response 






Chapter 7  
Study conclusion 
The observation that ATM protein levels are down-regulated in the peripheral tissue of obese and 
insulin resistant animals introduces a potential link between obesity and peripheral metabolic 
dysfunction. ATM plays a central role in maintaining intracellular metabolic homeostasis, therefore 
decreased cardiac ATM in response to an HFD might be a key event in the development of insulin 
resistance and cardiac dysfunction. The underlying mechanism of peripheral ATM protein down-
regulation in obesity, however, remains unclear. Various cancer studies have shown that ATM protein 
levels are down-regulated by specific miRNAs, and we were thus interested in investigating whether 
cardiac ATM is also susceptible to miRNA-mediated regulation in obesity. 
WAT constitutes a multicellular organ with important endocrine functions that are collectively 
responsible for systemic energy homeostasis. Obesity results in dramatic changes in WAT behaviour, 
including ectopic deposition around central organs and dysregulated adipocyte metabolism. In the 
current study, we determined the basal metabolic protein levels and activities of ATM, mTORC1 and 
AMPK, but observed no apparent differences between visceral and subcutaneous adipocytes under 
control or HFD conditions. Although the metabolic impact of adipocyte differentiation lies beyond 
the scope of this study, we observed a potential differentiation-dependent effect on the basal 
metabolic protein profiles.  
Abnormal circulating FFAs, adipokines and pro-inflammatory cytokines secreted by WAT have been 
suggested to link obesity with the development of peripheral insulin resistance and inflammation. In 
the current study, we analysed the FFA composition of the respective CM to determine the secretory 
profiles of the visceral and subcutaneous adipose cells under control and HFD conditions. Fat depot 
and diet did not significantly influence the secretion of the three most abundant FFAs, namely 
palmitic-, stearic-, and oleic acid, by adipocytes. However, adipocytes showed higher secretion of 
palmitic acid, but lower secretion of oleic acid, compared to the ASCs, emphasising a strong 
differentiation-dependent effect.   
Cardiac ATM total protein levels are influenced in HFD-induced obese rats, and we hypothesised 
that it might be due to miRNA-mediated regulation. In the current study, we were able to show that 
high concentrations of FFAs and insulin (Chapter 4) and adipocyte secretions (Chapter 6) influence 
cardiomyoblast ATM activity in vitro, but not its total protein levels. Even though these results do 
not mimic that of the animal study, perhaps it is important to consider that the factors secreted by 





combination of high circulating FFAs, glucose, insulin, adipokines and pro-inflammatory cytokines 
that accompany an obesogenic diet that drive the dysregulation of cardiac ATM total protein levels. 
Furthermore, we were able to show that adipose secretions further down-regulate the expression 
levels of miR-181b, a metabolic miRNA that targets ATM mRNA in silico, in a HFD setting. Previous 
studies have shown that miR-181b expression is influenced by nutrients (such as palmitate) and pro-
inflammatory molecules (such as TNF-α), and its down-regulation has been associated with 
intracellular inflammation, insulin resistance and cardiomyopathy. Although we observed no 
significant differences in the secreted FFA profiles between the adipocytes originating from different 
dietary backgrounds, it might be possible that other secreted factors, such as adipokines or cytokines, 
influence cardiomyoblast miR-181b levels. Therefore, we show, for the first time, that the down-
regulation of cardiomyoblast miR-181b levels is exacerbated in response to HFD-derived adipose 
secretions, before the dysregulation of metabolic protein activities are observed in the 
cardiomyoblasts, and before clinical signs of obesity and systemic insulin resistance manifest (see the 
biometric data of the HFD rats compared to control rats in Appendix A Table A2 and Figure A1). 
We speculate that reduced miR-181b levels might be an early indicator of metabolic dysfunction in 
cardiomyoblasts.  
Taken together, we demonstrate that adipocyte hypertrophy (ASC differentiation into adipocytes is 
characterised by increased lipid accumulation) alters the metabolic protein expression and FFA 
secretion, which in turn influence peripheral (cardiomyoblast) metabolic protein levels (AMPK and 
mTORC1) and activity (ATM), as well as miRNA expression (miR-181b). 
Future directions 
Chapter 5: We observed a potential differentiation-dependent effect on the basal metabolic protein 
profiles between ASCs and their adipocyte counterparts. The roles of these metabolic signalling 
proteins in the adipocytic differentiation of ASCs have not yet been elucidated and warrant further 
investigation, specifically pertaining to depot-specific differences and responses to different dietary 
conditions. 
Chapter 6: In accordance with the metabolic protein profiles, we also observed a strong 
differentiation-dependent effect on the FFA secretory profiles, which warrant further investigation. 
In order to improve our understanding of the potential posttranscriptional regulation of cardiac ATM 
in obesity, the ATM mRNA levels will have to be analysed. Although we did not observe significant 
differences in ATM total protein levels, it does not necessarily conclude that ATM levels are not 
regulated on the posttranscriptional level. Due to differential regulation, mRNA and protein levels 





2016). We have the isolated total RNA of H9c2 cells treated with the respective CM in -80°C storage, 
as well as an ATM mRNA primer, for future analysis. Furthermore, obesity is associated with 
oxidative stress, and ATM is directly activated by ROS, therefore the analysis of intracellular ROS 
levels in CM-treated cells will provide additional insights into the regulation of ATM in obesity. 
Lastly, other components present within the CM will have to be analysed, such as adipokines and 
cytokines, as these molecules can also affect metabolic protein expression and miRNA levels in 
cardiomyoblasts. 
Study limitations 
We acknowledge that all the in vitro experiments were underpowered, and that a larger n-value will 
have to be considered in order to confirm our results. 
Chapter 5: Two major limitations of this chapter included our inability to (i) pool the protein 
quantification data of the four biological replicates per diet group and (ii) compare the basal metabolic 
protein profiles between the two diet groups to investigate the effect of the HFD. This could have 
been achieved through the inclusion of a common control on each stain-free membrane. It is also 
important to emphasise that we investigated the metabolic protein profiles in adipose stem cells and 
differentiated adipocytes, which represent only two cell type within WAT. Therefore, we were unable 
to formulate conclusions regarding WAT as a multicellular organ. 
Chapter 6: We did not include the control media samples for the GC-FID analysis, therefore our data 
lacks a baseline to exclude background FFAs that are present in the FBS used for the complete 
DMEM media. In addition to metabolic stimuli, ATM is activated in response to double-stranded 
DNA breaks. However, we did not consider DNA damage as a mechanism for ATM activation, which 
could interfere with the interpretation of our results. Another limitation was that the volume of CM 
available to this study was very limited, therefore we were unable to perform a cell viability assay or 
assess apoptosis in the CM-treated H9c2 cells. Due to extreme time constraints, we were unable to 
assess fatty acid metabolism proteins, such as PPARα, or down-stream targets of AMPK (TSC2 and 
ACC) and mTORC1 (S6K and autophagy markers such as LC3) through Western blotting in CM-
treated H9c2 cells, which would have aided our understanding of how the H9c2 cells responded 
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Animal work was performed from October 2018 to May 2019 by Dr H. Sadie-van Gijsen. The 
conditioned media used in the current MSc study was derived from animals that formed part of a 
larger study. Only the dietary information (Table A1) and biometrical data (Table A2 and Figure A1) 
of the animals relevant to the current study will be included as described in the protocol by Dr H. 
Sadie-van Gijsen.  
Briefly, ethical approval was obtained from the Stellenbosch University Research Ethics Committee: 
Animal Care and Use (ethics number ACU-2018-6786). Animals were housed at the Animal 
Research Facility, Tygerberg campus, Stellenbosch University. At 4 weeks after weaning 
(approximately 6 weeks of age, body weight 170-200g), male Wistar rats were started on either a 
standard laboratory control (CON) chow diet (n=4) or a high fat/fructose/cholesterol (OB2) diet 
(n=4). The OB2 diet (referred to in this study as the HFD) was prepared by combining CON pellets 
with large amounts of Holsum, fructose, cholesterol and casein. A breakdown of the macronutrient 
composition for each diet is listed in Table A1. Animals had ad libitum access to food and water at 
all times and body weights were recorded weekly. Animals were sacrificed at 16 weeks by means of 
intraperitoneal injection with a lethal dose of sodium pentobarbital (160 mg/kg). 
Table A1: Composition of the control (CON) and high-fat (OB2) diets. 
 CON OB2 
Starch (g/100 g) 22.1 4.7 
Glycaemic carbohydrate (g/100 g) 27.4 11.5 
Total sugar (g/100 g) 5.2 6.7 
Glucose (g/100 g) 0.1 0.2 
Sucrose (g/100 g) 4.6 1.5 
Fructose (g/100 g) 0.3 4.4 
Other (maltose, lactose, galactose, trehalose) (g/100 g) 0.2 0.7 
Total fat (g/100 g) 5.04 24.09 





Saturated fat (g/100 g) 1.28 14.3 
Mono-unsaturated fat (g/100 g) 1.28 7.42 
Poly-unsaturated fat (g/100 g) 2.48 2.38 
Cholesterol (mg/100 g) 44 440 
Protein (g/100 g) 25.8 12.9 
Fibre (g/100 g) 16.8 5.5 
Energy (kJ/100 g) 1225 1350 
 
Biometric data 
The following biometric measurements relevant to the current MSc study were recorded per rat per 
diet group: 
Table A2: Biometric measurements of control (n=4) and HFD (n=4) rats. 








PR fat weight 
one side  
(g) 
% PR fat  
(of total body 
weight) 
CON A 359 176 118.4 0.57 0.318 
CON B 413 228 130.9 1.14 0.552 
CON C 431 221 183.7 1.05 0.487 
CON D 406 202 150.3 1 0.493 
 402.25 206.75 145.825 0.94 0.4625 
OB E 384 214 246.2 0.91 0.513 
OB F 399 223 274.9 0.98 0.491 
OB G 427 236 365 2.68 1.255 
OB H 410 224 68.7 1.27 0.62 
 405 224.25 238.7 1.46 0.71975 
AUC: area under curve; OGTT: oral glucose tolerance test; PR: peri-renal 







Figure A1: Biometric measurements of control diet animals (CON; n=4) and HFD animals (OB2; n=4). 
No significant differences between the diet groups were observed (two-tailed Student’s t-test; mean ± SD; 
p<0.05 considered statistically significant). 
ASC isolation and adipocytic differentiation 
Briefly, the ASCs were harvested from the inguinal subcutaneous fat pad and the peri-renal (visceral) 
fat pad of control and HFD rats. The isolated ASCs were maintained in culture until post-confluency 
was reached, whereafter a subset of ASCs was induced to differentiate to mature adipocytes using 
adipogenic induction media. A detailed protocol for the harvesting, culturing and adipocytic 
differentiation of primary ASCs has been published (Sadie-Van Gijsen, Kotzé-Hörstmann and 
Huisamen, 2020). The lipid accumulation of differentiated adipocytes was determined by Dr H. 
Sadie-van Gijsen through Oil Red O staining and quantified using ImageJ software. A two-tailed 
Student’s t-test was performed to compare the percentage staining of subcutaneous and visceral 






Figure A2: The lipid accumulation as determined by Oil Red O staining of subcutaneous (SC) and visceral 
(PR) adipocytes originating from control and HFD rats. No significant differences in lipid accumulation 
between the fat depots were observed (two-tailed Student’s t-test; percentage ± SD; p<0.05 considered 






Chapter 4: Additional information 
MTT viability assay 
The absorbance values (in triplicate) are displayed as OD (optical density) at 570 nm in Figure B1. 
 
Figure B1: The absorbance values (in triplicate) at 570 nm of H9c2 cells. (1) DMEM control, (2) EtOH 
control, (3) FFAs (palmitic- and oleic acid), (4) FFA and glucose, (5) insulin, and (6) insulin and FFAs 
(technical n=3 per condition). 
Western blot analysis: membrane images used for total protein normalisation 
The total protein of each sample lysate was transferred from hand-casted acrylamide gels onto stain-
free membranes (Figure B2-B6) and imaged using the ChemiDoc™ system for normalisation 
analyses.  
 






Figure B3: Representative membranes used for ATM normalisation. 
 
Figure B4: Membranes used for PKB normalisation. 
 






Figure B6: Representative membranes used for AMPK normalisation. 
qRT-PCR analysis: RNA concentrations and purity, primer optimisation and 
U6 snRNA as an appropriate endogenous control miRNA 
Total RNA concentration and purity (260/280 and 260/230 absorbance ratios) were determined using 
the NanoDrop™ 2000c spectrophotometer (Table B1). 
Table B1: Total RNA concentration and purity. 
RNA sample Concentration 
(ng/μl) 
260/280 ratio 260/230 ratio 
DMEM cnt 1 158.8 2.11 1.94 
DMEM cnt 2 255.5 2.09 0.87 
DMEM cnt 3 109.7 2.11 1.54 
FFA 1 152.2 2.12 2.00 
FFA 2 205.5 2.11 2.05 
FFA 3 104.8 2.11 1.57 
FFA + glu 1 154.6 2.12 1.89 
FFA + glu 2 194.1 2.09 1.99 
FFA + glu 3 88.1 2.12 1.84 
Ins 1 147.9 2.11 1.65 
Ins 2 193.0 2.12 0.87 
Ins 3 107.6 2.12 1.75 
Ins + FFA 1 147.4 2.13 1.88 
Ins + FFA 2 208.8 2.11 1.60 
Ins + FFA 3 120.7 2.12 1.41 
 
A 10x dilution series, ranging from a 100% neat sample to a 0.001% dilution, using a pooled cDNA 





standard curves for all miRNA primers (miR-421, miR-18a and U6 snRNA) using the QuantStudio™ 
7 Flex Real-Time PCR software. The amplification plots were used to assess whether the fluorescent 
signal from each miRNA primer could accumulate to threshold at a Ct-value below 35, whereas the 
standard curves were used to analyse the primer efficiencies, as well as identify the most optimal 
dilution factor for the cDNA samples.  
 
Figure B7: The qRT-PCR plate layout for the standard curve using a 10x dilution series in duplicate from 









1 2 3 4 5 6 7 8 9 10 11 12
A 100 100 100 100 100 100
B 10 10 10 10 10 10
C 1 1 1 1 1 1
D 0,1 0,1 0,1 0,1 0,1 0,1
E 0,01 0,01 0,01 0,01 0,01 0,01
F 0,001 0,001 0,001 0,001 0,001 0,001
G NTC NTC NTC NTC NTC NTC
H

















The cDNA samples of a single animal were analysed in duplicate on the same qRT-PCR plate (see 
Figure B11 for qRT-PCR plate layout). 
 
Figure B11: The qRT-PCR plate layout for the cDNA samples in duplicate.  
U6 snRNA is a common and widely-used endogenous control RNA used for normalising target 
miRNA expression. We have established that U6 snRNA is stably expressed in H9c2 cells treated 
with various combinations of FFAs, glucose and insulin (Figure B12). Each sample (biological n=3) 
was analysed in duplicate and the mean Ct-values were compared by one-way ANOVA, followed by 
a Bonferroni post-hoc test. No statistically significant differences in mean Ct-values were observed 
among the different treatment groups, confirming its stable expression and deeming U6 snRNA an 
appropriate endogenous control for H9c2 cells in response to high concentrations of nutrients and/or 
insulin. 
 
Figure B12: U6 snRNA displayed stable expression in H9c2 cells. No significant differences in U6 snRNA 
expression were observed in H9c2 cells were treated with combinations of high FFAs, glucose and insulin 
(one-way ANOVA, Bonferroni post-test; mean Ct-value ± SD; p<0.05 considered statistically significant).  
 
  
1 2 3 4 5 6 7 8 9 10 11 12
A cnt A cnt B cnt C FFA A FFA B FFA C FFA + glu A FFA + glu B FFA + glu C Ins A Ins B Ins C miR-421
B cnt A cnt B cnt C FFA A FFA B FFA C FFA + glu A FFA + glu B FFA + glu C Ins A Ins B Ins C
C Ins + FFA A Ins + FFA B Ins + FFA C NTC cnt A cnt B cnt C FFA A FFA B FFA C FFA + glu A FFA + glu B miR-18a
D Ins + FFA A Ins + FFA B Ins + FFA C Neg cnt A cnt B cnt C FFA A FFA B FFA C FFA + glu A FFA + glu B
E FFA + glu C Ins A Ins B Ins C Ins + FFA A Ins + FFA B Ins + FFA C NTC cnt A cnt B cnt C FFA A U6 snRNA
F FFA + glu C Ins A Ins B Ins C Ins + FFA A Ins + FFA B Ins + FFA C Neg cnt A cnt B cnt C FFA A
G FFA B FFA C FFA + glu A FFA + glu B FFA + glu C Ins A Ins B Ins C Ins + FFA A Ins + FFA B Ins + FFA C NTC






Chapter 5: Additional information 
Western blot analysis: membrane images used for total protein normalisation 
The total protein of each sample lysate was transferred from hand-casted acrylamide gels onto stain-
free membranes (Figures C1-C4) and imaged using the ChemiDoc™ system for normalisation 
analyses.  
 
Figure C1: Representative membranes used for ATM normalisation. 
 







Figure C3: Representative membranes used for AMPK normalisation. 
 








Chapter 6: Additional information 
Western blot analysis: establishment of common DMEM control and 
membrane images used for total protein normalisation 
To compare results between individual experiments (H9c2 cells treated with adipose-derived CM), a 
common control had to be established by comparing the DMEM control conditions for each 
individual experiment to ensure that no significant differences in metabolic protein activity were 
present to serve as a baseline. We compared the ATM total levels (Figure D1 A) and phosphorylated 
AMPK levels (Figure D1 B) between each DMEM control condition.  
 
Figure D1: Total ATM levels (A) and phosphorylated AMPK levels (B) were determined between the 
DMEM control conditions of each experiment. No significant differences were observed in total ATM levels, 
however significant differences were observed in phosphorylated AMPK levels (one-way ANOVA; Bonferroni 
post-test; *p<0.05). 
No significant changes were observed between the total ATM levels, however significant differences 
were observed in phosphorylated AMPK levels between experiments B and C (p<0.05), C and F 
(p<0.05), and F and H (p<0.05). The latter results are unexpected, as all the groups represent H9c2 
cells treated with complete DMEM media only. H9c2 cells of similar passage (17 or 18) treated with 
complete DMEM media were incubated for the same duration (24 hours) in a similar sterile 
environment (at 37°C in 95% humidified air). Furthermore, the protein lysates were prepared to the 
same protein concentration per sample, and proteins were normalised to the total protein per lane 
following Western blot analysis to compensate for unequal loading. In an attempt to correct for the 
significant differences observed in phosphorylated AMPK levels in the control-treated cells, the 





experiment) were pooled and served as a common DMEM control that was loaded onto each 
polyacrylamide gel. 
The total protein of each sample lysate was transferred from Criterion™ TGX Stain-Free™ gels onto 
stain-free membranes (Figures D2 and D3) and imaged using the ChemiDoc™ system for 
normalisation analyses. The control diet-derived CM-treated H9c2 cells are indicated in black, 
whereas the HFD-derived CM-treated H9c2 cells are indicated in grey. 
 
Figure D2: Representative membranes used for ATM and AMPK normalisation. 
 
Figure D3: Representative membranes used for mTORC1 and PKB normalisation. 
qRT-PCR analysis: RNA concentration and purity, RIN allocations, primer 
optimisation, U6 snRNA as an appropriate endogenous control miRNA, and 
establishment of common DMEM control 
Total RNA concentration and purity (260/280 and 260/230 absorbance ratios) were determined using 






Table D1: Total RNA concentration and purity as determined by NanoDrop™ spectrophotometry. 
RNA sample Concentration 
(ng/μl) 
260/280 ratio 260/230 ratio 
DMEM cnt A 135.4 2.15 1.95 
DMEM cnt B 189.2 2.09 1.69 
DMEM cnt C 177.5 2.11 2.07 
DMEM cnt D 224.5 2.13 2.07 
DMEM cnt E 124.8 2.14 1.35 
DMEM cnt F 191.6 2.13 2.21 
DMEM cnt G 227.0 2.11 1.78 
DMEM cnt H 128.6 2.14 1.71 
SC ASC A 138.2 2.16 1.86 
SC ASC B 165.9 2.11 1.85 
SC ASC C 180.8 2.13 2.10 
SC ASC D 178.5 2.14 1.92 
SC ASC E 84.4 2.11 1.88 
SC ASC F 136.6 2.12 2.13 
SC ASC G 170.9 2.10 0.74 
SC ASC H 105.1 2.14 1.45 
SC Adipo A 146.7 2.16 1.87 
SC Adipo B 173.1 2.11 2.15 
SC Adipo C 153.9 2.12 2.18 
SC Adipo D 166.8 2.14 2.04 
SC Adipo E 102.5 2.13 1.98 
SC Adipo F 120.6 2.14 2.24 
SC Adipo G 177.1 2.11 2.16 
SC Adipo H 95.0 2.13 1.32 
PR ASC A 136.6 2.17 2.01 
PR ASC B 173.1 2.11 1.75 
PR ASC C 148.1 2.13 1.89 
PR ASC D 189.6 2.13 1.62 
PR ASC E 83.6 2.14 1.39 
PR ASC F 124.8 2.14 2.24 
PR ASC G 169.5 2.11 2.17 
PR ASC H 98.3 2.11 1.34 
PR Adipo A 134.6 2.16 1.36 





PR Adipo C 163.8 2.11 1.46 
PR Adipo D 164.0 2.13 1.54 
PR Adipo E 80.7 2.13 0.80 
PR Adipo F 111.6 2.13 2.24 
PR Adipo G 149.5 2.10 2.14 
PR Adipo H 92.2 2.14 1.43 
 
12 total RNA samples were randomly selected across all 8 experiments and submitted to the Central 
Analytical Facility (CAF) for RNA integrity analysis (RIN allocation) with the Agilent 2100 
Bioanalyzer. Briefly, the RNA samples were separated on an agarose gel by electrophoresis based on 
size and visualised through laser-induced fluorescence detection (Figure D4). The gel image was 
used to compile RNA electropherograms (Figure D5) and the areas under the 18S and 28S ribosomal 
RNA (rRNA) peaks were calculated as a ratio of the total area under the curve (a high number 
indicates that little to no degradation has occurred). All 12 samples scored a RIN of 10, which 
confirms that the isolated RNA molecules were fully intact. 
 






Figure D5: RNA electropherograms displaying the 18S and 28S ribosomal RNA peaks used to calculate the 
RIN. Each RNA sample scored a RIN of 10, indicating high RNA integrity. 
A 10x dilution series, ranging from a 100% neat sample to a 0.001% dilution, using a pooled cDNA 
sample was used (see Figure D6 for qRT-PCR plate layout) to construct amplification plots and linear 
standard curves for all miRNA primers (miR-421, miR-18a, miR-194, miR-210, miR-322, miR-181b 
and U6 snRNA) using the QuantStudio™ 7 Flex Real-Time PCR software. The amplification plots 
were used to assess whether the fluorescent signal from each miRNA primer could accumulate to 
threshold at a Ct-value below 35, whereas the standard curves were used to analyse the primer 






Figure D6: The qRT-PCR plate layout for the standard curve using a 10x dilution series in duplicate from 





1 2 3 4 5 6 7 8 9 10 11 12
A 100 100 100 100 100 100 100 100 100 100 100 100
B 10 10 10 10 10 10 10 10 10 10 10 10
C 1 1 1 1 1 1 1 1 1 1 1 1
D 0,1 0,1 0,1 0,1 0,1 0,1 0,1 0,1 0,1 0,1 0,1 0,1
E 0,01 0,01 0,01 0,01 0,01 0,01 0,01 0,01 0,01 0,01 0,01 0,01
F 0,001 0,001 0,001 0,001 0,001 0,001 0,001 0,001 0,001 0,001 0,001 0,001
G NTC NTC NTC NTC NTC NTC NTC NTC NTC NTC NTC NTC
H
miR-421 miR-18a miR-194 miR-210 miR-322 miR-181b
Plate 2















Figure D7: The amplification plot, standard curve and relative expression graph of miR-421. The standard 
curve showed a primer efficiency outside of the normal range in H9c2 cells treated with adipose-derived CM. 









Figure D8: The amplification plot, standard curve and relative expression graph of miR-18a. The standard 
curve showed a primer efficiency outside of the normal range in H9c2 cells treated with adipose-derived CM. 




Figure D9: The amplification plot and standard curve of miR-194. The standard curve showed a primer 
efficiency outside of the normal range in H9c2 cells treated with adipose-derived CM. Therefore, miR-194 was 












Figure D10: The amplification plot and standard curve of miR-210. The amplification plot showed Ct-values 
of greater than 35 and the standard curve showed a primer efficiency outside of the normal range in H9c2 

















Figure D13: The amplification plot and standard curve of U6 snRNA. 
The cDNA samples of a single animal were analysed in duplicate on the same qRT-PCR plate (see 






Figure D14: The qRT-PCR plate layout for the cDNA samples in duplicate.  
U6 snRNA is a common and widely-used endogenous control RNA used for normalising target 
miRNA expression. We have established that U6 snRNA is stably expressed in H9c2 cells treated 
with adipose-derived CM harvested from control and HFD rats (Figure D15). Each sample (DMEM 
cnt, SC ASC, SC Adipo, PR ASC and PR Adipo) per experiment (biological n=4 per diet group) was 
analysed in duplicate and the mean Ct-values were compared by one-way ANOVA, followed by a 
Bonferroni post-hoc test. No statistically significant differences in mean Ct-values were observed 
among the different treatment groups, confirming its stable expression and deeming U6 snRNA an 
appropriate endogenous control for H9c2 cells treated with adipose-derived CM.  
 
Figure D15: U6 snRNA displayed stable expression in H9c2 cells. No significant differences in U6 snRNA 
expression were observed in H9c2 cells were treated with adipose-derived CM originating from control and 
HFD rats (one-way ANOVA, Bonferroni post-test; mean Ct-value ± SD; p<0.05 considered statistically 
significant). 
The Ct-values of the DMEM control groups for each experiment was compared to ensure that no 
significant differences in miRNA expression were present. No significant differences in Ct-values for 
miR-421, (Figure D16 A), miR-18a (Figure D16 B), miR-322 (Figure D16 C) and miR-181b 
(Figure D16 D) were observed between the DMEM control groups, therefore the Ct-values for each 
miRNA were averaged and used to calculate the fold-change for each treatment group. 
Plate 1:
1 2 3 4 5 6 7 8 9 10 11 12
A cnt cnt SC ASC SC ASC SC Adipo SC Adipo PR ASC PR ASC PR Adipo PR Adipo NTC Neg miR-421
B cnt cnt SC ASC SC ASC SC Adipo SC Adipo PR ASC PR ASC PR Adipo PR Adipo NTC Neg miR-18a
C cnt cnt SC ASC SC ASC SC Adipo SC Adipo PR ASC PR ASC PR Adipo PR Adipo NTC Neg miR-210
D cnt cnt SC ASC SC ASC SC Adipo SC Adipo PR ASC PR ASC PR Adipo PR Adipo NTC Neg miR-322
E cnt cnt SC ASC SC ASC SC Adipo SC Adipo PR ASC PR ASC PR Adipo PR Adipo NTC Neg miR-181b









Figure D16: The stable expression of (A) miR-421, (B) miR-18a, (C) miR-322 and (D) miR-181b in H9c2 
cells treated complete DMEM media to serve as control for H9c2 cells treated with CM originating from 
control and HFD rats. No significant differences in miRNA expression were observed, therefore the Ct-values 
of H9c2 cells treated with complete DMEM media were pooled per primer and used as a common control for 
fold-change calculations (two-tailed Student’s t-test; Bonferroni post-test; p<0.05 considered statistically 
significant). 
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